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Abstract 
Stroke is the third most common cause of death and the sixth major cause of disability 
around the world with ischemic stroke accounting for around 80% of all strokes. It has been 
clinically indicated in treating ischemic stroke patients that maximum benefits can be 
achieved with the speediest arterial recanalization by effective and fast application of 
existing acute therapies. These therapies comprise either (1) dissolving the blood clot using 
Intravenous Tissue Plasminogen Activator (IV tPA) treatment or (2) physically removing the 
clot from the artery using endovascular thrombectomy treatment. These treatments    should 
be performed within the hyperacute time window of 6 hours from stroke onset.  
For nearly two decades until late 2014, the intravenous thrombolysis delivered to patients 
was the most effective treatment for stroke patients. This was administrated within a 
maximum of 4.5 hours from stroke onset. In early 2015, results of five clinical trials from 
different parts of the world demonstrated the effectiveness of the endovascular 
thrombectomy therapy. This was provided within 6 hours of stroke onset for the eligible 
stroke patients who already have received thrombolysis treatment.  
Research presented in this thesis is the first attempt to quantify the link between the earlier 
treatment and long-term benefits for the hyperacute stroke patients. Moreover, with the 
gradual emergence of new evidence about effectiveness of the endovascular thrombectomy 
treatment in the hyperacute stroke care systems, new questions were raised in the clinical 
literature since not all hospitals have the expertise and equipment required for delivering the 
endovascular thrombectomy treatment. Some of the most burning questions were formulated 
in an Editorial article published in the Journal of the American Medical Association (JAMA) 
by Warach and Johnson (2016). These questions mainly concern the issue of treatment 
pathway selection between two groups of hospitals with different facilities and expertise to 
support new investigations in the hyperacute stroke care system by comparing the long-term 
benefits for individual patients.   
This research demonstrates how Operations Research (OR) models can be used to answer 
these and other questions in the hyperacute stroke care system. It is specifically focused on 
OR models for investigation and improvement to provide better understanding of the 
complex decisions arising in the hyperacute stroke care system. The main aimof this thesis is 
to investigate the issue of design, development and validation of OR models used for 
investigation and improvement of the hyperacute stroke care system. Thus, this work 
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addresses very recent and important questions in the field to support more effective and 
efficient provision of the services to stroke patients. 
Three OR models for investigation and improvement are designed and validated in this 
thesis: (1) ’IV tPA’ model, (2) ‘Endovascular Thrombectomy’ model, and (3) ‘Individual 
Patient’ model. The first two OR models are used to provide an understanding of the long-
term population benefits of faster access to stroke treatment interventions. Based on the first 
two OR models, one minute earlier of IV tPA and endovascular thrombectomy interventions 
respectively on average provide 1.8 days and 3.2 extra days of healthy life for the stroke 
patients. The third OR model is used to provide assistance with maximizing the individual 
patient’s life-time benefits over two pathways of the hyperacute stroke care system. Finally, 
we present a novel validation framework that is used to validate all three OR models 
developed in this thesis. 
This research contributes to OR/MS literature by design, development and validation of OR 
models used to provide an improved understanding of the long-term population and 
individual patient’s benefits due to faster delivery of stroke treatment interventions in the 
hyperacute stroke care system. A discussion on the validation of OR models is also novel 
and further addresses the existing gaps in OR/MS literature. 
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Chapter 1: Introduction 
Chapter 1 serves as an introduction to this research by first outlining the research gaps in the 
application of Operations Research (OR) models to assist with understanding of the 
hyperacute stroke care system. To address the identified research gaps, we present the aim of 
this research to investigating the issues of design, development and validation of OR models 
for investigation and improvement of hyperacute stroke care systems. To achieve this aim, 
we formulate three research questions and present the relevant outcomes. We then describe 
the research settings, outline and contribution of this research. 
1.1 Background to hyperacute stroke care system 
Stroke is the third most common cause of death and the sixth major cause of disability 
around the world with ischemic stroke accounting for 80% of all stroke types (Feigin, et al., 
2014). It has been clinically indicated that maximum benefits in treating ischemic stroke 
patients can be achieved by effective and fast application of existing acute therapies. These 
therapies are aimed at dissolving the blood clot using Intravenous Tissue Plasminogen 
Activator (IV tPA) (Emberson, et al., 2014; Fransen, et al., 2016), or physically removing the 
clot from the artery by using a clinical procedure known as Intra-arterial (IA) endovascular 
thrombectomy treatment (Saver, et al., 2016). An eligible ischemic stroke patient can either 
only receive IV tPA therapy within a maximum of 4.5 hours from stroke onset, or first 
receive IV tPA and then undergo the endovascular thrombectomy treatment with usually not 
more than 6 hours from stroke onset. This category of stroke patients who present in the 
stroke care unit within 6 hours from stroke onset are known as hyperacute stroke patients, 
with the care system being referred to as the hyperacute stroke care system. 
Even though clinical research has shown that maximum benefits in treating hyperacute 
stroke patients can be achieved by effective and fast application of existing acute therapies 
(Saver, 2006; Saver, et al., 2016), the effect of faster treatment for different treatment 
interventions on patient’s lifetime outcomes was not quantified prior to this research. 
Moreover, in reality, not all hospitals are capable of delivering the intra-arterial treatment to 
stroke patients. Therefore, delivering the right treatment intervention to the right group of 
patients within prescribed time-window has become a challenging issue for the clinicians in 
the field of hyperacute stroke care system. With recent and gradual emergence of new 
evidence about the effectiveness of the endovascular thrombectomy treatment in the 
hyperacute stroke care systems, new questions were raised in clinical literature. Some of the 
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most burning questions were formulated in an Editorial article published in Journal of the 
American Medical Association (JAMA) in 2016 as follows: “Should primary stroke centres 
be bypassed to transport patients to comprehensive centres, even if it means delaying the 
start of IV tPA? How much delay in bypass is acceptable? How much of a delay to start IV 
tPA would eliminate the benefit of earlier thrombectomy? (Warach & Johnston, 2016, p. 
1266)”. By addressing these research questions, clinicians can obtain the necessary insights 
for more effective and efficient provision of the stroke care services.  
1.2 Research gaps 
Despite a growing body of application of OR tools to the general domain of health care 
operations (Cooper, Brailsford, Davies, & Raftery, 2006; Fries, 2013; Osorio, Brailsford, & 
Smith, 2015), there is a clear research gap in the use of OR models to assist with 
understanding of the hyperacute stroke care systems, in particular: 
 There is a lack of OR models to understand the long-term benefits of faster access to 
different stroke treatment interventions on patients’ life-time outcomes. 
This is an important topic to address, since even though the benefits of faster treatment of the 
hyperacute stroke care patients have been demonstrated in the clinical literature, there is no 
OR model used to quantify the population benefits for the hyperacute stroke patients due to 
faster delivery of treatment interventions. 
 There is a lack of OR models to assist with hyperacute stroke care system pathway 
selection based on the individual patients’ life-time outcomes. 
With emergence of new evidence about the effectiveness of endovascular thrombectomy 
treatment in late 2014, new questions were raised by clinicians about how individual patients 
can maximize their long-term benefits in choosing different pathways of the hyperacute 
stroke care system. 
 There is a lack of reported knowledge about practical aspects of how to validate an 
OR model for investigation and improvement in the context of health systems and 
service operations. 
Proper validation of OR models used for investigation and improvement leads to an 
increased credibility of the model and its outcomes. Therefore, it is crucial to systematically 
address the issue of validation of such models. 
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1.3 Research aim and research questions 
The aim of this research is to address the identified research gap and to contribute to 
Operations Research/ Management Science (OR/MS) literature by investigating the issue of 
design, development and validation of OR models used for investigation and improvement of 
the hyperacute stroke care system. Following is a list of objectives and relevant research 
questions: 
 Objective 1: to design and validate OR models for better understanding of earlier 
treatment benefits for two different treatment interventions in hyperacute stroke care 
system; 
Research question 1: How OR models can be designed, developed, and validated to 
provide an improved understanding of the earlier treatment benefits on patients’ life-
time outcome for two different treatment interventions in hyperacute stroke care 
system? 
 Objective 2: to design and validate an OR model used to assist with maximizing the 
individual patients’ life-time benefits over two pathways of the hyperacute stroke 
care system; 
Research question 2: How OR models can be designed, developed, and validated to 
assist with maximizing the individual patients’ life-time benefits over two pathways 
of the hyperacute stroke care system? 
 Objective 3: to demonstrate how comprehensive validation of a complex OR model 
for investigation and improvement in the context of health systems and service 
operations can be conducted using the case of hyperacute stroke care. 
Research question 3: What are the conceptual and application issues of conducting 
comprehensive validation of an OR model for investigation and improvement in the 
context of health systems and service operations using the case of hyperacute stroke 
care? 
Outcomes of this research achieved by addressing these research questions are outlined in 
the next section.  
1.4 Research outcomes 
This research has produced the following outcomes: 
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1. Two validated OR models for understanding of the long-term effects of faster access 
to two different treatment interventions on stroke patients’ life-time outcomes in the 
hyperacute stroke care system. 
2. A validated OR model that can be used to assist with maximizing the individual 
patients’ life-time benefits over two pathways of the hyperacute stroke care system. 
3. Generic and structured set of validation techniques used to validate complex OR 
models in the hyperacute stroke care system with wide applicability for validating 
OR models in both health and non-health contexts.  
By generating these outcomes, this research contributes to OR/MS literature by design, 
development and validation of OR models used to provide an improved understanding of the 
long-term population and individual patient’s benefits due to faster delivery of stroke 
treatment interventions in the hyperacute stroke care system. A discussion on the validation 
of OR models used for investigation an improvement provided in this thesis is also novel and 
contributes further to existing OR/MS literature. 
1.5 Research settings of thesis 
This research was an industry-based project supported by the Florey Institute of 
Neuroscience and Mental Health, the largest neuroscience research institute in the Southern 
Hemisphere. The Florey Institute of Neuroscience and Mental Health has wide range of 
research projects on neuroscience-related diseases such as stroke, epilepsy, Alzheimer’s 
disease, depression, and spinal cord injury. The scope of the research presented in this thesis 
is limited to design, development and validation of OR models used for investigation and 
improvement of the hyperacute stroke care system. Strong research connections between the 
Florey Institute of Neuroscience and Mental Health and other clinical centers both locally 
and globally, facilitated the use of information obtained from different databases to develop 
the OR models in this thesis. Moreover, during the model building and validating stages we 
were working closely with many clinicians at Florey Institute of Neuroscience and Mental 
Health to further increase the accuracy and credibility of this research. 
1.6 Outline of thesis 
Discussion in this research is organized as follows:  
Chapter 2 provides a background to hyperacute stroke care system, followed by a discussion 
on the application of OR models with different intended use to address different problem 
areas in the stroke care system. This chapter also reports on literature review conducted to 
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investigate the OR applications published in the research and professional literature to 
address different problems of the hyperacute stroke care systems. 
Chapter 3 discusses challenges of validating OR models for investigation and improvement 
in the context of health systems and service operations. It then demonstrates how generic 
methods and approaches of validation as reported in OR/MS literature can be used to 
develop a generic framework of validation. 
Chapter 4 is dedicated to design, development, and validation of two novel OR models in the 
context of hyperacute stroke care system. These OR models are used for the first time to 
investigate the effect of time delays on population benefits for the stroke patients in the 
hyperacute stroke care system. Discussion on the validation of these models is provided in 
the same chapter. 
Chapter 5 reports on design, development, and validation of a novel OR model used to 
investigate the effect of time delays on individual patient’s life time outcomes over two 
pathways of the hyperacute stroke care system. Discussion on validation of this model is 
provided in the same chapter. 
Chapter 6 summarizes the findings, novelty and contributions, and limitations of the study as 
an indication to conduct future research in addressing the three research questions of this 
thesis. 
1.7 Contribution of thesis 
The contribution to knowledge of the research presented in this thesis is graphically 
presented in Figure 1-1. This can be summarized as five main points as listed below: 
1. Current use of OR interventions in stroke care system: In Chapter 2 of this 
thesis, we adopt a conceptual framework by Churilov and Donnan (2012) to classify 
the stroke-related OR studies found as a result of a literature review conducted in the 
same chapter, thus reporting on current use of OR interventions to address different 
problems of the stroke care system. Discussion on this topic was partially published 
in the Proceedings of Winter Simulation Conference in 2015, titled “Stroke care 
systems: can simulation modelling catch up with the recent advances in stroke 
treatment?” (Keshtkaran, Hearne, Abbasi, & Churilov, 2015) 
2. Current state of art of validating OR models: In Chapter 3 of this thesis, we 
conduct a literature review to investigate and report on current state of art of 
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validating OR models as reported in OR/MS literature. Discussion on this topic was 
partially published in the European Journal of Operational Research in 2016, titled 
“Validation of a decision support model for investigation and improvement in stroke 
thrombolysis” (Keshtkaran, Churilov, Hearne, Abbasi, & Meretoja, 2016) 
3. Generic framework for OR model validation: In Chapter 3 of this thesis, we 
propose a generic validation framework used to validate complex OR models in the 
context of hyperacute stroke care system with potential wide applicability for 
validating OR models in non-health contexts. Discussion on this topic was partially 
published in the European Journal of Operational Research in 2016, titled 
“Validation of a decision support model for investigation and improvement in stroke 
thrombolysis” (Keshtkaran, et al., 2016) 
4. Development and validation of OR models to estimating the population 
benefits: In Chapter 4 of this thesis, we develop and validate the ‘IV tPA’ and 
‘Endovascular Thrombectomy’ OR models used for the first time to provide 
understanding of the long-term effects of faster access to two different treatment 
interventions on stroke patients’ life-time outcomes in the hyperacute stroke care 
system. A discussion on the validation of these two models contribute to OR/MS 
literature by demonstrating how comprehensivevalidation of a complex OR model 
for investigation and improvement in the context of health systems and service 
operations can be conducted using the case of hyperacute stroke care. The content of 
this chapter is partially based on three journal articles:  
(1) article published in Stroke in 2014, titled “Stroke thrombolysis; save a minute, 
save a day”(Meretoja, et al., 2014);  
(2) article published in the European Journal of Operational Research in 2016, titled 
“Validation of a decision support model for investigation and improvement in stroke 
thrombolysis” (Keshtkaran, et al., 2016); and  
(3) article accepted for publication in Neurology at the time of submitting this thesis, 
titled “Endovascular therapy for ischemic stroke; save a minute – save a 
week”(Meretoja, Keshtkaran, Tatlisumak, Donnan, & Churilov, 2017). 
5. Development and validation of an OR model to assist with maximizing the 
individual patient’s benefits: In Chapter 5 of this thesis, we develop and validate 
the ‘Individual Patient’ OR model used for the first time to assist with maximizing 
the individual patient’s life-time benefits over two pathways of the hyperacute stroke 
care system. A discussion on the validation of this OR model contributes to OR/MS 
literature by demonstrating how comprehensive validation of a complex OR model 
for investigation and improvement in the context of health systems and service 
operations can be conducted using the case of hyperacute stroke care. 
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Figure 1-1 Summary of contributions of different chapters of this thesis 
1.8 Summary and conclusion 
This chapter laid the groundwork for all the other chapters in this thesis by identifying the 
problem areas in the hyperacute stroke care system, research gaps, objectives, questions, and 
outcomes. The contribution of this thesis to OR/MS literature is novel since for the first time 
it discusses the process of design, development and validation of OR models used to address 
some of the most current questions raised in clinical literature with the recent treatment 
advances in the hyperacute stroke care system since early 2015.   
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 Chapter 2: Review of the OR applications to stroke care systems 
Introduction  
Discussion provided in different sections of this chapter addresses all the three research 
questions proposed earlier in Chapter 1. Topics discussed in Section 2.1 serve as an 
introduction to problem domain of this research by providing a background to hyperacute 
stroke care system and reviewing the stroke care processes as reported in key policy 
documents for stroke care by four English-speaking countries.  
In Section 2.2, we discuss application of OR models with different intended use and 
interventions to address different problem areas in the hyperacute stroke care system. This 
includes discussing the link between the intended use of the model and model validation. 
This is an important topic as it provides background to third research question of this thesis: 
‘What are the conceptual and application issues of conducting comprehensive validation of 
an OR model for investigation and improvement in the context of health systems and service 
operations?’   
We then conduct a literature review in Section 2.3 to investigate the published OR 
applications in research and professional literature used to address different problems of the 
hyperacute stroke care system as reported in OR/MS literature. This assist us in better 
appreciation of the importance of research questions and objectives proposed in this research 
to address the existing knowledge gaps in OR/MS literature. Finally, in last section, 
summary of the findings of this chapter is provided. 
The content of this chapter is partially based on the conference paper “Stroke care systems: 
can simulation modelling catch up with the recent advances in stroke treatment?” published 
in the Proceedings of Winter Simulation Conference in 2015 (Keshtkaran, et al., 2015).  
2.1 Background to hyperacute stroke care system 
In this section, we provide a background to hyperacute stroke care system, focusing on 
stroke burden, stroke types, existing acute interventions, and challenges regarding 
administration of different interventions. In Section 2.1.1, we expand our discussion by 
describing the stroke care processes as reported in key policy documents from four English-
speaking countries; USA, UK, Canada, and Australia. 
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In 2016, stroke was ranked as the second most common cause of death in people aged above 
60 years and the second most common cause of disability worldwide (World Health 
Federation, 2017). According to latest statistics, in 2015 there were more than 50,000 new 
and recurrent strokes in Australia with one stroke occurring every 10 minutes. Moreover, 
65% of stroke victims are affected by long-term disability for the rest of their lives (Stroke 
Foundation - Australia, 2017). Financially, stroke accounts for more than 2-4% of total 
health-care costs and more than 4% of direct health-care costs in industrialised countries. 
This amount has been estimated to be around AUS$2.14 billion in Australia (Donnan, 
Fisher, Macleod, & Davis, 2008; Economics, 2013). 
There are two major types of strokes:  ischemic stroke and hemorrhagic stroke. Ischemic 
stroke happens when a blood clot or plaque blocks a blood vessel cause the brain cells 
become deprived of the oxygen and eventually stop functioning normally. If the vessel 
occlusion continues, after few minutes the brain cells may get damaged permanently, often 
leading to a significant long-term disability. This type of stroke accounts for 80% of all 
stroke types, while hemorrhagic stroke refers to the cases where an artery ruptures or breaks, 
causing bleeding in the brain (Feigin, et al., 2014).  
Existing acute therapies and interventions for ischaemic stroke are aimed at the speediest 
possible arterial recanalization, where a blood clot that has blocked a blood vessel is either 
removed or dissolved (Emberson, et al., 2014; Fransen, et al., 2016; Saver, et al., 2016). 
These proven acute interventions are used to help with restoring the cerebral blood flow in 
ischaemic stroke patients. Up until very recently, tissue plasminogen activator or IV tPA was 
the most effective treatment for ischemic stroke patients which is used to dissolve the blood 
clot formed in the artery (Wahlgren, et al., 2008). In early 2015, the results of five 
randomized controlled trials from different parts of the world were published in the New 
England Journal of Medicine, with all demonstrating that the intra-arterial clot removal is 
even more effective in treating the ischemic stroke patients when used in addition to IV tPA 
treatment comparing to IV tPA alone (Berkhemer, et al., 2015; Campbell, et al., 2015; 
Goyal, et al., 2015; Jovin, et al., 2015; Saver, et al., 2015). This new intervention is used to 
remove the blood clot from the artery using a clot retrieval device. 
As evidenced by the results of the modelling by Saver (2006), a typical stroke patient loses 
1.9 million neurons for each minute in which stroke is untreated. Compared with the normal 
rate of neuron loss in brain aging, this results in the ischemic brain ages 3.6 years for each 
hour without treatment (Saver, 2006). As a result, for patients experiencing acute ischemic 
stroke, and for the physicians and allied health personnel treating them, every second counts.  
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Existing evidence demonstrates that the earlier treatment in both interventions, leads to the 
higher chance of effective outcome in ischemic stroke patients (Emberson, et al., 2014; 
Fransen, et al., 2016), while the upper time limit to receive IV tPA treatment and 
endovascular thrombectomy is respectively set to 270 and 360 minutes according to majority 
of the clinical guidelines (Emberson, et al., 2014; Saver, et al., 2016). In medical terms, an 
ischaemic stroke patient presents in a hospital with stroke care unit within 6 hours of stroke 
onset time, is referred to as a hyperacute stroke patient. This group of patients can be 
categorized to those who are eligible to receive IV tPA treatment and then undergo the 
process of receiving the endovascular therapy, or only receive the IV tPA treatment (Saver, 
et al., 2016). In addition to the time eligibility of the patients to receive appropriate 
treatment, the clinical eligibility of the stroke patients to receive IV tPA and endovascular 
therapy is specified by the neurologist teams in the treating centres.  
With this introduction to hyperacute stroke care system and existing treatment interventions, 
in next section we discuss how different countries use different strategies and policies to 
address the problems in the system, thus improving the efficiency and the effectiveness of 
the services. 
2.1.1 Stroke care processes as reported in key policy documents  
With time being the most important factor in existing therapies for the ischemic stroke 
patients, different countries promote various strategies and policies for more effective and 
efficient management of the hyperacute stroke care system. The aim of this section is to 
provide a summary of the key recommendations by the public policy documents from USA, 
UK, Canada, and Australia in the field of stroke care systems. The first summary review of 
these documents were originally reported in a paper by Churilov and Donnan (2012). In this 
section, if available we report on the updated version of these documents; otherwise we refer 
to the original document as reported in the article by Churilov and Donnan (2012). The key 
findings of these policy documents are as follows: 
1. American Heart Association Public Policy Agenda 2010-14 report (American Heart 
Association/American Stroke Association, 2014): 
According to American Heart Association (AHA), there are six major components for 
the Establishment of Stroke Systems of Care as listed by the AHA’s task force on the 
Development of Stroke Systems. These include: Primordial and Primary Prevention, 
Notification and Response of Emergency Medical Services for Stroke, Acute Treatment 
for Stroke, Sub-Acute Stroke Care and Secondary Prevention for Stroke, Rehabilitation 
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of Stroke Patients, and Continuous Quality Improvement Initiatives (American Heart 
Association/American Stroke Association, 2014).   
2. Department of Health: National Stroke Strategy for England (Department of Health, 
2008) 
The National Stroke Strategy suggests following points to be considered by stroke 
service providers in order to improve their services: stroke awareness, stroke prevention, 
involvement of the patients in the stroke care process, Transient Ischaemic Attack (TIA) 
and acting on the warnings, stroke as a medical emergency, stroke unit quality, 
rehabilitation and community support, participation, workforce, and service 
improvement (Department of Health, 2008). Another relevant source to obtain 
information about treatment guidelines for stroke and transient ischemic attack in UK is 
the National Institute for Health and Care Excellence (NICE) which provides consistent 
recommendations with that of the Department of Health (National Institute for Health 
and care Excellence, 2017).   
3. Canadian Stroke Strategy (CSS) Core Performance Indicators 2010 report (CSS 
information and evaluation working group, 2010) 
This document categorizes and presents the core indicators associated with stroke best 
practices into two groups of system indicators and clinical indicators. The first category 
consists of 6 main indicators which are used for population level planning and system 
coordination, while the second category consists of 21 indicators used which are directly 
linked to quality of care for stroke patients (CSS information and evaluation working 
group, 2010). 
4. Australian National Stroke Foundation Clinical Guidelines for Stroke Management 
(National stroke foundation, 2010) 
According to this Guideline, there are nine areas to improve the stroke care management, 
these include: organization of care services, stroke recognition and pre-hospital care, 
early assessment and diagnosis, acute medical and surgical management, secondary 
prevention, rehabilitation, management of the complications, community participation 
and long-term recovery, social and financial issues (National stroke foundation, 2010).  
All the above public policy documents have been issued to address different challenges of 
the hyperacute stroke care system in the origin country. Therefore, strategies suggested by a 
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document from one country might not be directly applicable to another country. However, all 
these documents have been produced with the common objective of designing an efficient 
and effective system of care capable of addressing the time-sensitive treatment needs of the 
stroke patients.  
Churilov and Donnan (2012), have presented a list of ten broad problem areas of the stroke 
care system, specified by reviewing the above policy documents. In Section 2.3.3, we use 
these problem areas for classifying the stroke related OR studies. Following is the list of 
these problem areas:  
1. Stroke prevention: effective evaluation and management of risk factors and increasing the 
public awareness on lifestyle and available treatment options;  
2. Pre-hospital stroke care: increasing the number of eligible patients to receive tPA 
treatment by reducing the stroke-to-hospital delay times;  
3. Improving Information support for stroke patients;  
4. Appropriate and timely management of Transient Ischaemic Attack (TIA);  
5. Stroke unit care: patients suffering from stroke should have immediate access to required 
facilities and services within the stroke unit care;  
6. Rehabilitation: patients should have access to post-stroke rehabilitation services for as 
long as they need;  
7. Social and community care: to support the long-term needs of the stroke patients and their 
families;  
8. Stroke networks: to connect the key stakeholders across the stroke care system;  
9. Appropriate stroke care expertise: to facilitate the implementation of new therapeutic 
strategies;  
10. Financial viability: Cost-effectiveness analysis of different stroke care models to 
financially support people affected by stroke.  
The models developed in this thesis provide insights on the long-term impacts of faster 
access to treatment interventions for stroke patients, thus addressing the third, fifth, and ninth 
problem areas listed above.  
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Later in this chapter, we adopt these problem areas to classify the stroke-related OR studies 
found as a result of literature review conducted in Section 2.3.2. In the next section, we will 
provide a discussion on taxonomy of model use by Pidd (2010) and how OR models with 
different intentions can be used to address the above mentioned problem areas of the stroke 
care system. 
2.2  OR models with different intended use 
Pidd (2003) in his paper Why modelling and model use matter defines the model as “an 
external and explicit representation of part of reality as seen by the people who wish to use 
that model to understand, to change, to manage and to control that part of reality. This 
definition by Pidd (2003) describes important aspects of model which can be seen in any 
type of OR model. The first characteristic is its external representation as it attempts to build 
an artificial replica of the real-world problem. Second, he refers to the model as an explicit 
entity since we can explicitly distinguish between different components of the model once 
we design it. Third, the model developers will attempt to only model part of reality, thus 
calling explicitly for system boundaries of the phenomena being modelled. Fourth, model is 
a subjective artefact, where different modellers tend to develop different types of models 
based on their particular point of views (Pidd, 2010). Finally, OR models are developed with 
different intended use, which are models to understand, to change, to manage and to control.  
 
Pidd (2010), in his classification for different archetypes of model use has introduced four 
categories. Models for decision automation, models for routine decision support, models for 
investigation and improvement, and models to provide insight. Models belong to each of 
these categories are different in nature and therefore have different needs in terms of model 
validation. Since one of the objectives of this thesis is to address the conceptual and 
application issues of conducting comprehensive validation of OR models for investigation 
and improvement in the context of health systems, in this section we discuss how models 
with different intended use have different needs in terms of model validation. 
 
The category of decision automation refers to model use that is “frequent and routine, with 
in general no need to prepare the model for each use” (Pidd, 2010, p. 16). In such models, 
there is usually very little tolerance for any type of error, since decisions made based on the 
results of the model on a continuous basis in a less supervised environment. In terms of data 
requirements, these models often need extensive and representative data as model 
builders/users only rely on decisions made by the model and therefore data insufficiency will 
affect models functionality. Therefore, in terms of model validity all the model assumptions, 
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parameters, outputs, and their relationships should be examined critically before using the 
model in a decision making context (i.e. during the model-building stage) (Pidd, 2010).  
The second category is models for routine decision support which refer to models “used to 
assist, but not replace, people making routine, repeated decisions” (Pidd, 2010, p. 17). 
Similar to models for decision automation, in this type of models there is a high demand for 
large and detailed data which is not usually easy to acquire. Therefore, it has been suggested 
by literature to expand the model and revise the model parameters as higher quality data 
become available. In validation of these models, the focus is on assuring that combination of 
a decision proposed by a model and that made by a decision-maker will lead to a better 
overall decision outcome (Pidd, 2010).  
Third category of model use is modelling for investigation and improvement which refers to 
models used to “support investigations that are relatively unique, which may involve system 
design, system improvement or just an attempt to gain understanding of a very complex 
situation” (Pidd, 2010, p. 18). For this type of models, it is quite common to have very 
limited amount of historical data or even none at all, thus model developers are often unable 
to conduct an empirical “output-based” validation. As a result, validation of such models 
involves examining different components of the model, including model inputs, assumptions, 
and parameters to provide an improved understanding of the limitations of the model (Pidd, 
2010).  
The fourth category is modelling to provide insight where models are “not would-be 
representations of the real-world, but are rather attempts to understand and represent how 
different stakeholders and interest groups see the world” (Pidd, 2010). In models developed 
for providing insight, data is often much less demanding when compared to other model 
archetypes and it is usually in form of qualitative data based on different perceptions of 
various stakeholders of the model (Pidd, 2010). Validation of such models is very difficult 
and often involves the use of qualitative methods, rather than mathematical models to 
present viewpoints of different individuals and stakeholders.  
Models with different intended use can be employed by model developers to represent real-
world systems. A key concept here, is that these models often have different requirements 
and limitations in terms of input data and validation; thus, it is important to identify the 
nature of model intention, so the process of data acquisition and model validation is 
performed with the aim of providing enough confidence to decision makers to use the 
outcomes generated by the model. 
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For stroke care systems, Churilov and Donnan (2012) proposed four main categories of 
intended use of OR models used to address different problems in the hyperacute stroke care 
system. These are as follows: 
1. Stroke care operations improvement: (1.1) processes design and performance, risk, and 
quality measurement; (1.2) scheduling and workforce planning; (1.3) stroke specialist 
workload models; (1.4) stroke services utilization models; (1.5) social and support care 
services planning and utilization models; (1.6) ambulance service models; (1.7) equipment 
planning; (1.8) stroke units and thrombolysis facility location and layout; and (1.9) clinical 
and management decision support systems.  
2. Economic analysis: (2.1) imaging and surgical equipment evaluation and selection 
models; (2.2) optimal pricing and costing models; (2.3) stroke demand forecasting and 
planning models; (2.4) impact of prevention and knowledge dissemination policies on stroke 
care demand; and (2.5) long term evaluation of stroke burden and implications of various 
intervention strategies.  
3. Public policy: (3.1) stroke national and regional planning and network models; (3.2) 
stroke unit treatment access and availability population models; (3.3) stroke prevention and 
risk factors management models; and (3.4) risk screening subsequent to TIAs.  
4. Clinical applications: (4.1) stroke risk assessment and analysis; (4.2) stroke clinical 
decision support; (4.3) disease modelling at individual level; (4.4) drug selection and 
interaction models for stroke prevention; and (4.5) optimal therapy dose selection models. 
Each of these categories employ different modelling methodologies such as optimization 
modelling, analytical/statistical modelling, and simulation modelling to address different 
problems of the hyperacute stroke care system. These can be models used for decision 
automation, used for routine decision support, used for investigation and improvement, or 
used to provide insight. In next section, we provide a literature review to investigate the 
stroke related OR studies as reported in OR/MS literature.  
2.3 Evidence from literature 
In literature review conducted in this section, two search methodologies are used to identify 
the number of stroke related OR studies. In Section 2.3.2, we provide a short description of 
the studies found as a result of this literature review. In Section 2.3.3, we classify these 
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studies based on both the specific part of the stroke care system (problem area) being 
addressed and the nature and purpose of the modelling intervention. 
2.3.1 Literature search methodologies 
For the first search methodology, the stroke related OR studies were identified from the 
sources listed in Table 2-1. 
Database  
PubMed (no specific starting date before 2016 was fixed for this database) 
Conference Proceedings 
Winter Simulation Conference  (1971–2015)  
EURO (2007–2015) 
Journal Title 
Operations Research (1957–2016) Antimicrobial Agents and Chemotherapy (1963–
2016) 
Management Science (1929–2016) Journal of Operations Management (1980–2016) 
European Journal of Operational Research (1978–
2016) 
Omega (1973–2016) 
Computers and Operations Research (1978–2016) Annals of Operations Research (1996–2016) 
Operations Research for Health Care (2012–
2016) 
Decision Support System (1989–2016) 
The Journal of the Operational Research Society 
(1978– 2016) 
Chemosphere (1933–2016) 
International Journal of Simulation and Process 
Modelling (2005–2016) 
Preventive Veterinary Medicine (1982–2016) 
Pharmacoeconomics (1992–2016) Vaccine (1929–2016) 
Applied Health Economics and Health Policy 
(2002– 2016) 
Simulation: Transactions of The Society for 
Modelling and Simulation International (1963–
2016) 
Medical Decision Making (1981–2016) Health Policy (1984–2016) 
Current Medical Research and Opinion (1972–
2016) 
American Journal of Public Health (1954–2016) 
Journal of Simulation (2006–2016) Clinical Pharmacokinetics (1976–2016) 
Risk Analysis (1981–2016) IIE Transactions (1982–2016) 
Health Economics (1988–2016) International Journal of Nursing Studies (1965–
2016) 
Human and Ecological Risk Assessment (1998–
2016) 
Decision Analysis (1977–2016) 
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Table 2-1 List of different sources used for the selection of stroke studies in the first search 
methodology  
The search was conducted in two stages. At the first stage, we used different combinations of 
the terms “stroke”, “simulation”, and “simulation model*” as string search criteria in the 
article’s title, abstract or keywords. As a result, we found 149 articles which titles and 
abstracts were further screened to exclude both duplicates (n=9) and irrelevant studies 
(n=53). In the second stage, we screened the full text of the 87 remaining articles to include 
those which specifically addressed the stroke care system as a focus of the study or as a full 
illustrative example, as opposed to the studies not specifically focusing on stroke. This stage 
resulted in 40 studies being identified for the subsequent in-depth analysis. The summary of 
the search process is graphically presented in Figure 2-1. 
 
Figure 2-1 Flow diagram of the first search methodology for selection of the stroke related OR studies  
For the second search methodology, the stroke related OR studies we used “stroke” and 
“operations/operational research” as string search criteria in the full text of the articles 
published in Scopus database to find stroke related OR studies used to address different 
problems in the stroke care system. In total, we found 46 articles, which were further 
screened to exclude both duplicates (n=25) and the irrelevant studies (n=14). As a result, we 
included 11 articles which were specifically addressing the stroke care system as a focus of 
the study. The summary of the search process is graphically presented in Figure 2-2. 
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Figure 2-2 Flow diagram of the second search methodology for selection of the stroke related OR 
studies 
2.3.2 Literature search results  
In this section, we provide a summary of OR applications to stroke care systems as reported 
in OR/MS and clinical literature, identified as a result of the literature review conducted in 
previous section.  
We provide a reference number (in square brackets) for every study discussed to facilitate 
the future discussion in Section 2.3.3, as we classify these studies in relation to both the 
problem areas of the stroke care system and OR modelling interventions. 
[1] Parmigiani, et al. (1997) used both the Bayesian inference and resampling methods to 
quantify the cost uncertainty, effectiveness measures, and marginal cost-effectiveness ratios 
for a complex stroke prevention policy model.  
[2] Matchar, et al. (1997) used a Duke Stroke Policy Model, a continuous-time simulation 
model, to investigate the cost-effectiveness of the alternative therapies compared with 
placebo for secondary prevention of recurrent ischemic stroke patients. 
[3] Ozcan, Watts, Harris, and Wogen (1998) applied Data Envelopment Analysis (DEA) to 
investigate if there is any link between technical efficiency and care provider experience. 
The results of the study show that there is a relationship between technical efficiency, 
provider experience, and expenses.  
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[4] Lee , Vasilakis, Kearney, Pearse, and Millard (1998) used English Hospital Episode 
Statistics database to investigate the effect of weekends and public holidays on top of 
patients’ characteristics on admission and discharge patterns of aged stroke patients.  
[5] Heinrichs, Beekman, and Limburg (1999) used data from The Netherlands to model a 
patient flow in a stroke unit. Due to the high variability of admission rates for stroke patients, 
the model was used as a decision support tool to assist with the capacity planning and 
optimization in the stroke unit.  
[6] Jørgensen, Nakayama, Kammersgaard, Raaschou, and Olsen (1999) reported on using a 
mental simulation model to predict the impact of tPA on prognosis of general population of 
stroke patients. 
[7] Matchar and Samsa (1999) used a Stroke Prevention Policy Model, a semi-Markov 
simulation model, to identify the best treatment alternative for the prevention of stroke. This 
model factors the viewpoints of different stakeholders, incorporates the best evidence from 
multiple sources, and performs sensitivity analysis to assess the effect of uncertainty in the 
model parameters on the model outcomes. 
[8] Samsa, et al. (1999) described a simulation model used to perform the cost-effectiveness 
analysis of randomized controlled trials to provide a link between the short-term and long-
term effects of different treatment alternatives for the acute ischemic stroke patients. The 
authors concluded that treatment alternatives with moderate improvements in the health 
benefits for patients are more likely to be cost-effective.  
[9] Quaglini, Caffi, Cavallini, Micieli, and Stefanelli (2001) described a simulation model 
used to represent the careflow system for treating patients with ischemic stroke in a Stroke 
Unit (SU), adopted from both the process and organisational model. The simulation model 
was developed based on a database for 100 patients and was applied for identifying the 
bottlenecks in the workflow processes to optimize the recourse utilization within the stroke 
unit.  
[10] Sackley and Pound (2002) reported on the process of a panel of 12 members using the 
Nominal Group Technique, a decision making technique to conduct a formal priority-setting 
project for stroke patients of the nursing home care. This group of experts agreed on a 
discharge plan as evidenced by different experiments for the stroke patients in the nursing 
home care. 
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[11] Sundberg, Bagust, and Terént (2003) developed a model to estimate the costs associated 
with stroke services. The model was implemented by running simulations and comparing the 
results for three stages of stroke prevention, treatment and rehabilitation using a Swedish 
data. The authors concluded that the costs associated with stroke services can be reduced 
significantly by implementing a policy consists of all the three stages of stroke care. 
[12] Stahl, Furie, Gleason, and Gazelle (2003) presented the results of the cost-effectiveness 
analysis of implementing a protocol compliant with National Institute of Neurological 
Disorders and Stroke (NINDS) recommendations for ischemic stroke patients. The authors 
use Discrete Event Simulation (DES) to model the stroke care pathways from onset-to-
treatment time. Having obtained data for process times, performance of computed 
tomography, health outcomes, and cost estimates from literature, a “base-case” strategy was 
developed and compared with that of NINDS-compliant strategy based on the cost-
effectiveness analysis of the outcomes followed up by a sensitivity analysis. The authors 
conclude that applying NINDS-compliant strategy is cost-effective.  
[13] In a paper by Lee, Wang, Yau, and Somerford (2003) , the authors employed a zero-
truncated negative binomial mixed regression model to investigate how different patients’ 
characteristics at the index stroke can affect the number of readmissions. The findings of this 
study were further used to provide insight on the effect of number of readmissions on 
resource consumption, and planning of the rehabilitation and stroke care services. 
 [14] Marshall and McClean (2004) used Coxian phase-type distributions to model the length 
of stay for different groups of elderly patients (including stroke patients). The result of this 
study was expected to provide useful implications for the care providers and clinicians in 
service planning and bed allocation of the hospital wards. 
[15] Matchar, Samsa, and Liu (2005) used a continuous-time simulation model to investigate 
the cost-effectiveness of the alternative therapies using a dataset for male patients with non-
disabling stroke to measure the Quality-adjusted Life Years (QALYs), costs, and costs per 
QALYs for the patients. 
[16] Vasilakis and Marshall (2005) used different analytical and simulation modelling 
techniques to analyse the length of stay for stroke patients who were discharged from 
English hospitals over a 1-year period. The authors then provide a summary of the 
alternative methods and their similarity in terms of the parameters used to estimate the 
patient flow as calculated by the phase-type distribution and compartmental modelling 
techniques.  
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[17] Sullivan, Arant, Ellis, and Ulrich (2006)  reported on using a semi-Markov Monte Carlo 
simulation model to investigate the cost-effectiveness of a medication used to prevent stroke, 
specifically in old patients with high risk of stroke. The model was built based on an Arterial 
Fibrillation (AF) trial and a Medical Expenditure Panel Survey over 10-year time horizon to 
estimate the cost and QALYs for the patients.  
[18] Kongnakorn, et al. (2009) used Discrete Event Simulation (DES) to investigate the cost-
effectiveness of a medication used for prevention of stroke based on a trial. The simulation 
model generates two groups of patients one for those who only receive the usual care and 
one for those that also receive the medication under study. The simulation model was used to 
estimate the cost within a 5-year period and QALYs for the patient’s lifetime.  
[19] Geng, Augusto, Xie, and Jiang (2009) employed a stochastic programming model to 
assist with a faster service planning of Magnetic Resonance Imaging (MRI) examination 
used for stroke patients. In another paper, the authors reported on the effect of advance 
cancellation on system performance improvements for MRI examinations.  
[20] Garg, McClean, Meenan, El-Darzi, and Millard (2009) used stroke patients’ length of 
stay data obtained from the English Hospital Episode Statistics database and proposed an 
idea for a combined distribution using different components of Gaussian mixture and Coxian 
phase type distributions models.  
[21] Bayer, Petsoulas, Cox, Honeyman, and Barlow (2010) described a prototype model to 
support integrative planning for local stroke services by using DES to map the pathways for 
stroke patients. The authors concluded that simulation modelling provides a systematic 
approach to further understand the impact of service change and improvements within the 
system. 
[22] Bredno, Olszewski, and Wintermark (2010) used a brain perfusion simulation model to 
represent the physiological mechanisms associated with secondary stroke prevention. 
[23] Rivero-Arias, et al. (2010) reported on using both Ordinary least squares regression 
method and multinomial logistic regression with a Monte Carlo simulation approach to map 
the Modified Rankin Scale Measurement into a Generic Health Outcome. The study 
compared the performance of each of the mentioned models based on the magnitude of their 
predicted-to-actual mean health outcome tariff difference, their mean absolute and means 
squared errors, and associated 95% confidence intervals.  
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[24] Mar, Arrospide, and Comas (2010) reported on using a DES model to estimate the 
budget impact of thrombolysis on the prevalence rate of stroke-related disability in Spain and 
its consequent hospital and social costs. The results of this study suggest a decreased rate of 
dependent patients and financial savings on social communities’ budgets after 6 years.  
[25] Gillespie, et al. (2011) proposed a model associated with treating the stroke patient in a 
healthcare facility using a mixture of Coxian phase type model with multiple absorbing 
states. In the same paper, the authors also investigated whether benefits due to increase in the 
administration rate of thrombolysis would balance against its associated costs. 
[26] Hwang, Lee, and Shin (2011) designed a study in which two Korean Hospitals 
participated to investigate the effect of layout design and process improvement on the 
efficiency of the emergency departments for stroke patients. One of the participated hospitals 
employed a structured-oriented approach while the other one used a process-oriented 
approach. By comparing data before and after changes in both hospitals, the authors 
concluded that the implemented changes were effective in both hospitals, thus suggesting a 
combination of a structure-oriented and process-oriented strategy for further improvements 
in the hospitals. 
[27] Gantner-Bär, Djanatliev, Prokosch, and Sedlmayr (2011) and [28] Djanatliev, German, 
Kolominsky-Rabas, and Hofmann (2012)  used a technology assessment approach developed 
in Germany to assess the effects of using Mobile Stroke Units (MSUs) within the stroke care 
system in the metropolitan Berlin. The authors used both the System Dynamics (SD) and the 
Agent Based Simulation (ABS) to investigate the effect of using this new technology from 
perspective of different stakeholders before its implementation. The paper concludes that 
stroke patients benefit about 18% more from thrombolysis therapy by using the MSU 
technology. 
[29] Pitt, et al. (2012) used Monte Carlo Simulation (MCS) to investigate the effect of 
extended time window for thrombolysis treatment on stroke patients’ data form UK. The 
results of the study showed that, despite the benefits of the increased number of the treated 
patients due to the extended time window, the absolute benefit from thrombolysis were 
reduced by delayed treatments. 
[30] Monks, Pitt, Stein, and James (2012) used DES to investigate the stroke patients 
benefits from both reducing the in-hospital delays and extending the treatment time window 
from 3 to 4.5 hours. The study concluded that the patients’ benefits can be maximized when 
the two mentioned interventions are used to gather in the hospitals.  
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[31] Garg, McClean, Barton, Meenan, and Fullerton (2012) applied phase-type distribution 
methods to data of the stroke patients admitted to Belfast City Hospital for better hospital 
capacity planning. 
[32] AlMuhanna, et al. (2012) used a linear circuit simulation model to represent the 
anatomical mechanisms associated with the occurrence of ischemic stroke, and [33] 
Clemens, et al. (2012) used a pharmacokinetic model to investigate the effect of a 
medication dose on prevention of stroke in patients with Arterial Fibrillation (AF). 
[34] Barton, et al. (2012) used Irish data to investigate the benefits of investing on 
thrombolysis provision for the eligible stroke patients. The study used the results of survival 
analysis based on the length of stay and discharge destinations for stroke patients to create 
different groups of patients to form the basis of a DES model used to explore both the 
benefits on patient’s quality of life and the cost-effectiveness of increasing thrombolysis 
provision in the hospital, community rehabilitation and social services.  
[35] Davidson, Husberg, Janzon, Oldgren, and Levin (2013) reported on using a Markov-
based simulation model to compare the cost-effectiveness of dabigatran compared to 
warfarin used for stroke prevention. Data for Swedish patients were obtained to investigate 
the outcomes on the number of strokes prevented, life years gained, and Quality-adjusted 
Life Years (QALYs) gained. The study concluded that dabigatran is a cost-effective 
treatment in Sweden.  
[36] Geng, Xie, and Jiang (2013) reported on the results of using  new capacity reservation 
strategies to decrease the waiting times for MRI examinations for stroke patients. 
[37] Lahr, van der Zee, Vroomen, Luijckx, and Buskens (2013) reported on using a DES to 
reorganize the pre- and in-hospital pathways in community hospitals adopted from the 
organizational model performance achieved by centralized stroke care centres. The study 
investigated the number of patients treated with thrombolysis, and patient outcome at 90 
days for stroke onset to treatment time. 
[38] Lahr, van der Zee, Luijckx, Vroomen, and Buskens (2013) used a three-step simulation-
based approach to improve utilization of Tissue Plasminogen Activator (tPA) therapy for 
patients with acute brain infarction. Having identified the barriers and solutions to those 
barriers from literature and expert consultation, the authors used DES to test the solutions 
identified for Dutch acute stroke pathway. The results of this study showed that the tPA 
treatment rates and efficacy of thrombolysis can be increased by using a scoop-and-run 
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protocol for ambulance personnel and point-of-care diagnostic device instead of laboratory 
technician. 
[39] Churilov, et al. (2013) used a DES model to show how multi-factorial interventions in 
prehospital acute care system will impact the eligibility of acute stroke patients to receive 
thrombolysis treatment. 
[40] Yang, Chen, Chitkara, and Xu (2014) used a Markov simulation model to compare the 
long-term effect of three medications (aspirin, clopidogrel, and clopidogrel plus aspirin) used 
for prevention of stroke or transient ischemic attack (TIA) in patients with intracranial artery 
stenosis, demonstrating that an increased benefit of treatment with clopidogrel plus aspirin. 
[41] Ghijben, Lancsar, and Zavarsek (2014) used a Discrete Choice Experiment to 
investigate the patients’ preferences with different medications used for stroke prevention in 
patients with AF. The study used data for seventy-six participants, who completed the study 
followed up by an interview to check whether patients had moderate-to-high risk of stroke. 
Following the simulation-based sensitivity analysis, the study concluded that new 
medications are more cost-effective when compared to the currently most used medications. 
[42] Lich, et al. (2014) described a SD model to investigate the effect of different scenarios 
of prevention and rehabilitation interventions on reducing the burden of disease for stroke 
patients using the US Veteran population data. Different outcomes reported in this study 
were QALYs, stroke prevented, stroke fatalities prevented, and the number-needed-to-treat 
per QALY gained.  
[43] Aronsson, et al. (2015) presented the results of the cost-effectiveness analysis of 
screening patients with atrial fibrillation (AF) using an analytic Markov simulation decision 
support model. In this study, data was generated for 1000 individual patients, whom matched 
population data from STROKESTOP study. 
[44] Vidyanti and Basurto-Davila (2015) used a MCS model to investigate the cost-
effectiveness of policies involve reducing the level of dietary sodium on prevention of the 
hearth disease and stroke for residents of the Los Angeles County. 
[45] Mobbs, Boness, and Polden (2015) reported on using a DES to review the efficiency of 
service provision in the East of England Ambulance Service Trust (EEAST). Subsequent to 
the review, the authors assessed the potential gains for different stakeholders of the system 
by providing higher levels of performance. 
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[46] Micieli, Wijeysundera, Qiu, Atzema, and Singh (2016) used a patient-level Markov 
micro-simulation decision support model to assess the cost-effectiveness of two new 
medications compared to a commonly used medication for stroke patients with atrial 
fibrillation. 
[47] Monks, et al. (2016) used DES model as a tool to predict the number of patients at 
different stages of stroke care system from admission time in a stroke care unit through to 
rehabilitation services and patients’ discharge. The model can be used as a Decision Support 
(DS) tool for capacity planning of the stroke care pathways with an increased precision 
compared to previous methods published in literature. 
[48] Hoffmeister, et al. (2016) presented the results of the DES used to model the effect of an 
increased rate of thrombolysis administration on the prevalence of disability at population 
level for stroke patients. The authors conclude that the minimum rate of tPA to have an 
increased benefit for the stroke population is 12%.  
[49] Pandya, et al. (2016) used a microsimulation model to investigate how mismatch 
information obtained from two MRI techniques can be used to estimate the stroke onset time 
for ischemic stroke patients with unknown time of stroke onset. 
[50] Kypridemos, et al. (2016) presented the results of a microsimulation study to investigate 
the effect of universal screening on disease burden and related social and economic factors 
for cardiovascular disease, specifically focussing on heart attacks and strokes. The authors 
also compared their selected strategy with other feasible strategies. 
[51] Islek, et al. (2016) reported on using a Markov model to predict the effect of ischaemic 
stroke treatment on deaths associated with Stroke and Ischemic Heart Diseases, while 
comparing this strategy with system level policies for a population in Turkey.  
By reviewing the studies presented in this section, it can be concluded that the application of 
OR tools and techniques to address different problems in stroke care system has been long 
the interest of many researchers and OR practitioners. In next section, we adopt a conceptual 
framework proposed by Churilov and Donnan (2012) to classify these studies in relation to 
both the specific part of the stroke care system being addressed  and the nature of the OR 
modelling intervention. 
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2.3.3 Classification of OR studies in stroke care 
Table 2-2 summarizes the positioning of the stroke related OR studies reviewed above in 
relation to both the specific part of the stroke care system (problem area) being addressed 
and the nature and purpose of the modelling intervention as per Churilov and Donnan 
(2012). In this table, we use the reference numbers (in square brackets) of studies reported in 
Section 2.3.2 to refer to each study. 
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Interventions Problem areas 
 
Stroke 
prevention 
Pre-hospital 
stroke care 
Improving 
information 
support 
Transient 
Ischaemic Attack 
Stroke unit care Rehabilitation Social and 
community care 
Stroke networks Stroke care 
expertise 
Financial 
viability 
O
p
er
a
ti
o
n
s 
im
p
ro
v
em
en
t 
1.1 [37], [38], [12], 
[39], [28], [27] 
  [29], [37], [30], 
[38], [12], [9], [5], 
[16], [42] 
[12], [21], [19], 
[26], [36] 
[12], [21] [21]    
1.2  [37], [12], [21], 
[28], [27] 
  [37], [12], [9], [5], 
[21] 
[12], [21] [12], [21] [21]   
1.3     [12], [9], [5] [12] [12]    
1.4  [37], [38], [28], 
[27] 
  [29], [2], [7], [37], 
[30], [38], [34], 
[24], [12], [9], [5], 
[16], [4], [14], 
[19], [31], [36] 
[2], [7], [34], 
[24], [12] 
[2], [7], [34], 
[24], [12], [4], 
[31] 
   
1.5 [42] [21]   [21], [4], [31] [21], [42] [21], [42], [4], 
[10], [31] 
[21]   
1.6  [37], [38], [39], 
[21], [28], [27], 
[45] 
  [37], [12], [21], 
[4] 
[12], [21] 
 
[12], [21] [21]   
1.7  [37], [21], [28], 
[27] 
  [37], [12], [9], 
[21], [4], [14], 
[19], [36] 
[12], [21] [12], [21], [4] [21]   
1.8     [26]      
1.9  [37], [38], [39], 
[21], [28], [27], 
[45] 
  [29], [37], [38], 
[12], [9], [5], [16], 
[21], [47] 
[12], [21], [47] [12], [21] [21]   
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E
co
n
o
m
ic
 a
n
a
ly
si
s 
2.1           
2.2  [28], [27]   [25]     [25] 
2.3  [21]   [9], [21], [13], 
[20], [47] 
[21], [3], [13], 
[47] 
[21], [3] [21] [3] [3] 
2.4 [11], [51]     [11]    [11] 
2.5 [35], [2], [7], 
[8], [17], [41], 
[1], [18], [42], 
[33], [11], [44], 
[46], [50], [51] 
  [43] [15], [2], [7], [8], 
[17], [41], [1], 
[34], [24], [12], 
[18], [25], [48] 
[15], [2], [7], 
[8], [17], [41], 
[1], [34], [24], 
[12], [18], [42], 
[11] 
[15], [2], [7], 
[8], [17], [41], 
[1], [34], [24], 
[12], [18], [42] 
 [15] [23], [11], [25], 
[43] 
 
 
 
 
 
P
u
b
li
c 
p
o
li
cy
 
3.1 [42] [37], [21]   [37], [21], [42] [21], [42] [21], [42] [21]   
3.2  [39], [21], [28], 
[27] 
  [37], [21], [48] [21] [21] [21]   
3.3 [40], [35], [15], 
[2], [7], [8], 
[17], [41], [1], 
[18], [42], [33], 
[50], [51] 
 [40] [15], [2], [7], [8], 
[17], [41], [1], 
[18] 
[15], [2], [7], [8], 
[17], [41], [1], 
[18], [42] 
[15], [2], [7], 
[8], [17], [41], 
[1], [18], [42] 
    
3.4           
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C
li
n
ic
a
l 
a
p
p
li
ca
ti
o
n
 
4.1           
4.2  [28], [27]   [29], [30], [34], 
[24], [12], [6], 
[49] 
[34], [24], [12] 
 
[34], [24], [12]    
4.3 [7], [8], [1], 
[32], [22] 
   [2], [7], [1] [2], [7], [1] [2], [7], [8], [1]    
4.4 [40], [35], [15], 
[17], [41], [18], 
[44], [46] 
  [40] [15], [17], [41], 
[18] 
[15], [17], [41], 
[18] 
[15], [17], [41], 
[18] 
   
4.5 [33]          
Table 2-2 OR modelling studies in stroke care by problem areas and the purpose of the modelling. 
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As the result, we found that the following interventions have been addressed more actively 
than others: stroke care process design and performance, stroke team scheduling and 
workforce planning, stroke services planning and utilization models, long term evaluation of 
stroke burden, stroke prevention and risk factors management models, and stroke clinical 
and management decision support models. On the other hand, there was a lack of attention to 
interventions such as stroke units and thrombolysis facility location and layout, imaging and 
surgical equipment evaluation and selection models, optimal pricing and costing models for 
stroke care and insurance, impact of prevention and knowledge dissemination policies on 
stroke care demand, risk screening subsequent to TIAs, stroke risk assessment and analysis, 
and optimal therapy dose selection models.  
With regard to different problem areas, stroke prevention, pre-hospital, stroke unit care, 
rehabilitation and social and community care parts were identified as the most addressed 
areas; while information and support for stroke patients, appropriate management of TIAs, 
appropriate stroke care expertise, and financial viability were addressed least in the 
literature. The models developed in this thesis provide insights on the long-term impacts of 
faster access to treatment interventions for stroke patients, thus addressing the problems in 
the pre-hospital stroke care, stroke unit care, and appropriate stroke care expertise problem 
areas. 
2.4 Summary and conclusions  
In this chapter, we first provided a background to hyperacute stroke care system followed by 
reviewing the stroke care processes as reported in key policy documents by different 
countries. These is served as an introduction to the problem domain of this thesis, thus 
providing a background to first and second research questions proposed earlier in Chapter 1. 
Given the background to hyperacute stroke care system, we then discussed how we can use 
OR models with different intended use and interventions to address different problems in the 
hyperacute stroke care system. The key message here was that models with different 
intended use have different needs in terms of data requirements and validation. Discussion 
on this topic eventually provided a background to third research question of this research. 
In last section, we reported on methodology and results of a literature review conducted to 
demonstrate how OR models can be used to address different problems of the stroke care 
system. We then classified the stroke-related OR studies found as a result of this literature 
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search in relation to both the specific part of the stroke care system (problem area) being 
addressed and the nature and purpose of the OR modelling intervention as per Churilov and 
Donnan (2012). Although we found that problem areas in the field of pre-hospital and stroke 
unit care have been now addressed for many years by different OR modelling interventions, 
with recent advances in the hyperacute stroke care system, there is a need for OR models to 
further address the new questions raised by the clinicians in these areas. OR models 
developed in this thesis are used to address some of these questions. 
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 Chapter 3: Validation of health OR models for investigation and improvement 
Introduction  
In this chapter, we address the third research question of this thesis: ‘What are the 
conceptual and application issues of conducting comprehensive validation of an OR model 
for investigation and improvement in the context of health systems and service operations?’  
In Chapter 2 of this thesis we discussed that OR models for investigation and improvement 
are used to “support investigations that are relatively unique, which may involve system 
design, system improvement or just an attempt to gain understanding of a very complex 
situation” (Pidd, 2010, p. 18). According to Schlesinger, et al. (1979, p. 3), model validation 
is referred to as the “substantiation that a model within its domain of applicability possesses 
a satisfactory range of accuracy consistent with the intended application of the model”. 
According to Sargent (2013), validation of Operations Research (OR) decision models 
should be performed by model developers to increase the credibility of the model and its 
results before using the model’s recommendations to assist with decision making. In the 
context of health systems, OR models have often very complex nature as they rely on wide 
variety of data sources and parameters obtained from clinical literature, and thus validation 
of such models involves systematically validating different aspects of the model. 
Additionally, as discussed in Chapter 2, there is a relationship between the intended use of 
the model and its validation, which suggests using appropriate validation methods and 
techniques for models with different intended use to ensure that model can be used 
confidently by model users within its specified domain. 
In this chapter, we discuss validation of health OR models used for investigation and 
improvement as follows: In Section 3.1, we discuss different conceptual and application 
issues (e.g. lack of empirical data to validate model behaviour, using multiple sources to 
obtain model inputs) of validating complex OR models used for investigation and 
improvement in the context of health systems. We then dedicate Section 3.2 to the review of 
general approaches to model validation proposed in OR/MS literature by different authors. 
These general approaches are used later in this chapter to design and develop a generic 
validation framework. By developing this framework, we contribute to OR/MS literature by 
demonstrating how structured set of validation techniques adopted from literature in the four 
categories of data validation, conceptual model validation, computational model 
verification, and operational validation can be used to validate complex OR models. Since 
this validation framework is developed by reviewing the general validation approaches 
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reported in OR/MS literature, this framework is generic and can be applied to both health 
and non-health OR models. In Chapters 4 and 5 of this thesis we use this framework to 
systematically address different validation aspects of three health OR models in the context 
of hyperacute stroke care system, thus demonstrating how comprehensive validation of a 
complex OR model for investigation and improvement in the context of health systems and 
service operations can be conducted. 
The content of this chapter is partially based on the paper “Validation of a decision support 
model for investigation and improvement in stroke thrombolysis”, published in the European 
Journal of Operational Research in 2016 (Keshtkaran, et al., 2016). 
3.1 Validation of the models for investigation and improvement  
As discussed in Chapter 2, OR models with different intended use can be employed by 
model users to explicitly represent specific parts of different systems (Pidd, 2010). 
According to Pidd (2010), OR models can be used for decision automation, models for 
routine decision support, models for investigation and improvement, and models to provide 
insight.  
OR models used for investigation and improvement, can be employed to provide better 
understanding of a new real-world system which may not even physically exist or may be in 
the process of being designed. For this type of models, often there is very limited amount of 
empirical data available on the system behaviour, or even none at all (OR models developed 
in Chapter 4 and 5 of this thesis are of this type); therefore, empirical validation of the model 
is very challenging. In models for investigation and improvement, the accuracy needed is 
usually obtained by critically testing all the parameters and assumptions used to build the 
conceptual model, thus providing an improved understanding of the model boundaries; while 
the “output-based” validation of the model is not usually possible.  
Validation of OR models used for investigation and improvement in the context of health 
systems and service operations is even more challenging, due to wide variety of data sources 
and parameters used for model development. While often various elements used to develop 
such models are obtained from clinical literature and other relevant sources, there is more 
complexity in health OR models due to interactions between different modelling elements. 
These interactions often exist between different parameters and model inputs obtained from 
multiple sources. Therefore, it is important to use structured set of validation techniques and 
methods for systematically addressing different aspects of model validation. This ensures 
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that model and its results have enough credibility to be used within their specified domain by 
the users. 
In the next section, we provide review of the four general categories of model validation as 
reported in OR/MS literature: data validity, conceptual model validity, computational 
verification, and operational validity. 
3.2  General approaches to model validation  
According to Schlesinger, et al. (1979, p. 3), validation is the “substantiation that a model 
within its domain of applicability possesses a satisfactory range of accuracy consistent with 
the intended application of the model”. Other notions used in OR/MS literature are 
validation, verification, acceptability, and credibility, which are mainly used to address the 
confidence of model developers/users in using an OR model for its proposed application 
(Pidd, 2003). There is a strong link between these concepts, while the differences are often 
subtle: for example, the terms validation and verification are frequently used together, where 
verification is understood as the process of ensuring that a computerized model has 
implemented accurately to represent a conceptual model (Sargent, 2013; Schlesinger, et al., 
1979). Acceptability “usually refers to the entire study, which includes the model and is also 
clearly a reflection of the relationship between the modeller(s) and the user or client” (Pidd, 
2003, p. 298). Finally, Robinson (2002) describes credibility as the confidence of the model 
users and clients in using a model and its results. In this research we use the terms validity 
and validation to refer to this broad spectrum of related concepts and relevant techniques and 
methods used for assessing OR models.  
It is important to mention that while many authors repeatedly refer to different categories of 
model validation and corresponding techniques since early 1970s, it was Gass (1977, 1983) 
and Sargent (1979, 2013) who comprehensively summarized different categories of 
validation techniques. In the context of simulation model development, Sargent (1979, 2013) 
proposed a “development process” (2013, p.14) based on four categories of validation 
activities as well as a generic structure for model validation documentation (2013, p.22). 
Gass (1983) clearly outlined different categories of model validity and provided 
comprehensive discussion of specific technical steps involved in decision model validation.  
In this research we utilize both Sargent’s (2013) approach and that of Gass (1983) and 
categorize our subsequent review of the OR models’ validation into following four 
categories: data validity (Balci, 1989; Gass, 1977; Oral & Kettani, 1993; Sargent, 2013), 
conceptual model validity (Balci & Nance, 1985; Gass, 1983; Oral & Kettani, 1993; Sargent, 
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2013), computational verification (Adrion, Branstad, & Cherniavsky, 1982; Chattergy & 
Pooch, 1977; Deutsch, 1981; Dunn, 1987; Gass, 1983; Myers, 1978; Sargent, 2013; 
Schlesinger, et al., 1979; Whitner & Balci, 1989; Williams & Sikora, 1991), and operational 
validity (Boehm, Brown, & Lipow, 1976; Gass, 1977; Sargent, 2013).  
3.2.1 Data validation 
The purpose of data validation is to ensure that “the data necessary for model building, 
model evaluation and testing, and conducting the model experiments to solve the problem 
are adequate and correct” (Sargent, 2013, p. 14). Balci (1989) describes data validation as 
assuring that both input data and model parameters have the required accuracy, 
completeness, impartiality and appropriateness for the proposed objectives of the model. 
Historically, empirical disciplines such as health and social sciences emphasize examining 
the accuracy, consistency, and completeness of the study data (Rothman, Greenland, & Lash, 
2008). Oral & Kettani (1993) proposes a number of goals for a data validation procedure – 
these include ensuring data sufficiency, accuracy, appropriateness, availability, 
maintainability, reliability, as well as the  feasible cost of data collection and manipulation. 
For the OR/MS models, Gass (1983) distinguishes between raw data and structured data, i.e. 
the raw data that has undergone some types of manipulation. Three desirable properties for 
raw data validation are then recommended: accuracy, defined as “the ability to correctly 
identify, obtain, and measure what is desired”, impartiality, i.e. “the assurance that the data 
are recorded correctly”, and representativeness, namely “the assurance that the universe 
from which any sample data are drawn is properly identified and the sample was 
random”(Gass, 1983, p. 612). For the structured data validation, the emphasis should be 
placed on the auditing of every step of data manipulation before the data are used as a part of 
the OR model (Gass, 1983). 
Although there is a broad consensus in OR/MS literature as to what constitutes data validity, 
the recommendations in the literature as to how to perform data validation for an OR model 
are much less frequent. Empirical disciplines, including health sciences, emphasize the 
procedures of obtaining data and empirical estimates from accredited data sources and 
published research (Biau, Kernéis, & Porcher, 2008; Ellenberg, 1994). There is a strong 
emphasis on sampling procedures and sample size estimations to ensure that the precision 
and applicability of the outputs are adequate for the intended purpose of the study (Biau, et 
al., 2008). The recommendations also include screening the data for any unspecified outliers 
and missing values which might have been developed during the sampling process, or while 
raw data are being transformed to any type of structured data (Balci, 1989; Sargent, 2013). 
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According to Liu, Cheng, and Wu (2002) outliers either relate to measurement errors or 
phenomena of interest. Two methods that can be applied to locate outliers are the outlier 
identification and outlier accommodation (Lin & Brown, 2006). In the outlier identification 
the goal is to detect the outliers and decide whether they should be accepted or rejected 
(Hawkins, 1980), while in outlier accommodation, the researchers try “to develop some 
robust estimates that are insensitive to the existence of outliers” (Lin & Brown, 2006). 
Lastly, it is important to ensure that we document both raw input and parameters data, as 
well as all data modifications properly (Balci, 1989; Gass, 1983; Sargent, 2013; Williams & 
Sikora, 1991). 
In summary, variety of data validation approaches have been suggested by different authors 
in OR/MS literature which should be selected and utilized for model validation based on its 
intended use. For models used for investigation and improvement, data validation is 
especially very important while the “output-based” validation of the model is not often 
possible and thus, it is important to validate all the model inputs and parameters used to 
develop the model.  
3.2.2  Conceptual model validity  
Compared to the discussions on data validity, various aspects of conceptual model validity 
are studies in OR/MS literature in greater detail. Sargent (2013) defines the goals of the 
conceptual model validation as to ensure that the assumptions and theories used to build the 
model are correct, as well as that there is a “reasonable” logical, mathematical and causal 
relationship in place for the intended use of the model. Gass (1983) describes three main 
groups of assumptions that should be examined to achieve conceptual model validity as 
follows:  
 mathematical assumptions about the model structure;  
 content assumptions that are used to define terms and variables of the model; and 
 causal assumptions that reflect the hypothesized relationships between terms and 
variables.  
In addition, to ensure logical and mathematical validity, Gass (1983) suggests to check the 
accuracy of the mathematical and numerical calculations, to check the accuracy of the 
logical flow of data and relevant results, and to ensure that none of the essential variables in 
the model or their relationships have been neglected. The role of the conceptual model 
validation, according to Oral & Kettani (1993), is in examining the “appropriateness of the 
process of obtaining and using mental data bases”. Following a similar line of thought, Balci 
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and Nance (1985, p. 16) refer to the “formulated problem” verification as "substantiation 
that the formulated problem contains the actual problem in its entirety and is sufficiently 
well structured to permit the derivation of a sufficiently credible solution".  
According to OR/MS literature, different procedures can be used to validate the conceptual 
model. Balci (1994) and Sargent (1986) suggest the application of the graphical models (e.g. 
Event Graphs (Schruben, 1983), Data Flow Diagrams (Batini, Nardelli, & Tamassia, 1986)) 
to provide better understanding of the conceptual model and its specifications. The choice of 
these graphical models often depends on the required level of representation by the 
conceptual model. 
“Face validation” or “expert opinion” is another validation technique suggested by different 
authors (Balci, 1994; Hermann, 1967; Oral & Kettani, 1993; Williams & Sikora, 1991). 
Sargent (2013) refers to this as systematic investigation of the subjective opinions of 
individuals working on the model in order to examine whether the model and its behaviour 
are logical. Similarly, Gass (1983, p. 611) points out to the question of whether “the initial 
impression of the model’s realism is positive when reviewed by decision makers who know 
the system being modelled.” Finally, “structured walkthrough” – i.e. the process of 
explaining the model by the model developer to a peer group, is used to obtain the level of 
the accuracy of the conceptual model required for the intended use of the model (Balci, 
1994; Sargent, 2013). As discussed in Chapter 2, for OR models used for decision 
automation and routine decision support, there is often very little tolerance for the errors in 
the model outcomes, while for the models used for investigation and improvement the results 
generated by the model are often an approximation and design and development of more 
precise methods is necessary to increase the precision of the outcomes generated by the 
model. 
Another group of tests are techniques used to verify the logical behaviour of the model and 
all of its sub-models (Balci, 1989; Gass, 1983; Oral & Kettani, 1993; Schellenberger, 1974; 
Williams & Sikora, 1991). Such techniques are “tracing” where the logical behaviour of a 
model entity is checked to verify its correctness and accuracy (Balci, 1994; Sargent, 2013), 
the “degeneracy test” by verifying that inputs and internal parameters have reasonable values 
(Gass, 1983; Sargent, 2013), and the “data relationship correctness” test, to ensure that all 
data in the model have the “proper values regarding relationships that occur within a type of 
data, and between and among different types of data” (Sargent, 2013, p. 16). While some of 
these techniques can only be applied for conceptual model validation, validation tests such as 
“data relationship correctness” and “degeneracy test” can be used to ensure both data 
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validation and conceptual model validity. Lastly, it is also suggested to apply appropriate 
mathematical and statistical methods (e.g. mean, median, prediction intervals) to test the 
main theories and assumptions of the model to ensure that the logical behaviour of the model 
is correct (Balci, 1994; Gass, 1983; Schellenberger, 1974). 
As reviewed in this section, different techniques can be used by model developers to ensure 
that the conceptual model has enough accuracy for its intended use. For models used for 
investigation and improvement the conceptual model validation is especially very important 
to ensure that the assumptions and logical behaviour of the model are accurate enough within 
the scope of model use. In the next section, we discuss how computational model 
verification tests can be utilized for correct implementation of the conceptual model. 
3.2.3 Computational model verification 
The purpose of the computational model verification is to check the logic of the computer 
program and to ensure that all the numerical and data procedures based on the conceptual 
model have been implemented correctly (Gass, 1983). Not surprisingly, this topic has 
attracted major attention in the computer and computational science literature (Adrion, et al., 
1982; Chattergy & Pooch, 1977; Deutsch, 1981; Dunn, 1987; Myers, 1978; Sargent, 2013; 
Schlesinger, et al., 1979; Whitner & Balci, 1989; Williams & Sikora, 1991). 
In one of the earliest articles in this subject, Fairly (1976) suggests two main approaches to 
computational model verification: static and dynamic testing. Static testing is aimed to verify 
the correctness of the computer code of the computational model; while in dynamic testing 
the computer code is executed under different scenarios, and the outcomes are used to 
identify whether the code and its execution are correct. Balci (1994) and Balci and Nance 
(1985) suggest different techniques for validation, verification, and testing (VV&T) of the 
computational models. Some of these include debugging, walkthrough and execution 
tracing. Debugging is the process of locating the errors, correcting them and checking the 
computer program of the computational model to confirm the code correctness (Whitner & 
Balci, 1989). Although debugging is usually a long and non-trivial task, it is an inevitable 
part of the computational model verification process (Dunn, 1987).  
While both tracing and walkthrough techniques were mentioned in previous section as part 
of methods used for validation of the conceptual models, they can also be used for obtaining 
the computational verification of the OR models. The term walkthrough refers to “an effort 
to locate the flaws in the design and/or source code” by the model development team 
(Whitner & Balci, 1989, p. 7). Different authors refer to this as “structured walkthrough” 
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(Adrion, et al., 1982; Deutsch, 1981; Myers, 1978; Sargent, 2013), with Yourdon (1979) 
identifying seven different roles for this task which usually can be performed by a group of 
three members. Finally, execution tracing can be used with debugging to help the model 
builder with isolating the identified errors in the code script and is described as “locating 
model defects by watching the line-by-line execution activity of the model” (Whitner & 
Balci, 1989, p. 22).  
In summary, the literature on computational model verification shows variety of tests and 
techniques suggested by different authors which should be selected and utilized for OR 
models verification based on their intended use. In some cases, the choice of computational 
verification technique depends on the computer program used to build the model. For 
instance, for simulation models model developers often use dynamic techniques such as 
simulation animation for execution tracing of the model, while static techniques can be often 
used for computational verification of both simulation and non-simulation computer 
Software. 
3.2.4 Operational validity 
Operational validity refers to the accuracy of the model’s outputs being sufficient for the 
model’s intended use (Boehm, et al., 1976). Gass (1983) sees the role of operational validity 
as that of justifying the use of the model based on the observed and expected errors of the 
model. Similarly, Sargent (2013) defines the operational validity of an OR model as the 
degree to which the model’s outputs satisfy the accuracy requirements based on the intended 
use of the model and its applicability.  
Specific techniques and tests employed to examine the operational validity of the model 
include model output analysis, robustness analysis, comparison to the results produced by 
other models, and tests to validate an appropriate application of the model (Boehm, et al., 
1976; Gass, 1983; Pidd, 2010; Sargent, 2013). 
For output analysis, different types of visual graphs (e.g. histograms, pie charts, Venn 
diagrams) and analytical techniques (e.g. mean, median, prediction intervals, confidence 
intervals range) are usually employed to verify the accuracy of the model’s output (Balci, 
1994; Gass, 1983; Sargent, 2001). Gass (1983) and Boehm et al. (1976) advocate the use of 
robustness test through checking the model’s behaviour while changing parameters and 
inputs of the model. Whitner and Balci (1989), Balci (1994) and Sargent (2013), refer to 
extreme conditions test for testing the credibility of the model structure and output for any 
extreme value of the internal parameters, similar to the “degeneracy test” described earlier in 
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this chapter used to validate the conceptual model. Similarly, Myers, Sandler, and Badgett 
(2011) suggest application of boundary analysis technique which is used to observe the 
changes in model behaviour while changing the model inputs in specified manners.  
Wherever possible, it is important that the results of the developed OR model are compared 
to the results of other previously validated models (Williams & Sikora, 1991). Within the 
context of simulation models, this comparison can be made between two validated 
simulation models (Sargent, 2013). Finally, as suggested by Pidd (2010) and (Gass, 1983), 
the decisions made based on the model outputs should be verified in terms of the intended 
use of the model. 
In summary, the importance of model validation for OR models, as well as the specific 
methods and techniques for model validation, have been extensively addressed in the 
OR/MS literature with some techniques applicable to more than one area (e.g. tracing, 
walkthrough, data relationship correctness). At the same time, most of the effort in OR/MS 
model validation literature has been limited to broad descriptive articles and only little is 
reported on the specific cases of comprehensive validation of individual OR models in 
OR/MS literature.  
3.3 Systematic review of specific examples of validating OR models in Health 
OR/MS literature 
In this section, we conduct a systematic literature review to demonstrate the limited extent of 
studies reporting on comprehensive validation of OR models as found in OR/MS literature. 
In this chapter we explicitly limit the scope of the search to non-simulation OR models. 
Reasons for such a choice are as follows: firstly, the domain of simulation modelling within 
OR/MS is well known for its careful attention to detailed model validation (Balci, 1989; 
Sargent, 2001, 2013; Whitner & Balci, 1989), and secondly, as discussed by Brailsford and 
Vissers (2011), the domain of health care simulation modelling applications is expanding by 
the rate of up to 30 papers per day and conducting a comprehensive review of such a body of 
literature deserves its own special focus (such as in, e.g., (Fone, et al., 2003) and (Karnon & 
Afzali, 2014) and would have been impossible within the scope of this research. Lastly, 
although in this research we rely on numerical simulation for OR models used for 
investigation and improvement of the hyperacute stroke care system, none of the models 
developed in this thesis belong to the well-recognized classes of the simulation conceptual 
models including Discrete Event Simulation (DES), System Dynamics (SD), and Agent 
Based Simulation (ABS). 
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3.3.1 Literature search methodology 
To illustrate the extent of comprehensive model validation studies of OR models reported in 
health OR/MS literature, in December 2016 we conducted a systematic search of online 
journal archives of the following ten most popular OR/MS and DS journals: Health Care 
Management Science, Operations Research, Management Science, Journal of Operations 
Management, European Journal of Operational Research, Omega, Computers and 
Operations Research, Journal of the Operational Research Society, Annals of Operations 
Research, Operations Research for Health Care, and Decision Support Systems.  
The search was conducted in two stages. At the first stage, we used the “health*” & “model” 
& “valid*” strings as the search criteria in the full text of the online archives of the 
mentioned journals, initially identifying 1247 articles. These articles were then screened to 
ensure that only non-simulation studies that have reported on comprehensive validation of an 
OR model in the context of health systems and services applications are included. This 
resulted in inclusion of 148 articles for further study. 
At the second stage, the “valid”, “validated”, “validity” and “validation” strings were used as 
the search criteria to search the contents of the remaining 148 articles for the description of 
the validation tasks undertaken in this research. Four broad validation categories described in 
Section 3.2 of this chapter (data validation, conceptual model validation, computational 
model verification, and operational validation), formed a classification system and we 
classified each identified paper as belonging to one or more of these validation categories 
based on the reported validation activities performed in that paper.   
3.3.2 Literature search results 
The non-simulation health OR studies selected for this review were identified from ten most 
popular OR/MS and DS journals. Table 3-1, presents the number of studies identified in each 
of these journals from the first stage of literature search. 
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Year  Publication title  
Number of articles from 
keyword search  
1998- 2016 Health Care Management Science 160 
1971-2016 Operations Research  25 
1971-2016 Management Science 61 
1980-2016 Journal of Operations Management 81 
1977-2016 European Journal of Operational Research 330 
1973-2016 Omega 116 
1974-2016 Computers and Operations Research 90 
1971-2016 
The Journal of the Operational Research 
Society 
111 
1984-2016 Annals of Operations Research 100 
2012-2016 Operations Research for Health Care 20 
1985-2016 Decision Support System 153 
Total Number 1087 
Table 3-1 Summary of a systematic review of specific examples of Validating OR models in Health 
Operations Research/Management Science literature 
As the result, we identified 12 studies that reported on performing some data validation only, 
53 studies reporting elements of conceptual model validation only, and 28 articles reporting 
some operational validation as the only validation approaches applied or discussed in the 
study. Eight studies reported some aspects of both data and conceptual model validation, 29 
studies included elements of both conceptual and operational validation, and further five 
studies reported addressing data as well as operational validation issues. Finally, as presented 
in Figure 3-1 only 13 articles simultaneously address some aspects of data, conceptual 
model, and operational validation. Below we presents some examples of these articles: 
 Blake and Carter (2002) in the “A goal programming approach to strategic 
resource allocation in acute care hospitals” paper where authors report on using 
the linear goal programming models for strategic resource allocation in health 
services; 
 Zanakis et al. (2007) in the “Scio-economic determinants of HIV/AIDS pandemic 
and nations efficiencies” paper where the authors investigate the effect of 
epidemic HIV/AIDS socio-economic determinants across different countries; 
 Junglas et al. (2009) in the “Mobile technology at the frontlines of patient care: 
understanding fit and human drives in utilization decisions and performance” 
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paper employ both qualitative and quantitative techniques to report on medical 
staff decisions on using mobile technologies in healthcare centres; 
 Duque, Castro, Sörensen, and Goos (2015) in the “Home care service planning. 
The case of Landelijke Thuiszorg” paper report on using an optimization 
decision support model used to provide assistance in service planning for a 
“social profit” organization; 
 Gardner, Boyer, and Gray (2015) in the “Operational and strategic information 
processing: complementing healthcare IT infrastructure” paper use different 
methods to examine the Healthcare Information Technologies and their impacts 
on patient satisfaction; 
 Kortbeek, Braaksma, Smeenk, Bakker, and Boucherie (2015) in the “Integral 
resource capacity planning for inpatient care services based on bed census 
predictions by hour” paper use an analytical approach to investigate the effect of 
strategic, tactical, and operational decisions on bed occupancy in medical care 
units; and 
 Keshtkaran, et al. (2016) in the “Validation of a decision support model for 
investigation and improvement in stroke thrombolysis” paper demonstrate how a 
complex decision support model for investigation and improvement in the 
context of hyperacute stroke care system can be systematically validated. 
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Figure 3-1 The process of identifying specific cases of OR model validation in Health OR/MS  
The true extent to which various studies have reported validation issues of the OR models 
varied broadly, with the majority of the studies only claiming the fact of the application of 
one or more validation techniques or tests without providing sufficiently detailed information 
regarding the validation procedures or their results. One of the rare exceptions to this trend is 
the study by Blake and Carter (2002) in which the authors have provided an extensive 
section on theoretical, data and predictive validity of the model using a three-phase 
validation approach proposed by Schellenberger (1974). Another example is a study by 
Mason, Denton, Shah and Smith (2014) who employed a Markov decision process model to 
identify the optimal timing of blood pressure and cholesterol treatment for diabetes patients. 
The authors devoted a separate section to model validation, where data validation and 
comparison of model outputs to other validated models are discussed and a brief report on 
the validation procedures and outcomes are provided.    
In summary, despite both well-recognized need for appropriate validation of OR models in 
the OR/MS literature and the relative abundance of health OR/MS models reported in the 
literature, only very few health non-simulation OR/MS publications could be identified that 
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not only mention the fact of performing one or more OR model validation activities as a part 
of the reported study, but also systematically discuss both the process and the results of the 
undertaken OR model validation activities. 
3.4 A proposed generic framework for validation  
As a result of literature search, we identified that there is a research gap in the reported 
knowledge about practical aspects of how to validate an OR model excluding simulation 
models for investigation and improvement in the context of health systems and service 
operations. To address the identified research gap and to contribute to OR/MS literature, we 
specified the research question as follows:  What are the conceptual and application issues of 
conducting a comprehensive validation of an OR model for investigation and improvement 
in the context of health systems and service operations? To answer this research question we 
propose a generic validation framework which can be used to validate complex OR models 
for investigation and improvement. 
We base our proposed framework on four categories of data validity, conceptual model 
validity, computational verification, and operational validity, as specified earlier in Section 
3.2 of this chapter as the four generic aspects of model validation. For each category of 
model validation, we document the process of validation by addressing the applied validation 
task, motivation of each validation task (i.e. Why), the process of performing the validation 
task (i.e. How), and the conclusions/results achieved by the validation task. In this 
framework, we refer to following validation techniques for each aspect of model validation: 
1. Validation tasks relevant to data validation: representativeness of the dataset, proper 
documentation of the data components, searching for outliers, and searching for 
missing values. 
2. Validation tasks relevant to conceptual model validation: degeneracy tests, data 
relationship correctness, tracing, mathematical and statistical validation methods, 
and structured walkthrough. 
3. Validation tasks relevant to computational verification: debugging, walkthrough, 
and execution tracing. 
4. Validation tasks relevant to operational validation: output analysis, robustness, 
comparison of the model outputs, and intended use of the model. 
Based on our suggested validation framework, each of the model components is validated by 
describing why to perform the validation task, how to perform the validation task, and 
mentioning all the conclusions and results due to the validation task.  The process of data 
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validation, conceptual model validity, computerized verification, and operational validity has 
been summarized in Table 3-2 to Table 3-5. 
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Validation task Why performing the validation 
task 
How to perform the validation task The conclusions/results of the validation 
task 
Representativeness of 
the dataset 
Based on: (Biau, et al., 2008; Ellenberg, 1994) 
 
To ensure that demographics of 
different data obtained from 
multiple sources are similar. 
By comparing demographics of data obtained from multiple 
sources.  
The results of the study can potentially be 
generalized for a larger dataset with different 
demographics. 
To ensure that the data source used 
to estimate different parameters of 
the model is trustworthy. 
By using the most updated data from valid sources. Increased confidence in the accuracy of the 
estimations for different parameters of the 
model. 
To ensure that parameters used to 
build the model are obtained from 
a trustworthy data source. 
By obtaining the model parameters from valid sources. Increased accuracy of the parameters used in 
the model. 
Proper documentation 
of the data components 
Based on: (Balci, 1989; Gass, 1983; Sargent, 2013; Williams & Sikora, 1991) 
 
To enable the study replicability. Both the original and replicated data should be dated and stored 
on a password-protected computer. 
Both original and replicated data can be 
retrieved when needed. 
Searching for outliers  
 
Based on: (Balci, 1989; Sargent, 2013) 
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The existence of the outliers in the 
dataset can affect the accuracy of 
the results. 
Dataset should be searched for any outliers. Reason for the existence of any outliers in 
dataset should be specified. 
Searching for missing 
values  
Based on: (Balci, 1989; Sargent, 2013) 
 
Any data with missing values on 
parameters used to build the 
conceptual model cannot be 
included in the dataset. 
 
Dataset should be searched for any missing values on 
parameters used to build the conceptual model. In case of 
finding missing values, they should be retrieved from the source 
documentation; otherwise data should be excluded from the 
study. 
Under the assumption of missingness-at-
random, we only included data without 
missing values on parameters used to build the 
conceptual model. 
Table 3-2 Validation tests and techniques utilized for data validation of different components of OR models 
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Validation task Why performing the validation task How to perform the validation task The conclusions/results of the validation 
task 
Degeneracy test Based on: (Gass, 1983; Sargent, 2013) 
 
An appropriate selection of the internal 
parameters directly affects the accuracy of 
the logical behaviour of the conceptual 
model. 
By obtaining required information from 
valid sources. 
Increased credibility of the model. 
Data relationship correctness Based on: (Sargent, 2013) 
 
To ensure that there is a logical 
relationship between different parameters 
of the model. 
By comparing values of different 
parameters. 
Increased credibility of the model 
formulations. 
To ensure that there is a logical 
relationship between different data 
components used to build the conceptual 
model. 
 
By selecting large enough sample size to 
ensure that the precision of the developed 
conceptual model is no worse than the 
precision of the relationship between 
different parameters of the model. 
This increased the overall precision of the 
estimates leading to the increased validity of 
the model. 
Tracing Based on: (Balci, 1994; Sargent, 2013) 
 
To ensure that the logical behaviour of the 
model formulations is correct and the 
required accuracy obtained. 
The process of building and selecting the 
equations to formulate the conceptual 
model was performed separately by three 
members of the model development team 
The equations used to formulate the 
conceptual model were verified and the 
equations were corrected where necessary. 
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and the results were compared for any 
inconsistency. 
Mathematical and statistical validation 
methods 
Based on: (Balci, 1994; Gass, 1983; Schellenberger, 1974) 
 
To ensure that the equations used to build 
the conceptual model are accurate enough 
and logically correct. 
We verified the conceptual model and 
ensured that we derive the relevant 
analytical expressions with the best 
possible precision. 
Verifying the relationships between different 
parameters of the model; thus increasing the 
credibility and accuracy of the conceptual 
model. 
Structured walkthrough and face 
validity 
Based on: (Balci, 1994; Hermann, 1967; Oral & Kettani, 1993; Sargent, 2013; Williams & Sikora, 1991) 
 
To ensure that the conceptual model is 
accurate enough for its intended use. 
The logic of the model structure, 
assumptions, and parameters were 
explained step by step to an expert who 
asked questions and challenged the 
choices, leading to significant iterative 
model changes. 
The logic of the model follows the standard 
guidelines of the field. 
Table 3-3 Validation tests and techniques utilized for conceptual model validation of different components of health OR models 
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Validation task Why performing the validation task How to perform the validation task The conclusions/results of the validation 
task 
Debugging  Based on: (Dunn, 1987; Whitner & Balci, 1989) 
 
To confirm the correctness of the codes 
used to build the computational model. 
The code script used to develop the model 
was screened to locate and correct the 
potential errors. 
Typing and logic errors were identified and 
removed. 
Walkthrough  Based on: (Adrion, et al., 1982; Deutsch, 1981; Myers, 1978; Yourdon, 1979) 
 
To ensure that all the computations used 
to build the computational model are 
correct. 
The analytical expert verified the correct 
storage and execution of the 
computations. 
Storage and execution of relevant 
computations of the model were verified. 
Execution tracing  Based on: (Whitner & Balci, 1989) 
 
To confirm the correctness of the codes 
used to build the computational model. 
Defects of the code script were located 
and corrected by line-by-line execution of 
the code by an analytical expert. 
Typing and logic errors were identified and 
removed. 
Table 3-4 Validation tests and techniques utilized for computational model verification of different components of OR models 
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Validation task Why performing the validation task How to perform the validation task The conclusions/results of the validation 
task 
Output analysis Based on: (Balci, 1994; Gass, 1983; Sargent, 2001) 
 
To identify any unusual behaviour of the 
model and pin-pointing errors that would 
not have been identified solely through 
summary statistics. 
We created multiple graphical 
representations to validate the model 
outputs. 
 
We found errors in the outputs as a result of 
either incorrect logic or implementation of the 
model which were subsequently corrected. 
Robustness  Based on: (Balci, 1994; Boehm, et al., 1976; Gass, 1983; Myers, et al., 2011; Sargent, 2013; Whitner & Balci, 1989) 
 
To check the model’s behaviour while 
changing the parameters and inputs of the 
model.  
By checking the robustness of the model. Credibility of the outputs was increased by 
providing the users with estimates of 
uncertainty. 
Comparison of the model outputs Based on: (Sargent, 2013; Williams & Sikora, 1991) 
 
To ensure that the model’s outputs are 
accurate enough for the intended use of the 
model. 
By comparing the outcomes of the model 
to the results of other valid models. 
Credibility of the outputs was increased by 
providing the comparison to other relevant 
studies. 
Intended use of the model Based on: (Gass, 1983; Pidd, 2010) 
 
To verify the decisions made based on the 
model outputs. 
By discussing the limitations and 
boundaries of application of the model. 
Users of the decision support model will 
understand the limitations and will not 
overgeneralize or use the model outside of its 
intended use. 
Table 3-5 Validation tests and techniques utilized for operational validation of different components of OR models 
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The validation framework presented in Table 3-2 to Table 3-5 is generic and can be applied 
for validation of different types of models, even though not all validation techniques 
suggested in this framework are applicable to OR models with different nature and intended 
use and there is a wide variety of validation techniques which was not mentioned in this 
framework. In this thesis we use this framework specifically to validate three complex health 
OR models developed in Chapters 4 and 5 to demonstrate how comprehensive validation of 
OR models for investigation and improvement in the context of health systems and service 
operations can be performed. 
3.5 Summary and conclusions  
In this chapter, we first discussed the importance and needs of validating OR models, 
specifically for models with investigation and improvement intended use, in the context of 
health systems and service operations. We then reviewed the general approaches to model 
validation proposed in OR/MS literature by different authors. These were presented in the 
four distinct groups of data validity, conceptual model validity, computational verification, 
and operational validity.  
In Section 3.3, we conducted a systematic literature review to investigate the extent of 
studies reported on comprehensive validation of the health OR models, where we concluded 
that even though the concept of validation has been widely addressed by different authors in 
literature, there is a lack of reported knowledge about practical aspects of how to validate an 
OR model for investigation and improvement in the context of health systems and service 
operations. We then used four broad validation categories described in Section 3.2 of this 
chapter (data validation, conceptual model validation, computational model verification, and 
operational validation) for classifying the identified studies according to the reported 
validation activities performed in that study. As a result, we found only seven articles out of 
107 articles that simultaneously address some aspects of data, conceptual model, and 
operational validation. 
In the last section, we proposed a generic validation framework which can be used to 
validate complex OR models with respect to four aspects of model validation. This is 
achieved by using validation tasks described by different authors in Section 3.2 of this 
chapter, to perform model validation. The process of model validation is then systematically 
documented in this framework to describe the intention of each validation task (i.e. Why), 
the process of performing the validation task (i.e. How), and the developed 
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conclusions/results. This framework addresses the third research question proposed in 
Chapter 1 of this thesis: What are the conceptual and application issues of conducting 
comprehensive validation of an OR model for investigation and improvement in the context 
of health systems and service operations?   
In Chapters 4 and 5, we employ the generic validation framework proposed in this chapter to 
demonstrate how multiple aspects of data validity, conceptual model validity, computational 
model verification, and operational model validity can be systematically addressed when 
developing a complex OR model for investigation and improvement in the context of health 
systems and service operations. Even though in this thesis we use this framework for 
validation of OR models in the context of health systems and service operations, it is generic 
enough to be employed for validating OR models in non-health contexts. 
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 Chapter 4: Population OR models for investigation and improvement of the 
long-term benefits of early access to hyperacute stroke treatment interventions 
Introduction 
In this chapter, we address the first and third research questions, namely: (1) ‘How OR 
models can be designed, developed, and validated to provide an improved understanding of 
the earlier treatment benefits on patients’ life-time outcomes for two different treatment 
interventions in hyperacute stroke care system?’ and (2)‘What are the conceptual and 
application issues of conducting comprehensive validation of an OR model for investigation 
and improvement in the context of health systems and service operations?’   
As discussed in Chapter 2, there are two effective treatment interventions for ischemic stroke 
patients: IV tPA and endovascular thrombectomy with both treatments being very time-
sensitive. In this chapter, we design and validate two OR models used for better 
understanding of earlier treatment benefits for stroke patients for two treatment interventions 
in the hyperacute stroke care system. The first model is the ‘IV tPA’ model used to 
investigate the long-term benefits of early access to IV tPA treatment for ischemic stroke 
patients. The model is then validated using the general validation framework proposed in 
Chapter 3. We then extend the ‘IV tPA’ model to develop the ‘Endovascular Thrombectomy’ 
model used to investigate the long-term benefits of early access to endovascular 
thrombectomy therapy for ischemic stroke patients. The generic validation framework 
proposed in Chapter 3 is adopted to validate the ‘Endovascular Thrombectomy’ model. Both 
models developed in this chapter are used for quantifying the population benefits due to 
earlier treatment for ischemic stroke patients. 
Two OR models developed in this chapter can be used for understanding the long-term 
effects of faster access to different treatment interventions on stroke patients’ life-time 
outcomes in the hyperacute stroke care system. Discussion on validation is expected to 
provide further insights on the conceptual and application issues of conducting an 
comprehensive validation of an OR model for investigation and improvement in the context 
of health systems and service operations.  
The content of this chapter is partially based on the following papers: (1)“Stroke 
thrombolysis; save a minute, save a day” published in the leading journal of the field, Stroke 
in 2014 (Meretoja, et al., 2014); (2) “Validation of a decision support model for 
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investigation and improvement in stroke thrombolysis” published in the European Journal of 
Operational Research in 2016 (Keshtkaran, et al., 2016); and (3) “Endovascular therapy for 
ischemic stroke; save a minute – save a week” accepted for publication in Neurology at the 
time of submitting this thesis (Meretoja, et al., 2017). 
4.1 Problem description and intended use of the ‘IV tPA’ model 
Until 2014, intravenous thrombolysis (tPA) was the only medical therapy shown to improve 
patient outcomes in ischemic stroke patients (Jauch, et al., 2013). As evidenced by clinical 
trials, the earlier treatment for this intervention leads to higher chance of effective outcome 
in ischemic stroke patients (Emberson, et al., 2014; Lees, et al., 2010), while the upper time 
limit to receive this treatment is 270 minutes from stroke onset time. Despite the accepted 
health benefits of faster access to IV tPA treatment for stroke patients, prior to this research 
there was no method for quantifying the link between reductions in treatment delays for IV 
tPA treatment and patients’ lifetime benefits. In this chapter, we present the ‘IV tPA’ model 
which designed and validated to provide better understanding of the benefits of earlier access 
to IV tPA treatment for ischemic stroke patients. 
The ‘IV tPA’ model was constructed to investigate the effect of earlier tPA treatment on 
patient lifetime outcomes; thus, classified as a model for investigation and improvement with 
the aim of increasing the awareness of public policy decision makers, stroke campaigns, and 
stroke care system providers of the importance of benefits of faster thrombolysis treatment in 
an easier-to-understand manner. 
The results of the ‘IV tPA’ model were originally published in the flagship journal; Stroke, 
titled ‘Stroke thrombolysis; save a minute, save a day’ (Meretoja, et al., 2014) lead to a 
significant media exposure including sources like Bloomberg (Gale, 2014), The Times 
(Whipple, 2014), Reuters (Seaman, 2014), and Herald Sun (2014). American Heart and 
Stroke Association produced an infographics encapsulating the findings for the consumers 
(American Heart Association/American Stroke Association, 2014). The model’s findings are 
also used by the Australian National Stroke Foundation and Victorian Stroke Telemedicine 
Initiative (State of Victoria, Australia) to advocate for wider use of stroke thrombolysis 
telemedicine in remote an rural areas (Bladin & Cadilhac, 2014; Stroke Foundation 
Australia, 2016). Overall, current levels of the actual model use are quite consistent with the 
original modelling expectations.  
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4.2 Overview of the ‘IV tPA’ model 
The ‘IV tPA’ model is the first OR model used to explicitly quantify the link between 
reductions in treatment delays before IV tPA treatment and patients’ lifetime benefits. This 
model extends the discussion provided in a journal article titled ‘Stroke thrombolysis; save a 
minute , save a day’ originally published in Stroke in 2014 (Meretoja, et al., 2014). Inputs 
and parameters of the ‘IV tPA’ model are originating from a wide variety of data sources, 
empirical estimates and clinical literature. This includes observational real-life cohort data, 
pooled analysis of tPA effect over time, general population life expectancy data, and 
different parameters to derive the outcomes of the model. The main output of this model is 
expressed as number of disability-adjusted days saved per minute of earlier treatment for IV 
tPA treatment. Figure 4-1 presents an overview of the ‘IV tPA’ model with all the model 
inputs. Detailed description of these inputs is provided in next section. 
Summary of different parameters used to conceptualize the ‘IV tPA’ model is presented in 
Table 4-1. These parameters are further described in details in Section 4.3 and 4.4 and are 
used in Section 4.4 to develop the model. 
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Parameter name Definition  
K (K=1 or 0) age-weighting modulation factor 
β (β=0.04) age-weighting function 
C (C =0.1658) adjustment constant 
r (r=0.03 or 0) discounting rate 
DWs mRS specific disability weights 
S mRS specific annual risk of death 
A age of death  
As age of onset of disability 
L life expectancy of general population at the age of stroke 
Ld duration of disability at the age of stroke 
t0 (maximum 270 min) observed onset-to-tPA treatment time 
t (maximum 270 min) OR model onset-to-tPA treatment time 
PmRS 0-1 (t0) probability of mRS 0-1 at time t0 
PmRS 6 (t0) probability of mRS 6 at time t0 
PmRS 0-1(t) probability of  mRS 0-1 at time t 
PmRS 6(t) probability of  mRS 6 at time t 
odds ratio mRS 0-1(t) fitted value of odds ratios for mRS 0-1 at time t 
odds ratio mRS 6(t) fitted value of odds ratios for mRS 6 at time t 
odds ratio mRS 0-1(t0) fitted value of odds ratios for mRS 0-1 at time t0 
odds ratio mRS 6(t0) fitted value of odds ratios for mRS 6 at time t0 
YLL years of life lost due to premature death 
YLD years of life lost due to disability 
DALYs disability-adjusted life years lost 
Table 4-1  Summary of different parameters of the ‘IV tPA’ model 
The ‘IV tPA’ model is a model for investigation and improvement according to Pidd (2010) 
classification, as it is used to provide better understanding of the long-term effects of earlier 
treatment on patients’ outcomes with regard to IV tPA intervention. As discussed in Chapter 
2, this type of model is used to “support investigations that are relatively unique, which may 
involve system design, system improvement or just an attempt to gain understanding of a 
very complex situation” (Pidd, 2010, p. 18).  
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Figure 4-1 Overview of the ‘IV tPA’ model. mRS indicates modified Rankin Scale; NIHSS, National 
Institutes of Health Stroke Scale; tPA, tissue plasminogen activator; OR, odds ratio. 
4.3 Overview of the ‘IV tPA’ model inputs 
Following model inputs were used to construct the ‘IV tPA’ model: 
1. An observational cohort data of consecutive tPA patients: This is based on a 
combined sample of 2258 patients retrieved from two databases: the Helsinki Stroke 
Thrombolysis Registry (Meretoja, et al., 2012), and the Safe Implementation of 
Treatments in Stroke (SITS-Australia) database (Simpson, et al., 2010). Helsinki 
Stroke Thrombolysis Registry contains the information about all cases of acute 
stroke thrombolysis given to patients at the Helsinki University Central Hospital. 
mRS probability 
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The data used in this study was generated during the period between March 1998 
and December 2011 and included relevant patient information for 1727 patients 
treated with tPA (Meretoja, et al., 2012). Similarly, SITS-Australia contains the 
information about the cases of acute stroke thrombolysis administered in various 
centres in Australia (Simpson, et al., 2010). The data from the SITS-Australia 
dataset used in this study was generated between December 2002 and December 
2008 and included relevant patient information on 531 out of 704 patients from 14 
treating centres. 
We included 1727 patients from Helsinki registry dataset and 531 patients from 
SITS-Australia dataset to build a comparatively large sample size of 2258 patients, 
representing two potentially different demographic groups for the study. This cohort 
consisted of distribution data for age, sex, and stroke severity measured on the 
National Institutes of Health Stroke Scale (NIHSS)(Lyden, et al., 1994), onset-to-
tPA treatment times; and post-stroke disability level at 3 months, measured by 
modified Rankin Scale (mRS) (Rankin, 1957). Table 4-2 shows distributions of age, 
gender, NIHSS, onset-to-tPA treatment time, and mRS for Helsinki and SITS-
Australia databases.  
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Characteristics and 
Outcomes 
Total 
(n=2258) 
Helsinki 
(n=1727) 
SITS-Australia 
(n=531) 
P Value 
Age, y 70 (60-78) 
68±13 
70 (60-77) 
67±13 
73 (62-80) 
70±13 
<0.001 
<0.001 
Male sex 1247 (55%) 939 (54%) 308 (58%) 0.161 
NIHSS at baseline 9 (6-15) 
11±6 
8 (5-14) 
10±6 
13 (8-19) 
14±7 
<0.001 
<0.001 
Onset-to-tPA treatment time, 
min 
125 (92-162) 
129±46 
117 (86-160) 
125±49 
145 (123-167) 
143±32 
<0.001 
<0.001 
3-Month mRS score 0 to 1 850 (37.6%) 664 (38.4%) 183 (34.5%) 0.097 
3-Month mRS score 0 to 2 1290 (57.1%) 1031 (59.7%) 259 (48.8%) <0.001 
3-Month mRS 6 252 (11.2%) 155 (9.0%) 97 (18.3%) <0.001 
Table 4-2 Characteristics of the observational cohort. Data are n (%), median (interquartile range), 
or mean±SD. Distributions of Helsinki and SITS-Australia data compared with Mann-Whitney U test 
𝑥2 test, or Student t test as appropriate, with 2-sided statistical significance set at P=0.05. mRS 
indicates modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; and SITS, Safe 
Implementation of Treatments in Stroke. 
Since data from two different registries were used to build the ‘IV tPA’ model, in Figure 4-2 
we provide a comparison between onset-to-tPA treatment distributions of these two cohorts. 
Even though is some cases the characteristics of the two samples are different, the combined 
cohort increases the generalizability of the results generated based on the ‘IV tPA’ model.  
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Figure 4-2 Histogram of onset-to-tPA treatment time distributions 
The NIHSS scale is a validated tool used to assess the severity of stroke by clinicians in most 
stroke centres globally (Brott, et al., 1989). The mRS categorizes the functional disability 
into seven broad groups ordered from mRS 0 (No symptoms at all), to mRS 6 (Dead) as 
presented in Table 4-3 (Sulter, Steen, & De Keyser, 1999). 
Level  Description 
0 No symptoms 
1 No significant disability, despite symptoms; able to perform all usual duties 
and activities 
2 Slight disability; unable to perform all previous activities but able to look 
after own affairs without assistance 
3 Moderate disability; requires some help, but able to walk without assistance 
4 Moderately severe disability; unable to walk without assistance and unable to 
attend to own bodily needs without assistance 
5 Severe disability; bedridden, incontinent, and requires constant nursing care 
and attention 
Table 4-3 Descriptions of different levels of modified Rankin Scale (mRS) (Sulter, et al., 1999) 
2. Published pooled analysis of tPA effect over time (Emberson, et al., 2014; Lees, et 
al., 2010): The effect is graphically summarized as odds ratios with corresponding 
confidence intervals for tPA treatment compared to placebo of obtaining favourable 
outcome (mRS 0-1) and for mortality (mRS 6) vs. onset-to-tPA treatment time as 
reported in a paper by Lees, et al. (2010). Updated results of these analyses were 
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published in a paper by Emberson, et al. (2014) where the authors only provided the 
odds ratio curve for the mRS 0-1 without providing any relevant analytical 
expression for the curves. As a result, we used the odds ratio lines for mRS 0-1 and 
mRS 6 provided in the paper by Lees, et al. (2010) to run the main analysis for the 
‘IV tPA’ model and then replaced the odds ratio curve of mRS 0-1 in Lees, et al. 
(2010) paper with that of Emberson, et al. (2014) to validate the model outputs. 
3. General Australian population life expectancy age- and sex- specific data 
obtained from Australian Bureau of Statistics: These included age and sex 
specific life-expectancies of the male and female residents in the State of Victoria, 
Australia for the period of 2011-2013. The life expectancy data contained the 
mortality rates for a group of 100,000 hypothetical newborn babies throughout their 
entire life, and all the necessary information to calculate the life expectancy for the 
mentioned group, such as the number of persons surviving to exact age of x, the 
proportion of persons dying between exact age x and exact age x+1 (mortality rate), 
the number of person years lived within the age interval x to x+1; and life 
expectancy at exact age x (Australian Bureau of Statistics, 2011-2013). The latest 
version of this data at the time of developing the ‘IV tPA’ model was used to model 
the long-term survival of patients at various mRS categories compared with the 
general population (Australian Bureau of Statistics, 2011-2013). We compared this 
data with its updated version (Australian Bureau of Statistics, 2013-2015) at the time 
of submitting this thesis and observed no significant difference between the 
databases. 
4. Parameters necessary to translate the 3-month mRS outcome data into a long-
term metric of Disability-adjusted Life Years (DALYs) lost: The parameters 
include age-weighting modulation factor (k), age-weighting function (β), adjustment 
constant (C), discounting rate (r), mRS specific disability weights (DWs), and mRS 
specific annual risk of death (s) (Murray, 1996; World Health Organization, 2014). 
The values of K, β, C, and r were originally determined by World Health 
Organization (WHO) as a result of Global Burden of Disease Project (GBDP) 
undertaken jointly by the World Bank, and Harvard School of Public Health in 1992 
(Murray, 1996; World Health Organization, 2014). DWs were developed by WHO-
GBDP for chronic post-stroke states for each of the seven mRS grades (0.000, 0.053, 
0.228, 0.353, 0.691, and 0.998 for mRS categories 0-5, respectively). Lastly, the 
long-term annual risk of death after stroke is expressed as disability-linked mortality 
hazard ratios for premature annual mortality for mRS categories from 0 to 5 (1.53, 
1.52, 2.17, 3.18, 4.55, and 6.55 times that of the general population for mRS 
categories 0-5, respectively)(Hong & Saver, 2010). 
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4.4 Overview of the model-building process 
The ‘IV tPA’ model was constructed in four stages as shown in Figure 4-3. These stages 
have been discussed in details as follows:  
Stage 1: Generating patient-specific probabilities of achieving specific mRS categories 
at the cohort observed onset-to-tPA treatment time (t0) – We used a validated regression 
model with mRs categories as dependant variables and age, baseline NIHSS, and onset-to-
tPA treatment time as independent variables to generate the patient-specific probability 
distributions for each mRS level. The choices of age and baseline stroke severity as input 
parameters reflect an evidence-based understanding of these variables being strong 
prognostic factors for the functional outcome after stroke (Jauch, et al., 2013). Using a 
simple normalization scaling procedure, we ensured that the sum of patient-specific 
probabilities for each mRS category is equal to one, and then we used the estimated 
probabilities to generate patient-specific probability distributions of achieving a given mRS 
category at the observed onset-to-tPA treatment times t0. 
Stage 2: Modelling the change in probabilities of achieving mRS 0-1 and mRS 6 over 
time - The pooled analysis of thrombolysis randomized controlled trials by Lees et al. (2010) 
provides an estimation of the effect of thrombolysis treatment delays compared to placebo. 
This has been reported by the authors in a mentioned paper in two separate graphs for mRS 
0-1 and mRS 6 without providing any analytical expressions for the odds ratio curves. The 
graphical curves reported in that article demonstrate the change in the odds ratio of achieving 
mRS 0-1 and mRS 6 probabilities as a function of onset-to-tPA treatment for values between 
60 and 360 minutes.  
To build this model, since authors in Lees et al. (2010) paper have not provided any 
analytical equations for the odds ratio curves we derived relevant analytical expressions for 
odds ratios of mRS 0-1 and mRS 6 using the best fit (based on adjusted R2 criterion) and 
used these equations to estimate the odds ratios for mRS 0-1 and mRS 6 as a function of 
onset-to-tPA treatment time for any value of onset-to-tPA treatment time between 0 and 270 
(i.e. the currently accepted evidence-based upper time limit for tPA treatment) minutes 
(Jauch, et al., 2013; Lees, et al., 2010). 
The odds ratio reported by Lees et al. (2010) presents the ratio of odds of achieving mRS 0-1 
(or, respectively, mRS 6), by the patients treated with tPA at a time point t and the odds of 
achieving the same outcome by the patients not treated by tPA. To estimate the probabilities 
of mRS 0-1 and mRS 6 at any given time, we used formulae 4-1 and 4-2: 
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PmRS 0-1(t)=1/ {1+(odds ratio mRS 0-1 (t0)/odds ratio mRS 0-1(t)) * [(1-p mRS 0-1 (t0))/p mRS 0-1 (t0)]} (4-1) 
 
PmRS 6(t)=1/ {1+(odds ratio mRS 6 (t0)/odds ratio mRS 6(t)) * [(1-p mRS 6 (t0))/p mRS 6 (t0)]} 
 
(4-2) 
                                                
All the parameters used to develop these formulas are described earlier in Table 4-1. 
Stage 3: Estimating probabilities of achieving a specific mRS at any time - Since the 
graphs presented in Lees et al. (2010) only report on the odds ratios for mRS 0-1 and mRS 6, 
we used the patient-specific probabilities of achieving mRS 0-1 and mRS 6 at any given time 
t obtained at Stage 2 to estimate the probability distributions for each individual mRS 
category. These probabilities were estimated assuming that the ratios of probabilities for 
achieving individual mRS categories remain identical to those obtained in Stage 1 from the 
logistic regression models based on the observed cohort data. 
Stage 4: Estimating the expected Disability-adjusted Life Years (DALYs) lost - 
Disability adjusted life-years (DALYs) lost metric developed by the World Health 
Organization (WHO) was used to translate the 3-month mRS outcome data into a meaningful 
long-term metric. This metric expresses the total amount of optimal life-years lost due to 
both premature mortality and living with disability and consists of two components: years of 
life lost due to premature death (YLL) and years of life lost due to disability (YLD) (Rushby 
& Hanson, 2001).  
YLL is calculated as the difference between general population life expectancy of a person at 
a given age and sex, that is, life expectancy of a person without stroke, and age-and sex-
matched life expectancy of a stroke patient in a certain mRS category. The long-term annual 
risk of death after stroke was taken from published literature for mRS categories 0-5 times 
that of the general population for each mRS level (Hong & Saver, 2010).  
Equation 4-3 was used to estimate YLL: 
YLL[r,K]=KCerA/(r+β)2{e-(r+β)(L+A)[-(r+β)(L+A)-1]-e-(r+β)A[-(r+β)A-1]}+[(1-K)/r](1-e-rL)            (4-3) 
whereas described earlier, K indicates age-weighting modulation factor (K=1 or 0); β is the 
parameter from age weighting function (β = 0.04); r is the discount rate (r = 0.03 or 0); C is 
a constant (C= 0.1658); A is the age of death, and L is the life expectancy of general 
population at the age of stroke. 
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YLD is calculated by multiplying the life expectancy of a stroke patient by a disability 
weight and, therefore, demonstrates how much the value of life has diminished in years lived 
after stroke (Hong & Saver, 2009). Equation 4-4 was used to estimate YLD: 
YLD[r,K]=DKCerAs/(r+β)2{e-(r+β)(Ld+As)[-(r+β)(Ld+As)-1]-e-(r+β)As[-(r+β)As-1]}+[(1-K)/r](1-e-rLd) 
                                                                                                                                                           (4-4) 
where K, β, r and C are the same parameters as in YLL formula; As is age of onset of 
disability; Ld is duration of disability; and DWs is disability weights. 
Having estimated the values for YLL and YLD, DALYs are then derived by summing up the 
values of YLL and YLD as shown in equation 4-5. For the ‘IV tPA’ model, DALYs lost for 
each patient in the observational cohort at onset-to-tPA treatment time has been initially 
estimated, and then we have modeled the DALYs lost with regard to the treatment delays for 
each patient (Hong & Saver, 2010). 
DALYs[r,K]= YLL[r,K] + YLD[r,K]                                                                                              (4-5) 
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Figure 4-3 Overview of different stages of the model building process 
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4.5 Result of treating faster in the whole cohort and individual patients 
In the whole cohort, we generated the results for one minute earlier of real-life onset-to-tPA 
treatment time according to the World Health Organization (WHO) policy updated in 2012 
to report DALYs without age-weighting (K = 0) and discounting (r = 0) factors (Murray, et 
al., 2013). For these parameters (K=0, r=0), we estimated on average extra 1.8 days of 
DALYs saved per minute of earlier treatment (median 1.7, IQR, 1.1–2.3, standard deviation 
0.8, range 0.1–4.6 days of DALY) for the full cohort. 
It is evidenced by clinical trials that patients with various age and disease severity benefit 
differently from faster treatment. To evaluate these findings, we ran the ‘IV tPA’ model for 
five individual female patients, namely:  
 a patient with median age (70 y.o.) and median stroke severity (NIHSS 9); 
 two patients with old ages (90th decile, 83 y.o.) and respectively low (10th decile, NIHSS 
4) and high stroke severities (90th decile, NIHSS 20); and 
 two patients with young ages (10th decile, 50 y.o.) and respectively low (NIHSS 4) and 
high (NIHSS 20) stroke severities.  
On average a 70 years old female patient with median stroke severity gained extra 2.1 days, 
a 50 y.o. patient with mild stroke and severe stroke gained extra 2.7 and 3.5 days 
respectively, and a 83 y.o. patient gained extra 0.9 and 0.6 days respectively for each minute 
saved (Meretoja, et al., 2014). As it is evidenced by the results of the ‘IV tPA’ model, the 
younger patients gain more benefit from faster treatment as a result of their longer lifetime.  
Moreover, we generated disability adjusted days saved per minute of earlier treatment for 
female and male stroke patients for different age and severity groups. In two graphs 
presented in Figure 4-4, patients from cohort data has been categorized into five NIHSS 
severity groups (0-4, 5-9, 10-14, 15-19, 20+), and six age groups (<45, 45-54, 55-64, 65-74, 
75-84, 84+), while the point estimates show the disability adjusted days saved per minute of 
earlier treatment for that group of patients. Even though in these figures we categorized the 
patients into different groups in a way that we have enough number of patients in each 
group, those groups with very young and high disease severity or very old and mild severity 
eventually had fewer patients compared to other groups; thus changing the linear trend of 
age group lines.  
By comparing data between the female and male groups, it can be observed that female 
patients often benefit more from faster treatment over their longer life time. For patients 
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younger than 64, disability-adjusted days saved per faster treatment increases from NIHSS 
(0-4) to NIHSS (15-19). Lastly, by fixing the NIHSS group in any of the figures presented 
below, and moving from patients with younger ages towards those with older ages, the 
benefits of faster treatment decreases. Point estimates and 95% prediction intervals for each 
of these groups have been provided in Table 4-4. 
 
` 
 
 
 
 
 
 
Figure 4-4 Relationship between disability-adjusted days gained per minute of faster treatment, age, 
and stroke severity. Baseline stroke severity measured with the National Institute of Health Stroke 
Scale (NIHSS) where higher scores indicate more severe stroke 
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Sex, Age NIHSS 0-4 NIHSS 5-9 NIHSS 10-14 NIHSS 15-19 NIHSS 20 + 
Male      
<45 3.01 (1.02-5.01) 3.40 (1.56-5.24) 3.67 (1.62-5.73) 3.75 (1.91-5.60) 3.83 (2.18-5.48) 
45-54 2.30 (0.80-3.79) 2.70 (1.08-4.31) 3.02 (1.26-4.79) 3.17 (1.26-5.08) 2.86 (1.31-4.41) 
55-64 1.87 (0.73-3.01) 2.20 (0.97-3.43) 2.49 (1.08-3.90) 2.45 (1.23-3.68) 2.11 (1.06-3.15) 
65-74 1.45 (0.72-2.18) 1.61 (0.71-2.52) 1.81 (0.82-2.80) 1.69 (0.81-2.57) 1.19 (0.68-1.69) 
75-84 0.97 (0.51-1.44) 1.08 (0.48-1.68) 1.09 (0.56-1.62) 0.91 (0.44-1.37) 0.65 (0.29-1.01) 
85 + 0.59 (0.37-0.81) 0.63 (0.29-0.97) 0.57 (0.27-0.86) 0.45 (0.25-0.64) 0.26 (0.14-0.37) 
Female      
<45 3.24 (1.80-4.67) 3.79 (1.90-5.67) 4.05 (1.74-6.36) 4.30 (2.57-6.04) 3.86 (2.16-5.55) 
45-54 2.54 (1.03-4.05) 2.98 (1.25-4.71) 3.40 (1.33-5.47) 3.55 (1.80-5.29) 3.48 (0.47-6.50) 
55-64 2.14 (0.98-3.31) 2.48 (1.17-3.79) 2.89 (1.49-4.29) 2.95 (1.44-4.45) 2.45 (1.05-3.84) 
65-74 1.65 (0.78-2.52) 1.91 (0.91-2.91) 2.07 (0.97-3.18) 1.93 (0.96-2.90) 1.66 (0.74-2.58) 
75-84 1.16 (0.58-1.75) 1.28 (0.62-1.94) 1.32 (0.70-1.94) 1.09 (0.54-1.64) 0.76 (0.37-1.15) 
85 + 0.67 (0.37-0.98) 0.76 (0.46-1.06) 0.62 (0.35-0.89) 0.45 (0.27-0.63) 0.33 (0.15-0.51) 
Table 4-4 Point estimates and 95% prediction intervals for disability adjusted days gained per minute 
saved in tPA delivery, per sex, age, and stroke severity (NIHSS) 
Figure 4-5, is presenting the effect of treatment delay on Life Expectancy (LE) and 
Disability-adjusted Life Years (DALYs) for five individual female patients. While for the 
whole cohort DALYs was generated without age-weighting (K = 0) and discounting factor (r 
= 0) according to updated policy of the WHO in 2012 (Murray, et al., 2013), here DALYs 
estimations are provided with discounting to present values at 3% annually both with and 
without age-weighting as per standard methodology (Rushby & Hanson, 2001).  In Figure 4-
5, this has been presented by blue line for DALYs with age-weighting (K=1) and 
discounting rate (r=0.03), by green line for DALYs without age-weighting (K=0) and with 
discounting rate (r=0.03), and by red line for DALYs without age-weighting (K=0) and 
discounting factor (r=0).  As it can be seen in these figures, as the onset-to-tPA treatment 
time increases from 0 to 270 minutes, the DALYs lost also increases in all cases. Thus, it can 
be concluded that patients with different age and severity benefit by earlier tPA treatment. 
On the other hand, the life expectancy of the patients after stroke decreases in all cases with 
more delays of onset-to-tPA treatment time. This has been presented in Figure 4-5 by purple 
lines. The 95% prediction intervals in all cases have been plotted by dashed lines. The 
methodology used to estimate these prediction intervals have been described in details in 
Section 4.6. 
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Figure 4-5 Effect of treatment delay with 95% prediction interval on Life Expectancy (LE) and 
Disability-adjusted Life Years (DALYs) in 5 individual female cases with median, top, and bottom 
decile age/National Institute of Health Stroke Scale (NIHSS). tPA indicates tissue plasminogen 
activator. 
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4.6 Robustness analysis  
For the ‘IV tPA’ model, we first varied each model input to their upper and lower 95% CIs 
and evaluating the model robustness with regard to those uncertainties in the inputs. We refer 
to this method as one-way robustness analysis which was performed by substituting the 
upper and lower 95% CIs values for the regression coefficients for the age and NIHSS 
generated by the binary logistic regression models used to estimate different levels of mRS. 
To account for potential uncertainties of the pooled analysis by Lees et al. (2010), we 
modified the equations of odds ratio(t) for mRS 0-1 and mRS6 in the mRS probability 
distribution formula to sequentially reflect the upper and lower 95% confidence limits for 
these two mRS categories as reported by Lees et al. (2010).  
In one-way analysis by varying the odds ratio of mRS 0-1 to the lower and upper 95% CIs 
respectively adopted from the paper by Lees at al (2010), a patient benefits on average extra 
0.84 and 2.75 days for each minute saved. These values are changing between 1.41 and 2.08 
days when varying the odds ratio of mRS 6 to the lower and upper 95% CIs as presented in a 
paper by Lees at al (2010). With respect to the effect of age and NIHSS on outcome, a 
patient benefits vary from 1.65 to 1.90 days for age, and 1.75 to 1.81 days for NIHSS with 
respectively changing the lower and upper 95% CIs (Table 4-5). 
Inputs in the one-way analysis 
Disability-adjusted days saved per minute of faster 
treatment 
Lower value Upper value 
Odds of mRS 0-1a  0.84 2.75 
Odds of mRS 6a 1.41 2.08 
Effect of age on outcomeb 1.65 1.90 
Effect of NIHSS on outcomeb 1.75 1.81 
a Upper and lower 95% CIs from the pooled analysis of Lees at al (2010) 
b Upper and lower 95% CIs from the logistic regression model in the observational cohort.  
Table 4-5 Robustness of model when inputs changed one at a time. Abbreviations: mRS, modified 
Rankin Scale; NIHSS, National Institutes of Health Stroke Scale. The point estimate is 1.78 days per 
minute in all cases. 
The probabilistic analysis was performed by sampling according to an underlying Normal 
distribution from the feasible space of the mRS 0-1 and mRS 6 odds ratio curves bounded by 
the 95% confidence interval limits provided in a paper by Lees at al (2010) and reflecting 
various potential time effects based on the pooled analysis, through a set of 1000 
independent runs. The resulting probability profiles for all mRS categories were then used to 
estimate DALYs gained or lost if either the whole cohort or an individual patient would have 
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been treated faster or slower. As a result, we estimated a 95% prediction interval from 0.9 to 
2.7 days for each minute saved. Both one-way analysis and probabilistic analysis 
demonstrated that the results were robust overall, with the average point estimate of 1.78 
days for each minute saved for the robustness analyses. 
Appropriate validation of the ‘IV tPA’ model is particularly very challenging as the model 
relies on the wide variety of datasets and parameters used as model inputs, while it should 
address multiple aspects of conceptual model validity, computational verification, and 
operational validity. To achieve this, in the next section we adopt the validation framework 
developed in Chapter 3 to demonstrate how multiple aspects of data validity, conceptual 
model validity, computational model verification, and operational validity can be 
systematically addressed.  
4.7 Comprehensive validation of the ‘IV tPA’ model 
In this section, we provide comprehensive validation of the ‘IV tPA’ model using the 
validation framework presented earlier in Chapter 3. To achieve this, we validate the model 
with regard to the four categories of data validity, conceptual model validity, computational 
verification, and operational validity. 
4.7.1 Data validity 
Both input data (e.g. stroke thrombolysis cohort and general population life expectancy data) 
and previously published data in the form of various parameters estimators (e.g. pooled 
analysis of tPA, annual risk of death and disability weights) were used to build the ‘IV tPA’ 
model model. This data as shown in Figure 4-3 in orange boxes has been validated as 
follows: 
 Validation of input data 
Observational cohort data: Both registries used to build the observational cohort are valid in 
terms of the representativeness as they represent consecutive patients with prospectively 
collected data on age, sex, stroke severity, onset-to-tPA treatment time of ischemic stroke 
patients for Finland and Australia. They were created and maintained in accordance to the 
best practice guidelines for clinical registries and were approved by the relevant institutional 
authorities. 
Based on pre-specified inclusion criteria, in both datasets, the patients with onset-to-tPA 
treatment time greater than 4½ hours (n=150 in Helsinki database), and those with deviations 
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from standard treatment procedure (n=56 in Helsinki database) and missing value on onset-
to-tPA treatment time, stroke severity or mRS outcome (n=65 in Helsinki database and 
n=173 in Safe Implementation of Treatment in Stroke database) were excluded. Each dataset 
was searched separately for any outliers before inclusion to the study. We also searched the 
combined dataset for any outliers generated as a result of combining two different datasets 
and no outliers were found. The original databases as well as all the subsequent datasets used 
to develop the model were stored and documented on a password protected computer. 
Having validated the observational cohort in terms of the representativeness, outliers, 
missing values and documentation, we then used the individual patient data to generate the 
patient-specific probabilities of achieving specified mRS categories as described in Stage 1 
of the model development.  
General population life expectancy: As described at stage 4 of the model development, 
general population life expectancies data were used in the model to calculate DALYs. Being 
produced by the main government body in charge of the official statistics for the purposes of 
the analysis of life expectancy, this dataset was assumed to be valid. After ensuring that there 
are no outliers or missing values in the data, the full dataset along with its explanatory notes 
was documented in an Excel file for any retrieval purposes in the future. 
 Validation of parameters 
Pooled analysis of tPA effect over time: As described at stage 3 of the model development, 
pooled analysis of tPA treatment effect over time by Lees et al. (2010) was used to derive 
how the effect of tPA treatment varies with delays for onset-to-treatment time. The 
parameters obtained from this meta-analysis are most representative of the current state of 
the knowledge in the area of stroke thrombolysis as the study includes eight major 
randomized placebo-controlled trials of intravenous recombinant tissue plasminogen 
activator for acute stroke (Lees, et al., 2010).  
Parameters to calculate expected DALYs: As described at stage 4 of the model development 
different parameters were derived from previously validated and published literature to 
transfer the 3-month mRS outcome into a long-term metric. DWs were also developed by 
WHO-GBDP for chronic post-stroke states, using the person trade-off method where 
healthcare professionals judge health conditions from a broad public health point of view, 
ensuring equity across different health states (Murray, 1996; Nord, 1992). Hong and Saver 
(2009) then formed an international panel of 9 experts to use the trade-off procedure 
combined with a Delphi process to estimate DWs. Lastly, the long-term annual risk of death 
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after stroke was adopted from previously validated published literature (Hong & Saver, 
2010), even though this publication did not provide the CIs around DWs and long-term 
annual risk of death after stroke that could be used for model validation purposes. 
The summary of different validation methods and techniques used to obtain data validity for 
‘IV tPA’ model has been provided in Table 4-6. 
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Validation task Why we performed the 
validation task 
How we performed the validation task The conclusions/results of the validation task 
Representativeness of 
the dataset 
Based on: (Biau, et al., 2008; Ellenberg, 1994) 
Observational cohort 
data 
To ensure that demographics of 
the observed data have similar 
distributions to that of the 
published literature. 
We obtained consecutive prospective data from two registries in 
Finland and Australia. We compared patient demographics to 
those in published literature. 
The results of the study can potentially be 
generalized for a larger group of patients. 
 
General population life 
expectancy 
To ensure that the data source 
used to estimate the life 
expectancies is trustworthy. 
At the time of developing the ‘IV tPA’ model, we used the latest 
official data for age and sex specific life-expectancies of the 
residents of Victoria, Australia, obtained from ABS (2011-2013). 
We compared these with similar life-expectancy data from 
Finland, observing minimal differences (the average life 
expectancy at birth for men is 79.2 years in Australia versus 76.8 
years in Finland and for women 83.8 years versus 83.3 years). 
Increased confidence in the accuracy of the 
estimations for the general population life 
expectancy. 
 
Pooled analysis of tPA 
effect over time 
To ensure that parameters used 
to model the effect of tPA 
treatment over time were 
obtained from a trustworthy data 
The parameters used to model the effect of tPA treatment over 
time were obtained from the pooled analysis of individual patient 
data of tPA randomized controlled trials by Lees et al. This study 
includes eight major randomized placebo-controlled trials of tPA 
for acute stroke (86% of the total number of patients in all trials for 
Increased accuracy of the parameters used to 
model the effect of tPA treatment changing with 
onset-to-tPA treatment times. 
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source. 
 
 
tPA treatment), which is the most representative of the current 
state of the knowledge in the field of stroke thrombolysis. 
Parameters to calculate 
DALYs lost 
To ensure that the data source 
used to obtain parameters for 
estimating DALYs lost is 
trustworthy. 
We used the parameters obtained from WHO-GBDP, which was 
undertaken jointly with the World Bank, and Harvard School of 
Public Health. 
Increased accuracy of the parameters used to 
estimate the expected DALYs. 
Proper documentation 
of the data 
components 
Based on: (Balci, 1989; Gass, 1983; Sargent, 2013; Williams & Sikora, 1991) 
Observational cohort 
data 
To enable the study replicability. Both the original and replicated data were dated and stored on a 
password-protected computer. 
Both original and replicated data can be 
retrieved when needed. 
General population life 
expectancy 
To enable the study replicability. Both the original and replicated data were dated and stored on a 
password-protected computer. 
 Both original and replicated data can be 
retrieved when needed. 
Searching for outliers  
 
Based on: (Balci, 1989; Sargent, 2013) 
Observational cohort 
data 
The existence of the outliers in 
the dataset can affect the 
Each dataset from Finland and Australia as well as the combined 
dataset from these two registries were searched for any outliers. 
Neither improbable nor impossible outliers were 
found in the observed dataset. 
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accuracy of the results.  
General population life 
expectancy 
The existence of the outliers in 
the dataset can affect the 
accuracy of the results. 
The dataset was searched for any outliers. Neither improbable nor impossible outliers were 
found in the observed dataset. 
Searching for missing 
values  
Based on: (Balci, 1989; Sargent, 2013) 
Observational cohort 
data 
Any data with missing values on 
parameters used to build the 
conceptual model could not be 
included in the observational 
cohort. 
 
Each dataset from Finland and Australia as well as the combined 
dataset were searched for any missing value on age, sex, stroke 
severity, and onset-to-tPA treatment time. We tried to retrieve data 
from the source documentation where missing, if not found it was 
excluded from study. 
Under the assumption of missingness-at-
random, we included those patients from the 
observational cohort without missing values on 
age, sex, stroke severity, and onset-to-tPA 
treatment time to build the logistic regression 
model. 
General population life 
expectancy 
Any data with missing values on 
parameters used to build the 
conceptual model could not be 
included in the general 
population life expectancy 
dataset. 
The dataset was searched for any missing value on the parameters 
needed to estimate the life expectancy of the general population. 
No missing values were found in this dataset. 
We could include patients of all ages to estimate 
the life expectancy of the general population as 
we had life-expectancies for everyone. 
Table 4-6 Validation tests and techniques utilized for data validation of different components of the ‘IV tPA’ model 
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4.7.2 Conceptual model validity 
The conceptual model of the effect of onset-to-tPA treatment time delays on mRS 
probabilities was mainly developed at Stage 2 and Stage 3 of the model development. As 
shown in Figure 4-3 in yellow boxes, conceptual model validation consists of validating the 
model’s assumptions and its logical and mathematical structure. Different methods and 
validation tests used to validate the conceptual model were: degeneracy test, data 
relationship correctness test, mathematical and statistical methods, tracing and structured 
walkthrough. Each of these types of data has been validated as follows: 
 Validation of the model assumptions 
All the four mentioned assumptions were validated by formally obtaining the opinion of the 
clinical expert- the approach presented in the validation literature as walkthrough validation 
technique (Sargent, 1996). The choice of 270 minutes as the upper time limit to receive tPA 
treatment is the evidence-based upper time limit adopted by majority of international stroke 
clinical guidelines (Jauch, et al., 2013). The appropriate selection of this parameter was 
validated using what is known as the degeneracy test.  
 Validation of model structure/formulation 
The logical structure of the conceptual model was validated through checking the mRS 
probability distributions, change over time formulation, numerical relationships in the 
model, and DALYs mathematical formulation. 
The mRS probability distributions: We first validated the standard assumptions underlying 
the use of logistic regression (such as independence of individual observations, appropriate 
distributional assumptions, collinearity, and model fit). We then randomly selected 80% of 
the combined observational cohort and created seven separate binary logistic regression 
models; one for each individual mRS category as the dependent variable and age, baseline 
NIHSS, and onset-to-tPA treatment time as independent variables. Then, the statistical 
validity of the mRS prediction model was evaluated in the remaining 20% of the 
observational cohort, with no significant difference between predicted and observed mRS 
categories being identified (χ2 p-value=0.51). Using these regression models we then 
generated the patient-specific probability distributions for each mRS category, and ensured 
that the sum of the probabilities for each patient is equal to one; thus validating the 
normalization scaling procedure performed at Stage 1 of the model development. 
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Numerical relationships in the model: By selecting a large enough original cohort sample 
size we ensured that the relationship between age, NIHSS, and mRS at a given point of 
onset-to-tPA treatment time (based on the cohort data), is no worse than the precision of the 
relationship between mRS and time (based on meta-analysis data). 
Changes over time formulation: As previously stated in stage 2 of the model development, to 
model how the onset-to-treatment time affects the probability of mRS 0-1 and mRS 6 for a 
specific patient, we derived relevant independent analytic expressions for mRS 0-1 and mRS 
6 curves and validated the resulting equations using the best fit R2 criterion. For both curves 
the corresponding values were R2 =0.999.  
DALYs mathematical formulation: As described at Stage 4 of the model development, 
DALY is a measure consisting of two components: years of life lost due to premature death 
(YLL) and years of life lost due to disability (YLD). Data relationship correctness technique 
was employed to validate different parts of DALYs’ formulation. For instance, if we 
compare the values for DALYs between a female and a male patient with identical age and 
mRS category, the DALYs for a female patient is expected to be greater than that of the male 
patient. 
Each of the three mentioned components of the conceptual model structure were validated by 
tracing the formulation separately by different members of the model development team and 
the results were compared to identify and resolve inconsistencies. Also, the structured 
walkthrough validation technique was employed to ensure that the logical behaviour of the 
conceptual model is aligned with the clinical practice by explaining the model assumptions, 
parameters and formulation to a clinician. 
The summary of different validation methods and techniques used to obtain conceptual 
validity of the ‘IV tPA’ model has been provided in Table 4-7. 
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Validation task Why we performed the validation task How we performed the validation task The conclusions/results of the 
validation task 
Degeneracy test Based on: (Gass, 1983; Sargent, 2013) 
Limitation of upper treatment time to 270 
minutes 
An appropriate selection of the internal 
parameters directly affects the accuracy of 
the logical behaviour of the conceptual 
model. 
Based on published international stroke clinical 
guidelines we observed that the vast majority of 
these studies implemented the 270 minutes time 
window, although a few still used the old 180 
minutes, which was based on guidelines up to 
year 2008. 
Increased credibility of the model as the 
vast majority of the users of the model 
outputs will consider the time window 
appropriate. 
Data relationship correctness Based on: (Sargent, 2013) 
DALYs mathematical formulation To ensure that there is a logical 
relationship between DALYs’ values of 
female and male patients. 
The values for DALYs between a female and a 
male patient with similar characteristics were 
compared. 
Increased credibility of DALYs 
formulation used for male and female 
patients. 
Numerical relationships in the model To ensure that there is a logical 
relationship between different data 
components used to build the conceptual 
model. 
 
 
We selected a large enough original cohort 
sample size to ensure that the precision of the 
regression coefficient estimates describing the 
relationship between age, NIHSS, and mRS at a 
given point of onset-to-tPA treatment time 
(based on the cohort data) is no worse than the 
precision of the relationship between mRS and 
time (based on the meta-analysis data) 
This increased the overall precision of 
the estimates leading to the increased 
validity of the model. 
Tracing Based on: (Balci, 1994; Sargent, 2013) 
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Change over time formulation To ensure that the logical behaviour of the 
formulation is correct and the required 
accuracy obtained. 
The process of building and selecting the 
equations to formulate the effect of onset-to-
tPA treatment times on probability distributions 
was performed separately by three members of 
the model development team and the results 
were compared for any inconsistency. 
The equations used to formulate the 
effect of onset-to-tPA treatment times 
on probability distributions were 
verified and the equations were 
corrected where necessary. 
mRS probability distributions To ensure that the logical behaviour of the 
prediction model is correct and the 
required accuracy obtained. 
The statistical process of constructing the 
prediction model was performed separately by 
three members of the model development team 
and the results were compared for any 
inconsistency. 
We confirmed that there is no 
significant difference between predicted 
and observed mRS categories to be used 
for building the conceptual model. 
DALYs mathematical formulation To ensure that the logical behaviour of the 
DALYs formulation is correct and the 
required accuracy obtained. 
The logical behaviour of the DALYs 
formulations was reviewed separately by three 
members of the model development team and 
the results were compared for any 
inconsistency. 
DALYs formulations were verified and 
the equations were corrected where 
necessary. 
Mathematical and statistical validation 
methods 
Based on: (Balci, 1994; Gass, 1983; Schellenberger, 1974) 
Change over time formulation To ensure that the equations used to build 
the conceptual model are accurate enough. 
We derived the relevant analytical expressions 
for mRS 0-1 and mRS 6 curves by selecting 5 
point estimates in the lines and selected the best 
fit among the resulting equations using the 
Correct representation of the 
relationship between OR and time is 
achieved. 
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R2criterion (achieving R2 of 0.999). 
To ensure that the probability equations 
used to build the conceptual model are 
logically correct. 
We ensured that the sum of probabilities for 
each patient generated in Stage 1 of the model 
is equal to one. 
Increased credibility and accuracy of the 
probability equations. 
mRS probability distributions To ensure that the mRS probability 
distributions used to build the conceptual 
model are logically correct. 
We randomly selected 80% of the combined 
observational cohort and constructed binary 
logistic regression models for each individual 
mRS category. The statistical validity of the 
mRS prediction model was evaluated in the 
remaining 20% of the observational cohort. 
We ensured that the regression model 
constructed based on the 80% of the 
observational cohort was reflecting the 
nature of the relationships in the 
remaining 20%, therefore being valid 
for the full observational cohort. 
Structured walkthrough and face validity Based on: (Balci, 1994; Hermann, 1967; Oral & Kettani, 1993; Sargent, 2013; Williams & Sikora, 1991) 
Conceptual model building To ensure that the conceptual model is 
accurate enough for its intended use. 
The logic of the model structure, assumptions, 
and parameters were explained step by step to a 
clinician who asked questions and challenged 
the choices, leading to significant iterative 
model changes. 
The logic of the model follows true 
clinical practice. 
Table 4-7 Validation tests and techniques utilized for conceptual model validation of different components of the ‘IV tPA’ model 
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4.7.3 Computational verification 
By computational model verification, the modeller ensures that the computer programs and 
codes to build the computer model of the conceptual model have been used and implemented 
correctly. For the present model, this consisted of two main stages: (1) computations 
verification in Excel; and (2) code scripts verification in Stata. Different techniques used for 
computational verification were debugging, walkthrough and execution tracing. All the 
model components shown in Figure 4-3 have been verified using different techniques of the 
computational verification. 
 Computations validation in Excel 
The observational cohort data, mRS category-specific life expectancies, and DALYs lost for 
each combination of age and sex of stroke patients were all stored in Excel worksheets 
accessible to Stata software through a set of Stata codes. After running the model in Stata, 
the model outcomes were also exported and stored in a separate Excel worksheet for data 
processing purposes. The walkthrough verification technique was employed by the analytical 
expert to verify the correct storage and execution of the computations in the Excel 
worksheets. 
 Code scripts verification in Stata 
The conceptual model implementation and outcome analysis were mainly executed in Stata, 
through a set of codes developed within the software to run the model as well as to link Stata 
to Excel worksheets. Debugging and execution tracing verification techniques (Whitner & 
Balci, 1989) were employed to verify the codes in Stata.  
The summary of different verification methods and techniques used for computational 
verification of the ‘IV tPA’ model has been provided in Table 4-8. 
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Validation task Why we performed the validation task How we performed the validation task The conclusions/results of the validation 
task 
Debugging  Based on: (Dunn, 1987; Whitner & Balci, 1989) 
Code scripts in Stata To confirm the correctness of the codes 
used to build the computational model. 
The code script in Stata was screened to 
locate and correct the potential errors. 
Typing and logic errors were identified and 
removed. 
Walkthrough  Based on: (Adrion, et al., 1982; Deutsch, 1981; Myers, 1978; Yourdon, 1979) 
Computations in Excel To ensure that all the computations used 
to build the computational model are 
correct. 
The analytical expert verified the correct 
storage and execution of the computations 
in the Excel worksheets. 
Storage and execution of relevant 
computations of the model were verified and 
revised in Excel worksheets. 
Execution tracing  Based on: (Whitner & Balci, 1989) 
Code scripts in Stata To confirm the correctness of the codes 
used to build the computational model. 
Defects of the code script in Stata were 
located and corrected by line-by-line 
execution of the code by an analytical 
expert. 
Typing and logic errors were identified and 
removed. 
Table 4-8 Validation tests and techniques utilized for computational model verification of different components of the ‘IV tPA’ model 
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4.7.4 Operational validity 
To achieve operational validity, the outputs of the DS model as shown in Figure 4-3 in blue 
box, were verified to obtain the accuracy needed for the intended use of the model. Since the 
‘IV tPA’ model presents the first OR model used to investigate the effect of faster access to 
thrombolysis treatment, there was no data available in a real-life system to be used for 
specifying a clear range of the values of the DALYs per unit of onset-to-treatment time. 
However, other studies in stroke literature have addressed the issues of a plausible range of 
expected DALYs in the absence vs the presence of treatment, thus providing an acceptable 
range for the model outputs over the full range of plausible onset-to-treatment time. In this 
scenario, different techniques used to validate the operational model are output analysis, 
robustness analysis, comparison to the results produced by other known models, and tests to 
validate an appropriate application of the model. The summary of different validation 
methods and techniques used to obtain operational validity of the ‘IV tPA model’ model has 
been provided in Table 4-9. 
 Validation of the model output 
The accuracy of the expected DALYs (as the final output of the model) was validated by 
output analysis, robustness analysis, and comparison to the results produced by other models 
as described below:  
Different graphs and summary statistical measures (i.e. mean, median, 95% CIs) were 
generated to validate the model outputs (Meretoja, et al., 2014). The updated results of the 
tPA randomized controlled trials published by Emberson, et al. (2014) were used to validate 
the model outputs. In that update, the authors only provided the odds ratio of the mRS 0-1 
graphically which we used with that of the mRS 6 provided earlier in a paper by Lees, et al. 
(2010) to validate the initial outcomes of the ‘IV tPA’ model. As a result, for every minute of 
onset-to-tPA treatment time saved the patients gained on average extra 1.5 days of healthy-
life; which was consistent with the results obtained earlier from the meta-analysis by Lees, et 
al. (2010). 
Also, DALYs gained per tPA treated patient for this study were compared to the results of a 
long-term utility of tPA (DALY/QALY gains) from other studies (Meretoja, et al., 2014). 
Additionally, we ran both one-way analysis and probabilistic analysis to validate the model 
outputs with results from both analyses confirming the robustness of the model.  
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 Validation of the model application 
In order to ensure operational validity, the model developers and users should formulate their 
understanding of the intended application of the model and its boundaries before employing 
the model and its results as a decision support tool. For our model, these included the 
following considerations: 
1. Intended model use in different population demographics: since the study dataset 
is based on two separate populations, the characteristics of the Helsinki and SITS-
Australia cohort, as well as the mixed cohort were provided for comparison (Table 
4-2). In addition, as presented in Figure 4-2, we developed a histogram of onset-to-
treatment time distributions for each of the two cohorts separately to be considered 
before generalizing the results of the study (Meretoja, et al., 2014). 
2. Intended model use in different patient groups: the findings of the study 
demonstrate that patients with different gender, age and NIHSS benefit differently in 
terms of disability-free life over their full life-time. These differences were presented 
earlier in Figure 4-4 and Table 4-4 (Meretoja, et al., 2014).Therefore, caution should 
be exercised if the model were to be used as a decision support tool to understand 
the long term effects of earlier tPA treatment for specific patient groups. 
3. Intended model use compared to other studies: The results generated by this 
study seem to be consistent with other studies with regard to an increased benefit in 
patient’s outcome when treated with tPA. Table 4-9 provides the summary of studies 
comparing the long-term utility of tPA vs. no tPA in acute ischemic stroke 
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Study Population Time horizon 
Discount rate 
of future 
utilities 
QALYs or 
DALYs gained 
per tPA 
treated patient 
Fagan, et al. (1998)  USA 30 years 0% 0.75 
Sinclair, et al. (2001)  Canada 30 years 3% 3.46 
Sandercock, et al. (2004)  UK Lifetime 6% 0.04 
J. Mar, Begiristain, and 
Arrazola (2005) 
Spain Lifetime 3% 0.53 to 0.66 
Ehlers, Andersen, 
Clausen, Bech, and 
Kjolby (2007) 
Denmark 30 years 5% 0.43 
Johnston (2010) USA 30 years 0% 0.75 
Tung, Win, and Lansberg 
(2011) 
USA Lifetime 3% 0.28 
National Institute for 
Health and Clinical 
Excellence (NICE) (2012)  
UK Lifetime 3.5% 0.33 
Present paper (Meretoja, 
et al., 2014) 
Finland and 
Australia 
Lifetime 
0% 0.71* 
3% 0.52* 
*Median onset-to-treatment of 125 minutes compared to not treating at all. 
 
Table 4-9 Studies comparing long-term utility of tPA vs. no tPA in acute ischemic stroke. DALYs, 
Disability-Adjusted Life Years; QALYs, Quality-Adjusted Life Years. 
4. Actual model use in terms of benefits for the stroke patients: In practice, IV tPA 
treatment is successful only in half of the patients who are given this treatment 
(Lees, et al., 2010). Therefore, while half of the patients do not benefit from faster 
tPA treatment, the other half benefit twice as much as we stated here for the whole 
cohort, since these are often patients with younger ages and lower stroke severities. 
While in medical practice, there is no accurate method of distinguishing between 
these two groups of the patients, it is important to provide the fastest possible 
treatment for all the patients. 
5. Actual model use for increased public awareness: The ‘IV tPA’ model was 
developed to provide better understanding of the effect of faster tPA treatment on 
patient lifetime outcomes. Ideally, this is supposed to directly lead to an increased 
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awareness of public policy decision makers, stroke campaigns, and stroke care 
system providers of the importance of faster treatment for stroke patients. The 
summary of different validation methods and techniques used to obtain operational 
validity of the ‘IV tPA’ model has been provided in Table 4-10. 
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Validation task Why we performed the validation task How we performed the validation task The conclusions/results of the validation 
task 
Output analysis Based on: (Balci, 1994; Gass, 1983; Sargent, 2001) 
Model output To identify any unusual behaviour of the 
model and pin-pointing errors that would 
not have been identified solely through 
summary statistics. 
We created multiple graphical 
representations of individual patients and 
time series to validate the model outputs. 
 
We found errors in the outputs as a result of 
either incorrect logic or implementation of the 
model which were subsequently corrected. 
Robustness  Based on: (Balci, 1994; Boehm, et al., 1976; Gass, 1983; Myers, et al., 2011; Sargent, 2013; Whitner & Balci, 1989) 
Model output To check the model’s behaviour while 
changing the parameters and inputs of the 
model.  
Two approaches of the robustness were 
used: one-way analysis and probabilistic 
robustness analysis. 
Credibility of the outputs was increased by 
providing the users with estimates of 
uncertainty. 
Comparison of the model outputs Based on: (Sargent, 2013; Williams & Sikora, 1991) 
Model output To ensure that the model’s outputs are 
accurate enough for the intended use of the 
model. 
DALYs gained per tPA treated patient for 
this study was compared to the results of a 
long-term utility of tPA (DALY/QALY 
gains) from other studies (DALYs gained 
per tPA treated patient for the “Save a 
minute – save a day” model is 0.72 
compared to 0.75 of QALYs gained for 
Credibility of the outputs was increased by 
providing the comparison to other relevant 
studies. 
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two other similar studies.) 
To ensure that the model’s outputs are 
accurate enough for the intended use of the 
model. 
The updated results of tPA randomized 
controlled trials used to estimate the tPA 
effect treatment over time published by 
(Emberson, et al. (2014)) were used to 
generate the model outputs, and the results 
were compared to the previous results 
obtained by the model. 
Increased credibility of the model’s outputs.  
 
Intended use of the model Based on: (Gass, 1983; Pidd, 2010) 
Model application To verify the decisions made based on the 
model outputs. 
We discussed the limitations and 
boundaries of application of the model in 
the original article discussion section. 
Users of the decision support model will 
understand the limitations and will not 
overgeneralize or use the model outside of its 
intended use. 
Table 4-10 Validation tests and techniques utilized for operational validation of different components of the ‘IV tPA’ model. 
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To summarize, the ‘IV tPA’ model is a model for investigation and improvement as it was 
used to provide better understanding of the effects of early access to IV tPA treatment on 
patients’ long-term benefits. The generic validation framework developed in Chapter 3 was 
adopted to validate the model in four aspects of data validity, conceptual model validity, 
computational verification, and operational validity. This increased the credibility of the 
outcomes generated by this model for its intended use. 
4.8 Problem description and intended use of the ‘Endovascular Thrombectomy’ 
model 
The results of a new generation of acute stroke trials from different parts of the world, all 
published in one of the prominent medical journals in the world called ‘New England 
Journal of Medicine’ has shown that the intra-arterial (IA) endovascular thrombectomy 
intervention is a new gold treatment for ischemic stroke patients (Berkhemer, et al., 2015; 
Campbell, et al., 2015; Goyal, et al., 2015; Jovin, et al., 2015; Saver, et al., 2015). According 
to these studies, this intervention can be successfully used to further improve the outcomes 
when given within 6 hours from stroke onset to eligible stroke patients who already have 
received tPA treatment. Despite the accepted health benefits of faster access to endovascular 
thrombectomy treatment for stroke patients, prior to this research there was no method for 
quantifying the link between reductions in treatment delays for endovascular thrombectomy 
and patients’ lifetime benefits. In this thesis, we describe the ‘Endovascular Thrombectomy’ 
OR model which is designed and validated to provide better understanding of the benefits of 
earlier access to endovascular thrombectomy therapy.  
The ‘Endovascular Thrombectomy’ model is a model for investigation and improvement as 
it is used to provide better understanding of the long-term effects of earlier treatment on 
patients’ outcomes with regard to endovascular thrombectomy intervention. As discussed in 
Chapter 2, this type of model is often used to “support investigations that are relatively 
unique, which may involve system design, system improvement or just an attempt to gain 
understanding of a very complex situation” (Pidd, 2010, p. 18).  
At the time of the submission of this thesis, the results of the ‘Endovascular Thrombectomy’ 
model were accepted for publication in ‘Neurology’ (Meretoja, et al., 2017). The findings of 
this model are expected to be used by service providers in the hyperacute stroke care system 
to advocate for equipping the stroke unit centres with expertise and facilities needed for 
endovascular thrombectomy intervention. 
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4.9 Overview of the ‘Endovascular Thrombectomy’ model 
The ‘Endovascular Thrombectomy’ model is the first OR model used to explicitly quantify 
the link between reductions in treatment delays before endovascular thrombectomy treatment 
and patients’ lifetime benefits. The ‘Endovascular Thrombectomy’ model was developed by 
extending the ‘IV tPA’ model presented in this chapter. Most inputs and parameters used to 
develop this model were adopted from the ‘IV tPA’ model; this includes pooled analysis of 
tPA effect over time, general population life expectancy data, and different parameters to 
estimate DALYs. Other model inputs used to develop this model are observational real-life 
cohort data of endovascular eligible patients and pooled analysis of endovascular 
thrombectomy effect over time.  
Summary of new parameters used to conceptualize the ‘Endovascular Thrombectomy’ 
model is presented in Table 4-11. These parameters are used in Section 4.12 to develop the 
‘Endovascular Thrombectomy’ model. 
Parameter name Definition  
t (maximum 270 min) onset-to-tPA treatment time 
tIA (maximum 360 minutes) onset-to-IA treatment time 
I different levels of mRS 
tPA cumulative odds mRSi (t) cumulative odds ratio of a specific mRS level at 
time t after delivery of the IV tPA intervention 
IA effect odds ratio (tIA) fitted value of the odds ratio for common mRS 
outcome at time t 
IA cumulative odds mRSi (tIA) cumulative odds ratio of a common mRS at time 
tIA after delivery of the endovascular 
thrombectomy intervention 
Table 4-11 Summary of different parameters of the ‘IV tPA’ model 
The main output of this model is expressed as number of disability-adjusted days saved per 
minute of earlier treatment for endovascular thrombectomy. Figure 4-6 presents an overview 
of the ‘Endovascular Thrombectomy’ model with all the model inputs. Detailed description 
of these inputs is provided in the next section.  
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Figure 4-6 Overview of the ‘Endovascular Thrombectomy’ model. mRS indicates modified Rankin 
Scale; NIHSS, National Institutes of Health Stroke Scale; tPA, tissue plasminogen activator; IA, intra-
arterial clot removal therapy; OR, odds ratio of tPA effect of mRS 0-1 and mRS 6 over time; acOR, 
accumulative odds ratio of the IA effect of common mRS over time 
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4.10 Overview of the ‘Endovascular Thrombectomy’ model inputs 
To build the ‘Endovascular Thrombectomy’ model, part of data was adopted from the ‘IV 
tPA’ model, which has been described in Section 4.2. In this section, we describe the new 
model inputs used to build the ‘Endovascular Thrombectomy’ model as follows: 
1. An observational cohort data of consecutive tPA patients: While for the ‘IV tPA’ 
model we retrieved data from both Finnish and Australian databases, for the 
‘Endovascular Thrombectomy’ model, we extracted the observational cohort only 
from an updated Helsinki Stroke Thrombolysis Registry database since only data in 
this registry included eligible patients to receive endovascular thrombectomy 
treatment. Data for this registry was generated during the period between June 1995 
and September 2014 and included relevant patient information for 2799 patients 
treated with tPA. Of this population, we included data for 2474 patients with their 
distributions of age, sex, and stroke severity, onset-to-tPA treatment times; and 
mRS. Of these patients, 2328 did not receive endovascular thrombectomy therapy, 
and 729 would have been eligible to receive endovascular therapy (i.e. patients who 
already have received or would have been eligible to receive endovascular therapy). 
Table 4-12 shows distributions of age, gender, NIHSS, onset-to-tPA treatment time, 
and mRS for IV tPA only and endovascular suitable cohorts. 
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Characteristics and 
outcome 
IV tPA only cohort 
(n=1745) 
Endovascular suitable 
cohort (n=729) 
P Value 
Age, y 70 (60-77) 
68±13 
69 (61-76) 
67±13 
0.209 
0.360 
Male sex 1247 (55%) 939 (54%) 0.704 
NIHSS at baseline 7 (4-11) 
8±5 
13 (7-18) 
13±6 
<0.001 
<0.001 
Onset-to-tPA treatment 
time, min 
120 (88-163) 
129±52 
106 (79-150) 
120±53 
<0.001 
<0.001 
3-Month mRS score 0 to 1 801 (45.9%) 187 (25.7%) <0.001 
3-Month mRS score 0 to 2 1164 (66.7%) 333 (45.7%) <0.001 
3-Month mRS 6 112 (6.4%) 103 (14.1%) <0.001 
Table 4-12 Characteristics of the observational cohort. Data are n (%), median (interquartile range), 
or mean ± SD. Distributions of IV tPA only and endovascular suitable data compared with Mann-
Whitney U test 𝑥2 test, or Student t test as appropriate, with 2-sided statistical significance set at 
P=0.05. mRS indicates modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale. 
2. Published pooled analysis of IV tPA and endovascular thrombectomy effects 
over time: We used the results of a published pooled analysis by Lees, et al. (2010) 
as described earlier in this chapter for the ‘IV tPA’ model to model the effect of tPA 
over time. Then, to model the effect of endovascular therapy in addition to tPA 
treatment compared with tPA alone over time, we used the common odds ratio for 
the improved outcome of the 6-level of mRSs with corresponding confidence 
intervals as summarized graphically in a paper by Saver, et al. (2016). This pooled 
analysis has been derived from the results of the five recent randomized trials, all 
published in the New England Journal of Medicine (Berkhemer, et al., 2015; 
Campbell, et al., 2015; Goyal, et al., 2015; Jovin, et al., 2015; Saver, et al., 2015). 
3. General Australian population life expectancy age- and sex- specific data 
obtained from Australian Bureau of Statistics: An updated version of the life 
expectancy data used in the ‘IV tPA’ model (available at the time of developing this 
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model), were adopted here to model the long-term survival of patients at various 
mRS categories compared with the general population (Australian Bureau of 
Statistics, 2013-2015). The average life-expectancy of this updated database was 
compared to that of the ‘IV tPA’ model and no significant difference was observed. 
Similar to the ‘IV tPA’ model, this data was used to model the long-term survival of 
patients at various mRS categories compared with the general population. 
4.11 Model assumptions 
Five main assumptions were formulated to build this model. The first two assumptions are 
adopted from the ‘IV tPA’ model, while the other three assumptions have been specifically 
formulated to build the ‘Endovascular Thrombectomy’ model as follows: 
1. The upper time limit to receive tPA treatment was set to 270 minutes. 
2. To generate mRS probabilities after tPA intervention, we assumed that the 
relative ratios of probabilities of achieving mRS 0 and mRS 1 are identical to 
those at the baseline onset-to-tPA treatment time. Similarly, we assumed that the 
relative ratios of achieving mRS categories 2-5 at any time, are identical to those 
at the baseline onset-to-tPA treatment time. 
3. To build this model, we assumed that endovascular eligible cohort patients first 
receive tPA treatment and then undergo endovascular thrombectomy therapy. 
4. The upper time limit to receive thrombectomy treatment was set to 360 minutes.  
5. We assumed 90 minutes delay between IV tPA and thrombectomy intervention 
to estimate the added value of endovascular therapy over and above tPA alone 
for stroke patients.  
4.12 Overview of the model building process 
The ‘Endovascular Thrombectomy’ model was constructed in six stages as shown in Figure 
4-7. These stages have been discussed in details as follows: 
To build this model, we first repeated Stages 1 to 3 of the ‘IV tPA’ model (i.e. described in 
Section 4.4 of this chapter), to model the effect of onset-to-tPA treatment time delays on the 
probability of achieving each mRS category for stroke patients. A difference to the ‘IV tPA’ 
model here is that, in this model we used data of the observed 3-month outcomes of the 
patients from cohort who did not receive endovascular thrombectomy therapy (n=2328) to 
construct the binary logistic regression model. We then used data of the endovascular 
eligible cohort patients (n=729) to build the rest of the model. These included patients who 
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already received or were eligible to receive endovascular thrombectomy therapy. We then 
built the rest of the model using Stages 4 to 6 as described below:  
Stage 4: Generating patient-specific cumulative odds for each mRS outcome after tPA 
intervention- We used the probabilities of achieving a specific mRS level at any time 
generated earlier in Stage 3 of the model building process to generate the patient-specific 
cumulative odds for each mRS category after IV tPA treatment (tPA cumulative odds mRSi 
(t)). The cumulative odds for each mRS category is estimated using the equation 4-6. This 
will be used in the next stage to generate the probabilities of achieving each mRS category 
after endovascular thrombectomy intervention.  
tPA cumulative odds mRSi (t) = tPA cumulative mRSi (t)/(1- tPA cumulative mRSi (t))              (4-6) 
i = 0, 1, 2, 3, 4, 5, 6                                                                                                                          
Stage 5: Modelling the change in probabilities of achieving a specific mRS outcome 
after endovascular thrombectomy intervention at any time - We used the result of a 
recent pooled analysis trial recognized as HERMES (Saver, et al., 2016), where the authors 
provide a graphical estimation of the effect of endovascular therapy treatment delays in 
addition IV tPA treatment compared to tPA alone for ischemic stroke patients. This has been 
reported by the authors in a graphical format for improved outcome of the 6-level of mRSs 
without providing any analytical expressions for the odds ratio curve. The graphical curve 
reported in that article demonstrates the change in the odds ratio of achieving a common 
mRS outcome as a function of onset to expected-arterial-puncture time between 120 and 510 
minutes (Saver, et al., 2016). In this thesis, we refer to this time as onset-to-IA treatment 
time (tIA). 
To build this model we derived relevant analytical expressions for common mRS odds ratio 
using the best fit (based on adjusted R2 criterion) and used this equation to estimate the odds 
ratio for common mRS as a function of onset-to-IA time for any value of onset-to-IA time 
between 0 and 360 minutes (i.e. the currently accepted evidence-based upper time limit for 
tPA treatment) (Berkhemer, et al., 2015; Powers, et al., 2015). 
The IA effect odds ratio(tIA) reported by Saver, et al. (2016) presents the ratio of odds of 
achieving common mRS, by patients treated with endovascular thrombectomy in addition to 
IV tPA treatment at onset-to-IA treatment time (tIA) and the odds of achieving the same 
outcome by the patients treated with tPA alone. As it will be stated explicitly in the model 
assumptions, in this model we assume that the patients receive endovascular therapy with 
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90-minutes delay after they receive tPA treatment. Then, using the patient-specific tPA 
cumulative odds mRSi (t) estimated earlier in Stage 4, we calculate the cumulative odds for 
each mRS category after endovascular therapy using the equation 4-7: 
IA cumulative odds mRSi (tIA) = IA effect odds ratio (tIA) * tPA cumulative odds mRSi (t)             (4-7) 
i = 0, 1, 2, 3, 4, 5, 6 
We stated earlier in Section 4.11 of this chapter, that to build this model we assumed 90 
minutes delay between the IV tPA and endovascular thrombectomy intervention, thus: 
t = t0 + 90                                                                                                                                           (4-8) 
Having generated the IA cumulative odds for each mRS outcome (IA cumulative odds mRSi 
(tIA)), we then estimated the probabilities of achieving a specific mRS after endovascular 
thrombectomy intervention at any time for individual patients. 
Stage 6: Estimating the expected Disability-adjusted Life Years (DALY) lost - Using 
DALYs equation as described in Stage 4 of Section 4.4 of this chapter, we estimated DALYs 
lost for each patient in the observational cohort at onset-to-IA treatment time, and then we 
modelled the DALYs lost with regard to the treatment delays for each patient after 
endovascular thrombectomy treatment. 
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Figure 4-7 Overview of different stages of model building process 
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4.13 Result of treating faster in the whole cohort and individual patients 
In the whole cohort, we generated the results for one minute earlier of onset-to-IA treatment 
time according to the World Health Organization (WHO) policy updated in 2012 to report 
DALYs without age-weighting (K = 0) and discounting (r = 0) factors (Murray, et al., 
2013). For these parameters (K=0, r=0), we estimated on average extra 3.2 days of DALYs 
saved per minute of earlier treatment (median 3.0, IQR, 2.0-4.1, SD 1.5, range 0.2-9.6 days 
of DALY) for the full cohort.  
It is evidenced by clinical trials that patients with various age and disease severity benefit 
differently from faster treatment. To evaluate these findings, we ran the ‘Endovascular 
Thrombectomy’ model for five individual female patients, namely: 
 a patient with median age (69 y.o.) and median stroke severity (NIHSS 13);  
 two patients with old ages (90th decile, 83 y.o.) and respectively low (10th decile, NIHSS 
4) and high stroke severities (90th decile, NIHSS 21); and 
  two patients with young ages (10th decile, 50 y.o.) and respectively low (NIHSS 4) and 
high (NIHSS 21) stroke severities.  
On average a 69 years old female patient with median stroke severity gained extra 3.7 days, 
a 50 y.o. patient with mild stroke and severe stroke gained extra 2.9 and 6.9 days 
respectively, and a 83 y.o. patient gained extra 1.2 and 1.6 days respectively for each minute 
saved. As it is evidenced by the results of the model, the younger patients gain more benefit 
from faster treatment because of their longer lifetime.  
Moreover, as it can be seen in Figure 4-8, we generated disability adjusted days saved per 
minute of earlier treatment for female and male stroke patients for different age and severity 
groups. In two graphs presented in Figure 4-8, patients from cohort data has been 
categorized into five NIHSS severity groups (0-4, 5-9, 10-14, 15-19, 20+), and five age 
groups (<55, 55-64, 65-74, 75-84, 84+), while the point estimates show the disability 
adjusted days saved per minute of earlier treatment for that group of patients. Due to small 
number of patients in few groups (those with very young and high disease severity or very 
old and mild severity), the linear trend of age group lines is changed for these cases. As 
shown in Figure 4-8, this non-linear trend can be observed especially for male patients above 
age 84, and female patients below age 55.  
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By comparing data between the female and male groups, it can be observed that female 
patients often benefit more from faster treatment over their longer life time. For patients with 
different age groups, disability-adjusted days saved per faster treatment often increases as 
NIHSS increases. Also, by fixing the NIHSS group in any of the figures presented below, 
and moving from patients with younger ages towards those with older ages, the benefits of 
faster treatment decreases. Point estimates and 95% prediction intervals for each of these 
groups have been provided in Table 4-10. 
 
 
 
Figure 4-8 Relationship between disability-adjusted days gained per minute of faster treatment by age 
and stroke severity. Baseline stroke severity measured with the National Institute of Health Stroke 
Scale (NIHSS) where higher scores indicate more severe stroke 
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Sex, Age NIHSS 0-4 NIHSS 5-9 NIHSS 10-14 NIHSS 15-19 NIHSS 20 + 
Male      
<55 2.61 (0.63-3.45) 3.98 (1.12-5.00) 5.26 (1.37-6.61) 5.66 (1.28-7.31) 6.99 (1.88-8.25) 
55-64 2.09 (0.54-2.72) 2.77 (0.70-3.61) 3.85 (1.02-4.88) 4.57 (1.11-5.70) 4.97 (1.36-5.93) 
65-74 1.81 (0.53-2.27) 2.35 (0.72-2.88) 2.95 (0.76-3.76) 3.50 (0.95-4.25) 3.24 (0.84-3.94) 
75-84 1.23 (0.37-1.53) 1.60 (0.48-1.99) 1.95 (0.60-2.35) 2.01 (0.50-2.54) 2.00 (0.55-2.43) 
85 + 1.18 (0.30-1.44) 0.88 (0.24-1.41) 1.35 (0.40-1.73) 1.20 (0.23-1.77) 0.76 (0.22-0.93) 
Female 
     
<55 3.59 (1.10-4.36) 4.06 (1.00-5.15) 5.27 (1.23-6.67) 6.06 (1.45.-7.54) 7.61 (1.82-9.04) 
55-64 2.55 (0.71-3.15) 3.12 (0.84-3.87) 4.54 (1.33-5.39) 5.23 (1.31-6.38) 5.47 (1.26-6.63) 
65-74 1.98 (0.61-2.41) 2.72 (0.81-3.27) 3.51 (0.96-4.24) 4.00 (1.23-4.59) 3.99 (0.92-4.87) 
75-84 1.50 (0.47-1.82) 1.91 (0.55-2.33) 2.37 (0.74-2.77) 2.55 (0.75-3.01) 2.11 (0.61-2.49) 
85 + 1.04 (0.33-1.23) 1.04 (0.36-1.18) 1.16 (0.34-1.54) 1.35 (0.42-1.70) 0.98 (0.29-1.26) 
Figure 4-9 Point estimates and 95% prediction intervals for disability adjusted days gained per 
minute saved in tPA delivery, per sex, age, and stroke severity 
Figure 4-10 presents the effect of treatment delay on Disability-adjusted Life Years 
(DALYs) for five individual female patients. For the ‘IV tPA’ model, this was presented 
using different age weighting and discounting factors without observing significant 
difference between the generated results associated with these parameters. Therefore, in this 
model we only report the results for DALYs without age-weighting (K = 0) and discounting 
factor (r = 0) with its 95% prediction intervals.  
As it is shown in Figure 4-10, by increasing the onset-to-IA treatment time from 90 to 360 
minutes, the DALYs lost increases for all the five individual patients. Thus, it can be 
concluded that all patients with various characteristics will benefit by earlier endovascular 
thrombectomy treatment. The choice of 90 minutes as the minimum onset-to-IA treatment is 
based on the assumption stated earlier for the ‘Endovascular Thrombectomy’ model that 
there is 90 minutes delay between the IV tPA and endovascular thrombectomy treatments for 
the patients receiving these interventions.  
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Figure 4-10 Effect of treatment delay with 95% prediction interval on Disability-adjusted Life Years 
(DALYs) in 5 individual female cases with median, top, and bottom decile age/National Institute of 
Health Stroke Scale (NIHSS). IA indicates Intra-arterial clot removal therapy. 
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4.14 Robustness analysis 
Similar to the ‘IV tPA’ model, we ran both one-way analysis and probabilistic analysis to 
evaluate the model robustness. To account for potential uncertainties in the cohort data, we 
performed a series of one-way analyses by systematically and sequentially substituting the 
upper and lower 95% CIs values for the regression coefficients for the age and NIHSS 
generated by the binary logistic regression models used to estimate different levels of mRS. 
To account for potential uncertainties of the pooled analysis of tPA and endovascular therapy 
effects over time, we modified the equations of odds ratio for mRS 0-1 and mRS6 and 
common mRS odds ratio reported respectively in a paper by Lees et al. (2010) and Saver, et 
al. (2016) to sequentially reflect the upper and lower 95% confidence limits for these odds 
ratio curves. 
In one-way analysis by varying the odds ratio of mRS 0-1 to the lower and upper 95% CIs 
respectively adopted from the paper by Lees at al (2010), a patient benefits on average extra 
2.29 and 4.02 days for each minute saved. These values are changing between 2.34 and 3.38 
days when varying the odds ratio of mRS 6 to the lower and upper 95% CIs as presented in a 
paper by Lees et al (2010). These values are changing between 2.85 and 3.32 days when 
varying the odds ratio of IA common mRS to the lower and upper 95% CIs as reported in a 
paper by Saver, et al. (2016).  
Regarding the effect of age and NIHSS on outcome, a patient benefits vary from 2.83 to 3.51 
days for age, and 3.08 to 3.23 days for each minute saved. For all of these robustness 
analyses a point estimate was 3.15 days for each minute saved (Table 4-13). 
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Inputs in the one-way analysis 
Disability-adjusted days saved per minute of faster treatment 
Lower value Upper value 
Odd of endovascular on mRS* 2.85 3.32 
Odds of tPA on mRS 0-1†  2.29 4.02 
Odds of tPA on mRS 6† 2.34 3.38 
Effect of age on outcome ‡ 2.83 3.51 
Effect of NIHSS on outcome ‡ 3.08 3.23 
* Upper and lower 95% CIs from the pooled analysis of Saver, et al. (2016) 
† Upper and lower 95% CIs from the pooled analysis of Lees et al (2010) 
‡ Upper and lower 95% CIs from the logistic regression model in the observational cohort.  
The point estimate is 3.15 days per minute in all cases. 
 
Table 4-13 Robustness of model when inputs changed one at a time. mRS, modified Rankin Scale; 
NIHSS, National Institutes of Health Stroke Scale. 
 
The probabilistic analysis was performed by sampling according to an underlying Normal 
distribution from the feasible space of the mRS 0-1 and mRS 6 odds ratio curves of the tPA 
effect (Lees, et al., 2010) and the common mRS odds ratio of the endovascular 
thrombectomy effect (Saver, et al., 2016) over time bounded by the 95% confidence interval 
limits. Sampling from this area will reflect various potential time effects based on the pooled 
analysis, through a set of 1000 independent runs. The resulting probability profiles for all 
mRS categories were then used to estimate DALYs gained or lost if either the whole cohort 
or an individual patient would have been treated faster or slower. As a result, we estimated a 
95% prediction interval from 2.24 to 4.05 days for each minute saved. Both one-way 
analysis and probabilistic analysis demonstrated that the results were robust overall, with the 
average point estimate of 3.15 days for each minute saved for the robustness analyses. 
Lastly, we assumed different delay times between IV tPA and endovascular thrombectomy 
interventions adopted form individual trials included in the HERMES pooled analysis trial, 
and regenerated DALYs to test the robustness of the model when changing the delay time 
between the two interventions. As shown in Table 4-14, results of these analyses were 
consistent and did not change much compared with the original outcome of the model while 
assuming 90 minutes delay between the two interventions. 
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Name of the trial Delay between tPA and 
endovascular interventions, 
min 
Average disability-adjusted 
days saved per minute of 
faster treatment 
MR CLEAN (Berkhemer, et 
al., 2015) 
155 3.3 
EXTEND IA (Campbell, et al., 
2015) 
74 3.1 
ESCAPE (Goyal, et al., 2015) 51 3.0 
SWIFT PRIME (Saver, et al., 
2015) 
110 3.2 
REVASCAT (Jovin, et al., 
2015) 
150 3.3 
Table 4-14 Average disability-adjusted days saved per minute of faster endovascular provision for the 
cohort patients 
4.15 Comprehensive validation of the ‘Endovascular Thrombectomy’ model 
In this section, we provide comprehensive validation of the ‘Endovascular Thrombectomy’ 
model using the validation framework presented earlier in Chapter 3. To achieve this, we 
validate the model with respect to four categories of data validity, conceptual model validity, 
computational verification, and operational validity. Since ‘Endovascular Thrombectomy’ 
model is an extension to the ‘IV tPA’ model, most parts of the model have been previously 
validated in Section 4.7 of this chapter; while in this section, we mainly focus on validating 
the new developed parts of the model.  
4.15.1 Data validity 
Both input data (e.g. observational cohort and general population life expectancy data) and 
previously published data in the form of various parameters estimators (e.g. pooled analysis 
of IV tPA and endovascular thrombectomy effects, annual risk of death, and disability 
weights) were used to build the ‘Endovascular Thrombectomy’ model. These data as shown 
in Figure 4-7 in orange boxes has been validated as follows: 
 Validation of input data 
Observational cohort data: The Helsinki Stroke Thrombolysis Registry used to build this 
model was previously used and validated to build the ‘IV tPA’ model. 
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Based on pre-specified inclusion criteria, the patients with onset-to-tPA treatment time 
greater than 4½ hours (n = 192), and those with deviations from standard treatment 
procedure (n = 88) and missing value on onset-to-tPA treatment time, stroke severity or mRS 
outcome (n = 43) were excluded.  
General population life expectancy: The updated version of life expectancy tables for the 
period of 2011-2013 (Australian Bureau of Statistics, 2011-2013) were adopted and 
validated to estimate DALYs, as described earlier in Section 4.7.1 of the ‘IV tPA’ model. 
 Validation of parameters 
Both the validated pooled analysis of tPA effect over time, and parameters to calculate 
expected DALYs were adopted from ‘IV tPA’ model to build the ‘Endovascular 
Thrombectomy’ model. Moreover, the pooled analysis of IA effect over time by Saver, et al. 
(2016) were used to drive how the effect of IA treatment varies with delays for onset-to-IA 
treatment time. The parameters obtained from this meta-analysis are most representative of 
the current state of the knowledge in the area of stroke endovascular intervention as the study 
includes five major randomized placebo-controlled trails of endovascular intervention for 
acute stroke patients (Berkhemer, et al., 2015; Campbell, et al., 2015; Goyal, et al., 2015; 
Jovin, et al., 2015; Saver, et al., 2015). 
The summary of different validation methods and techniques used to obtain data validity of 
the ‘Endovascular Thrombectomy’ model has been provided in Table 4-15. 
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Validation task Why we performed the validation 
task 
How we performed the validation task The conclusions/results of the 
validation task 
Representativeness of the dataset Based on: (Biau, et al., 2008; Ellenberg, 1994) 
Observational cohort data To ensure that demographics of the 
observed data have similar 
distributions to that of the published 
literature. 
We obtained consecutive prospective data from 
the Helsinki Stroke Thrombolysis registry, and 
compared patient demographics to those in 
published literature. 
Increased credibility of the data used to 
construct the model. 
To ensure that we have used suitable 
data to model the effect of tPA alone.  
We used the observed 3-month outcomes of the 
patients who did not receive endovascular therapy 
to estimate an outcome after IV tPA alone. 
Increased confidence in data used to build 
the logistic regression model for 
investigating the effect of IV tPA alone. 
To ensure that we have used suitable 
data to model the effect of 
endovascular therapy.  
We used data for patients who either received or 
were eligible to receive endovascular therapy to 
estimate an outcome after endovascular 
thrombectomy treatment. 
Increased confidence in data used to 
model the effect of time in endovascular 
thrombectomy therapy. 
General population life expectancy To ensure that the data source used to 
estimate the life expectancies is 
trustworthy. 
At the time of developing the ‘Endovascular 
Thrombectomy’ model, we used the latest official 
data for age and sex specific life-expectancies of 
the residents of Victoria, Australia, obtained from 
ABS (2013-2015). We compared these with 
dataset obtained from ABS for development of 
the ‘IV tPA’ model and we observed minimal 
Increased confidence in the accuracy of 
the estimations for the general population 
life expectancy. 
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differences.  
We also compared these with similar life-
expectancy data from Finland which was the 
source country for our cohort. We observed 
minimal differences (the average life expectancy 
at birth for men is 80.1 years in Australia versus 
78 years in Finland and for women 84.3 years 
versus 84.1 years). 
Pooled analysis of endovascular effect 
over time 
To ensure that parameters used to 
model the effect of endovascular 
therapy over time were obtained from 
a trustworthy data source. 
The parameters used to model the effect of 
endovascular thrombectomy treatment over time 
were obtained from the pooled analysis of 
individual patient data of endovascular 
thrombectomy randomize trials by Saver et al. 
This study includes five major randomized trials 
of the effect of endovascular thrombectomy for 
acute stroke, which is the most representative of 
the current state of the knowledge in the field of 
stroke endovascular thrombectomy therapy. 
Increased accuracy of the parameters used 
to model the effect of endovascular 
thrombectomy treatment changing with 
onset-to-IA treatment times. 
Table 4-15 Validation tests and techniques utilized for data validation of different components of the ‘IV tPA’ model 
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4.15.2 Conceptual model validity 
The conceptual model of the effect of treatment delays on mRS probabilities was mainly 
developed at Stages 1 to 8 of the model development. As shown in Figure 4-7 in yellow 
boxes, its validation consisted of the validation of the model’s assumptions and its logical 
and mathematical structure. Different methods and validation tests similar to the ‘IV tPA’ 
model were used to validate the conceptual model. These included: degeneracy test, data 
relationship correctness test, mathematical and statistical methods, tracing and structured 
walkthrough. 
 Validation of the model assumptions 
All the five mentioned assumptions were validated by formally obtaining the opinion of the 
clinical expert. The choice of 270 minutes as the upper time limit to receive tPA treatment 
(Jauch, et al., 2013) and 360 minutes as the upper time limit to receive endovascular 
thrombectomy were adopted according to majority of international stroke clinical guidelines 
(Berkhemer, et al., 2015; Campbell, et al., 2015; Saver, et al., 2015). The choice of 90-
minutes delay between tPA and IA intervention assumed earlier to build this model allows 
for treatment of a stroke patient with endovascular therapy when the patient receives the tPA 
treatment with maximum 270 minutes delay from stroke onset. Lastly, based on the recent 
trials (Saver, et al., 2016) all eligible patients first receive IV tPA and then undergo the 
process of receiving endovascular thrombectomy therapy.  
Using the walkthrough validation technique, these five assumptions were validated by 
formally obtaining the opinion of the clinical expert (Sargent, 1996).  
 Validation of model structure/formulation 
The logical structure of the conceptual model was validated through checking the mRS 
probability distributions, numerical relationships in the model, change over time formulation, 
and DALYs mathematical formulation separately after tPA and endovascular thrombectomy 
interventions. 
To validate the mRS probability distributions, we applied the 80-20 validation method, as 
described earlier in 4.7.2, to IV tPA cohort patients, and as a result we observed no 
significant difference between predicted and observed mRS categories (χ2 p-value equal to 
0.53). 
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Having generated the probability distributions for individual mRS categories after tPA 
treatment, we ensured that the sum of the probabilities for each patient is equal to one. Then, 
we used these tPA mRS probabilities to generate the endovascular thrombectomy mRS 
probabilities which we ensured again that the sum of the probabilities for each patient is 
equal to one; thus validating the normalization scaling procedure performed at Stage 1 of the 
model development. 
To validate the numerical relationships in the model similar to the ‘IV tPA’ model, we 
selected a large enough original cohort sample size to ensure that the relationship between 
age, NIHSS, and mRS at a given point of onset-to-treatment time for both tPA and 
endovascular interventions (based on the cohort data), is no worse than the precision of the 
relationship between mRS and time (based on the meta-analyses data). 
Validating the change over time formulation was performed by deriving relevant 
independent analytic expressions for common mRS odds ratio curve for the effect of 
endovascular thrombectomy over time and validating the resulting equation using the best fit 
R2 criterion. The corresponding value for this curve was R2 =0.996. 
Last but not least, we validated the DALYs mathematical formulation using the same 
approach as described earlier in Section 4.7.2. 
Each of the three mentioned components of the conceptual model structure were validated by 
tracing the formulation separately by different members of the model development team and 
the results were compared to identify and resolve inconsistencies. Also, the structured 
walkthrough validation technique was employed to ensure that the logical behaviour of the 
conceptual model is aligned with the clinical practice by explaining the model assumptions, 
parameters and formulation to a clinician. The summary of different validation methods and 
techniques used to obtain conceptual validity of the ‘Endovascular Thrombectomy’ model 
has been provided in Table 4-16. 
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Validation task Why we performed the validation task How we performed the validation task The conclusions/results of the validation 
task 
Degeneracy test Based on: (Gass, 1983; Sargent, 2013) 
Limitation of upper treatment time to 360 
minutes for endovascular thrombectomy 
treatment 
An appropriate selection of the internal 
parameters directly affects the accuracy of 
the logical behaviour of the conceptual 
model. 
Based on published international stroke 
clinical guidelines we observed that the 
vast majority of these studies 
implemented the 360 minutes time 
window to receive the endovascular 
thrombectomy treatment. 
Increased credibility of the model as the vast 
majority of the users of the model outputs 
will consider the time window appropriate. 
Delay time between tPA and endovascular 
thrombectomy treatment 
An appropriate selection of the internal 
parameters directly affects the accuracy of 
the logical behaviour of the conceptual 
model. 
In this model, we assumed 90-minutes 
delay between tPA and IA interventions. 
This assumption allows for treatment of 
all patients within 6 hours of onset as 
adopted in current guidelines.  
Increased credibility of the model as the vast 
majority of the users of the model outputs 
will consider the time delay appropriate. 
Tracing Based on: (Balci, 1994; Sargent, 2013) 
Change over time formulation To ensure that the logical behaviour of the 
formulation is correct and the required 
accuracy obtained. 
The process of building and selecting the 
equations to formulate the effect of onset-
to-IA treatment time on probability 
distributions was performed separately by 
three members of the model development 
team and the results were compared for 
any inconsistency. 
The equations used to formulate the effect of 
onset-to-IA treatment time on probability 
distributions were verified and the equations 
were corrected where necessary. 
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Mathematical and statistical validation 
methods 
Based on: (Balci, 1994; Gass, 1983; Schellenberger, 1974) 
Change over time formulation To ensure that the equations used to build 
the conceptual model are accurate enough. 
We derived the relevant analytical 
expressions for mRS common odds ratio 
curve by selecting 5 point estimates in the 
line, and choosing the best fit among the 
resulting equations using the R2 criterion 
(achieving R2 of 0.996). 
Correct representation of the relationship 
between odds ratio and time is achieved 
 
To ensure that the probability equations 
used to build the conceptual model are 
logically correct. 
We ensured that the sum of probabilities 
for each patient generated after the 
endovascular thrombectomy effect in the 
model is equal to one. 
Increased credibility and accuracy of the 
probability equations. 
 
Table 4-16 Validation tests and techniques utilized for conceptual model validation of different components of the ‘IV tPA’ model 
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4.15.3 Computational verification 
Similar to the ‘IV tPA’ model, this was performed by verifying the computations in Excel 
and code scripts in Stata as described earlier is Section 4.7.3, using debugging, walkthrough 
and execution tracing techniques. All the model components shown in Figure 4-7 have been 
verified using these techniques. The summary of different validation methods and techniques 
used to obtain computational model verification of the ‘Endovascular Thrombectomy’ model 
has been provided in Table 4-8. 
4.15.4 Operational validity 
To achieve operational validity, the outputs of the ‘Endovascular Thrombectomy’ model (i.e. 
shown in Figure 4-7 in blue box) were verified to obtain the accuracy needed for the 
intended use of the model. This model presents the first OR model used to investigate the 
effect of faster access to endovascular therapy, there was no data available in a real-life 
system to be used for specifying a clear range of the values of the DALYs per unit of onset-
to-IA treatment time. However, since according to clinical trials giving the endovascular 
therapy in addition to tPA treatment has even more benefits for stroke patients compared to 
tPA alone, we expected that for the ‘Endovascular Thrombectomy’ model, that patients 
benefit even more compared to the results of the ‘IV tPA’ model for every minute that they 
receive the IA therapy earlier. In this scenario, different techniques were used to validate the 
operational model are output analysis, robustness analysis, and tests to validate an 
appropriate application of the model. The summary of different validation methods and 
techniques used to obtain operational validity of the ‘Endovascular Thrombectomy’ model 
has been provided in Table 4-17. 
 Validation of the model output 
We validated the expected DALYs (as the final output of the model) using output analysis, 
robustness, and comparison to the results produced by other models as described below: 
Different graphs and summary statistical measures (i.e. mean, median, 95% CIs) were 
generated to validate the model outputs. The ‘Endovascular Thrombectomy’ model was an 
extension to the ‘IV tPA’ model which was previously validated in this chapter. This 
eventually resulted in the increased credibility of the outputs for the ‘Endovascular 
Thrombectomy’ model. We compared DALYs gained per endovascular thrombectomy 
treated patient from this model with DALYs gained per tPA treated patient from the ‘IV 
tPA’ model. According to ‘IV tPA’ model, each minute of the onset-to-tPA treatment time 
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saved resulted in on average extra 1.8 days of healthy life, while for the ‘Endovascular 
Thrombectomy’ model the patients benefit on average extra 3.2 days of healthy life; thus 
confirming the results of the clinical trials regarding the increased benefits for the stroke 
patients when they receive endovascular thrombectomy therapy compared to tPA alone.  
Also, we varied the delay time between tPA and endovascular therapy and compared the 
results for DALYs gained per endovascular thrombectomy treated patient. Lastly, we ran 
both one-way analysis and probabilistic analysis to validate the model outputs with results 
from both analyses confirming the robustness of the model.  
Similar to the ‘IV tPA’ model, different techniques used to validate the operational model 
are output analysis, robustness analysis, comparison to the results produced by other known 
models, and tests to validate an appropriate application of the model.  
 Validation of the model application 
The intended use of the model and its limitations were validated by the model developers to 
ensure the operational validity of the model as a decision support tool. For our model, these 
included the following considerations: 
1. Intended mode use in different population demographics: Since the study dataset 
is based on two subgroups, the characteristics of the tPA only cohort and 
endovascular suitable cohort was provided for comparison in Table 4-12. 
2. Intended model use in different patient groups: Similar to the ‘IV tPA’ model, 
findings of the ‘Endovascular Thrombectomy’ model demonstrate that patients with 
different gender, age and NIHSS benefit differently in terms of disability-free life 
over their full life-time. Therefore, the younger patients and women with longer 
overall life-expectancies, gain more over their life-time. 
3. Intended model use for true effect of the IV tPA and endovascular treatment 
interventions: In practice, it is not clear for the clinicians how long it takes for the 
individual stroke patient to fully realizing the effect of IV tPA treatment. Thus, while 
the goal is to deliver both IV tPA and endovascular thrombectomy interventions to 
the eligible patients at the earliest possible time, it is not evident how different 
patients would benefit from each of these interventions separately, if we stretch or 
shorten the delay time between the two interventions. To build the ‘Endovascular 
Thrombectomy’ model, we consulted an expert team of neurologists and assumed 
90-minutes delay between the interventions. 
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4. Actual model use for increased public awareness: The ‘Endovascular 
Thrombectomy’ model was developed to provide better understanding of the effect 
of faster endovascular thrombectomy therapy on patient lifetime outcomes. 
Compared to the results of the ‘IV tPA’ model, speed is even more essential in 
endovascular therapy, and the results of this model supposed to directly lead to an 
increased awareness of public policy decision makers, stroke campaigns, and stroke 
care system providers of the importance of faster treatment for stroke patients. As 
endovascular therapy is being set up around the world, time needs to be taken into 
account as a critical component of service design. We expect that the findings of this 
model promote the rational allocation of endovascular services and ambulance 
transfer patterns. 
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Validation task Why we performed the validation task How we performed the validation task The conclusions/results of the validation 
task 
Output analysis Based on: (Balci, 1994; Gass, 1983; Sargent, 2001) 
Model output To ensure that the model’s outputs are 
accurate enough for the intended use of 
the model. 
We extended the ‘IV tPA’ model to build 
the ‘Endovascular Thrombectomy’ model. 
The ‘IV tPA’ model was previously 
validated by comparing the results of the 
model with that of a long-term utility of 
tPA (DALY/QALY gains) from other 
studies; thus ensuring the outputs are 
accurate enough for the intended use of 
the model. 
Credibility of the outputs was increased by 
providing the comparison to other relevant 
studies. 
Comparison of the model outputs Based on: (Sargent, 2013; Williams & Sikora, 1991) 
 To ensure that the model’s outputs are 
accurate enough for the intended use of 
the model. 
DALYs gained per IA treated patient for 
this study was increased compared to 
DALYs gained per tPA treated patient 
from the ‘IV tPA’ model; thus confirming 
the results of clinical trials regarding the 
increased benefits for the patients when 
they receive IA therapy compared to tPA 
alone. 
Increased credibility of the model’s outputs. 
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Robustness Based on: (Balci, 1994; Boehm, et al., 1976; Gass, 1983; Myers, et al., 2011; Sargent, 2013; Whitner & Balci, 1989) 
Model output To check the model’s behaviour while 
changing the parameters and inputs of the 
model. 
We adopted different time delays between 
tPA and IA interventions from the five 
clinical trials included in the HERMES 
study and generated the model outputs 
accordingly. Results from different 
studies were compared for consistency. 
Increased credibility of the model’s outputs. 
Table 4-17 Validation tests and techniques utilized for operational validation of different components of the ‘IV tPA’ model. 
 
. 
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To summarize, the ‘Endovascular Thrombectomy’ model is a model for investigation and 
improvement as it was used to provide better understanding of the effects of early access to 
endovascular thrombectomy treatment on patients’ long-term benefits. The generic validation 
framework developed in Chapter 3 was adopted to validate the model in four aspects of data validity, 
conceptual model validity, computational verification, and operational validity. This increased the 
credibility of the outcomes generated by this model for its intended use. 
4.16 Summary and conclusions  
The chapter started with a brief description of the ‘IV tPA’ model followed by description of the 
model inputs, model-building process, and model results. As a result of this model, it was identified 
that each minute of onset-to-tPA treatment time saved result in on average extra 1.8 days of healthy 
life for stroke patients. A generic validation framework as described in Chapter 3 was then adopted to 
provide comprehensive validation of the model by demonstrating how multiple aspects of data 
validity, conceptual model validity, computational verification, and operational validity can be 
systematically addressed for a complex OR model.  
The validated ‘IV tPA’ model was then extended to construct the ‘Endovascular Thrombectomy’ 
model adopting the similar model development stages for the base model followed by comprehensive 
validation of the model using the generic validation framework. For the ‘Endovascular 
Thrombectomy’ model, it was demonstrated that on average acute ischemic stroke patients who 
undergo endovascular therapy stand to gain 4.2 days of healthy life for every minute of reduction in 
treatment delays. Additionally, it was concluded that younger patients and women with longer overall 
life-expectancies gain more over their life-time.  
As far as the modelling purpose is concerned, both ‘IV tPA’ and ‘Endovascular Thrombectomy’ 
models are fall into the category of models for investigation and improvement. In both models, there 
was very limited or no data on the model behaviour to be used for ‘output-based’ validation of the 
model, and therefore model validation was performed by critically testing all the model inputs, 
assumptions, parameters, and comparing the model outputs with the results of other similar studies. 
Insights obtained by validating these two models addressed the third research question of this thesis. 
Two OR models developed in this chapter were used to measure the population benefits for stroke 
patients due to earlier treatment thus addressing the first research question of this thesis. Both models 
also provided important insights on the benefits of earlier treatment for the individual patients. 
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Chapter 5 relies on the results of the ‘IV tPA’ model and ‘Endovascular Thrombectomy’ models 
developed in this chapter to design and develop an effective OR model to assist with maximizing the 
individual patients’ life-time benefits over two pathways of the hyperacute stroke care system. We 
then adopt the validation framework described in Chapter 3 to validate the developed model. 
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 Chapter 5: Individual patient OR model for investigation and improvement of long-
term benefits of early access to hyperacute stroke treatment interventions 
Introduction  
In this chapter, we address the second research question of this thesis: ‘How OR models can be 
designed, developed, and validated to assist with maximizing the individual patient’s life-time benefits 
over two pathways of the hyperacute stroke care system?’ 
As discussed in the previous chapter, existing stroke treatment interventions (i.e. IV tPA and 
endovascular thrombectomy) should be used for the speediest arterial recanalization of the eligible 
ischemic stroke patients, with time being even more important for endovascular thrombectomy 
compared to tPA alone. Two OR models developed and validated in the previous chapter, were used 
to measure the population benefits for stroke patients due to earlier treatment, while these models 
could also be applied to individual patient cases to provide insights on the gained benefits for the 
individual patients. In this chapter, we reflect even more on the individual patients’ benefits 
associated with earlier treatment by developing a new OR model used for understanding the patient-
specific benefits due to faster access to IV tPA and endovascular thrombectomy treatment 
interventions. 
With emergence of new evidence about effectiveness of endovascular thrombectomy treatment in late 
2014, new questions were raised in the clinical and health management domain in an attempt to 
design new protocols that support the new time sensitive treatment needs of the stroke patients. These 
questions mainly concern the issue of treatment pathway selection between two groups of hospitals 
with different facilities and expertise providing treatments for the stroke patients. In general, there are 
two types of treatment centres internationally:  
(1) primary hospital which is the hospital that is only capable of providing IV tPA treatment, and 
(2) comprehensive hospital which is the hospital that is capable of providing both IV tPA and 
endovascular thrombectomy treatment.  
Questions associated with pathway selection were formulated in an Editorial article published in 
Journal of the American Medical Association (JAMA) as follows: “Should primary stroke centres be 
bypassed to transport patients to comprehensive centres, even if it means delaying the start of IV tPA? 
How much delay in bypass is acceptable? How much of a delay to start IV tPA would eliminate the 
benefit of earlier thrombectomy? (Warach & Johnston, 2016, p. 1266)” 
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To answer these questions, we used selected components of the ‘IV tPA’ and ‘Endovascular 
Thrombectomy’ models developed and validated in Chapter 4, to design the ‘Individual Patient’ 
model in this chapter. The model developed in this thesis is a model for investigation and 
improvement, since it is intended to support new investigations in the hyperacute stroke care system 
by comparing the long-term benefits for individual patients, associated with different pathways of the 
hyperacute stroke care system. However, in the future, with some extra refinements, this model can be 
adopted for routine decision support which are used to “assist, but not replace, people making routine, 
repeated decisions” (Pidd, 2010, p. 17). 
The ‘Individual Patient’ model developed in this chapter compares the patient-specific benefits 
between the two pathways of Drip and Ship and Mothership as described later in next section of this 
chapter. The main objective of this model is to assist with maximizing the individual patients’ life-
time benefits in choosing different pathways of the hyperacute stroke care system. Similar to the OR 
models validated in Chapter 4, the generic validation framework provided earlier in Chapter 3 is 
adopted in this chapter to validate the ‘Individual Patient’ model.  
By the end of this chapter, a validated OR model used to assist with maximizing the individual 
patient’s life-time benefits associated with different pathways of the hyperacute stroke care system is 
developed. Discussion on validation is expected to provide further insights on the conceptual and 
application issues of conducting comprehensive validation of an OR model for investigation and 
improvement in the context of health systems and service operations. 
5.1 Problem description and intended use of the ‘Individual Patient’ model 
The results from a new generation of acute stroke trials became available in late 2014 and early 2015 
(Berkhemer, et al., 2015; Campbell, et al., 2015; Goyal, et al., 2015; Jovin, et al., 2015; Saver, et al., 
2015; Saver, et al., 2016). These trials demonstrated that endovascular thrombectomy intra-arterial 
clot removal can be successfully used to further improve the outcomes in patients with ischemic 
stroke who already have received tPA treatment. Now that the benefit of the intra-arterial (IA) therapy 
has been convincingly proven, stroke care systems worldwide face a serious challenge of 
incorporating the intra-arterial treatment into the existing care processes by providing and optimizing 
the necessary resources for such a change. One of the main issues here is that in reality, there are two 
types of medical centres with only one type being capable of delivering the necessary services for the 
endovascular thrombectomy treatment in the hyperacute stroke care system. In this scenario there are 
two options for a suspected stroke patient:  
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(1) Drip and Ship pathway: to take the patient to the closest non-endovascular capable centres (non-
ECC) to receive the IV tPA treatment and then transfer the patient to the closest endovascular capable 
centre (ECC) to receive endovascular thrombectomy treatment if needed; or  
(2) Mothership pathway to take the patient directly to the nearest ECC, where the patient first receives 
the IV tPA treatment and then, if eligible, in the same centre receives the endovascular thrombectomy 
treatment.  
With the important effect of time delays on individual patient’s life-time outcomes, it is crucial for the 
stroke care providers to compare the benefits associated with each treatment pathway for each 
individual patient. In this chapter, we present the ‘Individual Patient’ model which is designed and 
validated to provide insights on how to maximizing the individual patients’ benefits over two 
pathways of the hyperacute stroke care system. 
The ‘Individual Patient’ model is constructed to investigate the effect of earlier treatment 
interventions on individual patient’s life-time benefits; thus, is as a model for investigation and 
improvement. The insights obtained from this model can be used in the clinical and health 
management domains to design more efficient and effective stroke care system pathways, thus 
maximizing the individual patient’s benefits associated with choosing different pathways of the 
hyperacute stroke care system. This is achieved by comparing DALYs metric between the Drip and 
Ship pathway and the Mothership pathway for different scenarios of time delays associated with each 
of these pathways. The outcome of this model is reported in this chapter as the proportion that an 
individual patient will benefit more by the Mothership pathway over the Drip and Ship pathway, thus, 
assisting the health service providers in effective and improved provision of the services for the 
patients. 
5.2 Overview of the ‘Individual Patient’ model 
To build the ‘Individual Patient’ model described in this chapter, we used inputs and parameters of the 
‘IV tPA’ and ‘Endovascular Thrombectomy’ models developed and validated in Chapter 4; this 
includes pooled analyses of tPA and endovascular thrombectomy effect over time, general population 
life expectancy data, and different parameters to estimate DALYs. The ‘Individual Patient’ model can 
be used to provide insights on how to maximizing the individual patients’ life-time benefits over the 
two pathways of the hyperacute stroke care system (i.e. Drip and Ship pathway and Mothership 
pathway).  
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The summary of different parameters used to conceptualize the ‘Individual Patient’ model is provided 
in Table 5-1. These parameters are used to develop the ‘Individual Patient’ model in Section 5.5. 
Parameter name Definition  
T1 onset-to-tPA treatment delay for the Drip and 
Ship pathway 
T2 onset-to-tPA treatment delay for the Mothership 
pathway 
T3 transfer delay time between non-ECC and ECC 
for the Drip and Ship pathway 
T4 in-hospital delay time in the ECC to receive 
endovascular thrombectomy for both pathways 
t IA-drip and ship onset-to-IA treatment delay for the Drip and Ship 
pathway 
t IA-mothership onset-to-IA treatment delay for the Mothership 
pathway 
p probability of receiving endovascular 
thrombectomy for both pathways 
Exp_DALY mothership-tPA expected DALYs lost after tPA intervention in 
ECC for the Mothership pathway 
Exp_DALY drip and ship-tPA expected DALYs lost after tPA intervention in 
non-ECC for the Drip and Ship pathway 
Exp_DALY mothership-IA expected DALYs lost after endovascular 
thrombectomy intervention in ECC for the 
Mothership pathway 
Exp_DALY drip and ship-IA expected DALYs lost after endovascular 
thrombectomy intervention in ECC for the Drip 
and Ship pathway 
Exp_DALY drip and ship expected DALYs lost for the Drip and Ship 
pathway 
Exp_DALY mothership expected DALYs lost for the Mothership 
pathway 
Table 5-1 Summary of different parameters of the ‘Individual Patient’ model 
Even though that based on the results of the OR models developed in Chapter 4, stroke patients 
benefit more when they receive endovascular thrombectomy intervention rather than tPA alone, not 
every patient is eligible to receive the endovascular treatment. As a result, it is crucial to know which 
treatment strategy is suitable for individual patients, thus maximizing the patient’s life-time benefits 
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depending on time delays associated with the two pathways of the hyperacute stroke care system. 
Moreover, since these benefits often vary for individual stroke patients with different age, stroke 
severity, gender and treatment delay times, the results of the ‘Individual Patient’ model are generated 
for patients with different characteristics to provide insights on these varied gained benefits for 
different groups of patients. 
Last but not least, based on the results of the OR models developed in Chapter 4 it was concluded that 
there is a link between treatment delay times and patients’ long-term benefits, with every minute 
being counted when a stroke patient intervened with either IV tPA or endovascular thrombectomy 
interventions. As a result, for the ‘Individual Patient’ model the results are generated for different 
scenarios associated with Drip and Ship and Mothership pathways to investigate how the long-term 
benefits for the individual patients will be affected by changing delay time parameters for the two 
pathways of the hyperacute stroke care system. Figure 5-1, represents an overview of the ‘Individual 
Patient’ model, while detailed description of these inputs is provided in next section. 
 
Figure 5-1 Overview of the hyperacute stroke care system. T1 and T3 respectively represent the onset-to-tPA 
treatment time and transfer time between non-ECC and ECC for the Drip and Ship pathway shown by the solid 
lines. T2 represent the onset-to-tPA treatment time for the mothership pathway. T4 is the in-hospital delay time in 
the ECC to receive endovascular thrombectomy for both pathways. p indicates the eligibility of the patients to 
receive endovascular thrombectomy. 
5.3 Inputs of the ‘Individual Patient’ model 
Parts of data used to build ‘Individual Patient’ model has been adopted from the previously developed 
and validated ‘IV tPA’ and the ‘Endovascular Thrombectomy’ models, for which we refer to the 
relevant sections in Chapter 4. These are as follows: 
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 Published pooled analysis of tPA randomized controlled trials to estimate the tPA treatment 
effect over time (refer to Section 4.3 of Chapter 4) (Emberson, et al., 2014; Lees, et al., 2010). 
 Published pooled analysis of endovascular thrombectomy randomized controlled trials to 
estimate the endovascular thrombectomy treatment effect over time (refer to Section 4.10 of 
Chapter 4) (Saver, et al., 2016). 
 An updated version of the general Australian population life expectancy age- and sex- 
specific data obtained from Australian Bureau of Statistics at the time of developing this 
model (refer to Section 4.3 of Chapter 4) (Australian Bureau of Statistics, 2013-2015) 
 Parameters necessary to translate the 3-month mRS outcome data into a long-term metric of 
Disability-adjusted Life Years (DALYs) lost (refer to Section 4.3 of Chapter 4) (Hong & 
Saver, 2010; Murray & Lopez, 1996). 
Since at the time of developing this model, there was no adequate prediction tool with enough 
accuracy to be used for estimating the patients’ eligibility for thrombectomy treatment, we consulted 
an expert team of neurologists who work in several treating centres in Melbourne, Australia. These 
experts advised on using the NIHSS and Large Vascular Occlusion (LVO) as two main parameters to 
build a prediction model. While we used LVO and NIHSS as two key parameters to develop this 
prediction model, other studies globally are investigating development of more accurate prediction 
methods. In some of these studies, researchers and clinicians suggest to use Los Angeles Motor Scale 
(LAMS) as a key parameter for specifying the eligibility of the patients to receive endovascular 
thrombectomy (Holodinsky, et al., 2017).  
We used a new observational cohort of stroke patients based on a combined sample of 391 patients 
retrieved from two medical centres in Melbourne, Australia: Box Hill Hospital and Royal Melbourne 
Hospital. The database contains information about stroke patients admitted in these two hospitals in 
2016. Of 391 patients included in this study, 334 cases were obtained from the Royal Melbourne 
Hospital and 57 cases were obtained from the Box Hill Hospital. This cohort contained distributions 
data of stroke severity and Large Vascular Occlusion (LVO). To build the prediction model, we 
constructed a logistic regression model with LVO as a dependant variable, and stroke severity as an 
independent variable. The validation process of constructing this prediction model has been explained 
in more details in Section 5.7.2 of this chapter. 
5.4 Model assumptions 
Similar assumptions to that of the ‘IV tPA’ and ‘Endovascular Thrombectomy’ models discussed in 
Chapter 4 were used to build this model. All the assumptions listed here are validated later in this 
chapter in the validation section.  
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1. To build this model, the only criterion for specifying the eligibility of the patients to 
receive tPA treatment was onset-to-tPA treatment time, with the upper time limit to 
receive tPA treatment set to 270 minutes. 
2. To generate mRS probabilities after tPA intervention, we assumed that the relative ratios 
of probabilities of achieving mRS 0 and mRS 1, as well as the relative ratios of achieving 
mRS categories 2-5 at any time, are identical to those at the baseline onset-to-tPA 
treatment time. 
3. To build this model, we assumed that patients first receive tPA treatment and then 
undergo IA therapy. 
4. The upper time limit to receive IA treatment was set to 360 minutes.  
5. For specifying the eligibility of the patients to receive endovascular therapy, in addition to 
onset-to-IA treatment time eligibility criteria, we also used the LVO as a predictive 
parameter to estimate the clinical eligibility of the patients to receive endovascular 
thrombectomy. 
6. Because of the time restrictions on the eligibility of the stroke patients to receive 
endovascular therapy, for any scenario combination of T1, T3, T4 where sum of these 
parameters exceeds 360 minutes, we assume that the patient goes to the ECC. 
7. For T1 and T2, we assumed 60 minutes as the minimum range, and 270 minutes as the 
maximum range, with 15-minutes interval between the values within these ranges. For T3, 
we assumed 35 minutes as the minimum range, and 260 minutes as the maximum range, 
with 15-minutes interval between this range. For the in-hospital delay time (T4), we 
assumed 40-minutes delay in all cases. 
5.5 Model building process 
To build the ‘Individual Patient’ model we repeated some stages of the model building process 
described in Sections 4.4 and 4.12 of Chapter 4, respectively for the ‘IV tPA’ and ‘Endovascular 
Thrombectomy’ models. To avoid repeating those stages, we have explained different stages of 
developing the ‘Individual Patient’ model through 11 Stages as shown in Table 5-2. 
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Stage 1: Create simulation delay times 
For T1 = 60, 75, …, 270 
   For T2 = 60, 75, …, 270 
      For T3 = 35, 50, …, 260 
         For T4 = 40 
Stage 2: Create patient population 
For Gender i = 0,1 
   For Age j = 20, 30, 40, 50, 60, 70, 80, 90 
      For NIHSS k = 2, 7, 12, 17, 22, 27, 32, 37 
      Let 
         patient (i, j, k) =p i,j,k 
         p = probability of the patient (i, j, k) to receive endovascular thrombectomy 
Stage 3: Generating patient-specific probabilities of achieving specific mRS category at baseline 
onset-to-tPA treatment time  
For baseline onset-to-tPA treatment time = 270 
   Get the logistic regression equations from the ‘Endovascular Thrombectomy’ model 
   Generate patient-specific mRS probabilities at baseline onset-to-tPA as per the ‘IV tPA’ model 
Stage 4: Estimating the probabilities of achieving a specific mRS after IV tPA intervention for both 
pathways 
For any feasible combination of (T1, T3, T4) for Drip and Ship pathway 
   For any feasible combination of (T2, T4) for Mothership pathway 
      Get the analytical expression of tPA mRS odds ratios with 95% CIs from the ‘IV tPA’ model 
         For counter number m = 1, 2, …, 1000 
            For counter number n = 1, 2, …, 1000 
               Get mth  to sample from an underlying distribution between the mRS 0-1 odds ratio  
               Generate mRS probabilities after tPA intervention for Drip and Ship pathway at T1 
               Get nth to sample from an underlying distribution between the mRS 6 odds ratio  
               Generate mRS probabilities after tPA intervention for Mothership pathway at T2 
Stage 5: Estimating patient-specific expected DALYs lost after IV tPA intervention for both 
pathways 
Get DALYs formula from the ‘IV tPA’ model 
Generate DALYs after tPA intervention for Drip and Ship pathway (Exp_DALYdrip and ship-tPA) 
Generate DALYs after tPA intervention for Mothership pathway (Exp_DALYmothership-tPA) 
Stage 6: Estimating the probabilities of achieving a specific mRS after endovascular intervention 
for both pathways 
130 
 
Get the analytical expression for IA common mRS odds ratio with 95% CIs from the ‘Endovascular 
Thrombectomy’ model 
    For counter y = 1, 2, …, 1000 
       Get yth to sample from an underlying distribution between the common mRS odds ratio  
       Generate mRS probabilities after IA intervention for Drip and Ship pathway at (T1+ T3+ T4) 
       Generate mRS probabilities after IA intervention for Mothership pathway at (T2 +T4) 
Stage 7: Estimating patient-specific expected DALYs lost after endovascular thrombectomy for both 
pathways 
Get DALYs formula from the ‘IV tPA’ model 
Generate DALYs after thrombectomy intervention for Drip and Ship pathway (Exp_DALYdrip and ship-IA) 
Generate DALYs after thrombectomy intervention for Mothership pathway (Exp_DALYmothership-IA) 
Stage 8: Estimating the expected DALYs lost for both pathways 
Let Exp_DALYdrip and ship = (1-p) * (Exp_DALYdrip and ship-tPA) + p * (Exp_DALYdrip and ship-IA) 
Let Exp_DALYmothership = (1-p) * (Exp_DALYmothership-tPA) + p * (Exp_DALYmothership-IA) 
Stage 9: Specifying the outcome of the model for each individual patient out of 1000 runs for a 
given scenario of delay times 
Let the patient (i, j, k) follow the mothership pathway, if Exp_DALYdrip and ship > Exp_DALYmothership, 
Estimate the proportion that a patient (i, j, k) benefit more by the Mothership pathway 
Increment m, n, y by one unit 
Stage 10: Increment time delays 
Next feasible combination of (T1, T3, T4)where the sum of time delays is less than 360 minutes 
Next feasible combination of (T2, T4)where the sum of time delays is less than 360 minutes 
Stage 11: Repeat Steps 1 to 10 for the next patient 
Next patient (i, j, k) =p i,j,k 
Table 5-2  Simulation pseudocodes for the ‘Individual Patient’ model 
To investigate the effect of time delays associated with different pathways of the hyperacute stroke 
care system on individual patient’s life-time outcomes, in this model we run simulations for different 
combination of T1, T2, T3, and T4. These parameters and values assigned to them were generated in Stage 
1 of the simulation model as shown in Table 5-2. We sought the opinion of the clinical experts from 
several treating centres in Melbourne. As a result, we chose15 minutes granularity to cover the 
plausible range of delay times associated with different pathways of the hyperacute stroke care 
system.  
The implemented simulation model allows generating the results of the ‘Individual Patient’ model for 
patients with different characteristics. This includes 64 male and 64 female patients, to whom we 
assigned different age (20, 30, 40, 50, 60, 70, 80, 90) and severity (2, 7, 12, 17, 22, 27, 32, and 37). 
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The baseline onset-to-tPA treatment time was set to 270 minutes for all the 128 patients. These 
parameters were generated in Stage 2 of the simulation model as shown in Table 5-2. Finally, To 
capture the variability of the model outputs when testing different interventions, each individual 
scenario was implemented through 1000 simulation runs. This was performed in Stages 4 and 6 of the 
simulation model as shown in Table 5-2. In the next section, we report on the results of the simulation 
model for patients with different characteristics, and for different scenarios of delay times. 
5.6 Model results 
Running the simulation experiments over 128 individual “model” patients, for the total of 3600 
scenarios of delay times, each simulated 1000 times, result of this model is reported as proportion of 
the runs that an individual patient will benefit the Mothership pathway over the Drip and Ship 
pathway for a given scenario. It is evidenced by clinical trials that patients with various age and 
disease severity benefit differently from faster treatment. Since it is not possible to fully report the 
results of this model given the large number of simulation runs, in this section, we illustrate the results 
of the ‘Individual Patient’ model for six individual patients. For the first patient, we provide three 
examples to demonstrate how individual patient’s long-term benefits change depending on time 
delays associated with different pathways of the hyperacute stroke care system. Last example 
illustrated for the first patient is used for the rest of the patient examples provided in this section to 
discuss how different characteristics of individual patients affect their long-term outcomes. 
1. Patient 1 (age 50, NIHSS 17, p 0.33):  Three illustrative examples are described for this patient to 
investigate the effect of time delays associated with different pathways of the hyperacute stroke 
care system on patient’s life-time outcomes.  
Example 1: The first example shows the results generated for different scenarios by fixing the 
values of T2, T3, T4 and tabulating the values of T1 as presented in Figure 5-2. As described below, 
the values assigned to T2, and T3 are selected from the mid-range values used to run the 
experimental design: 
1. Onset-to-tPA treatment delay for the Drip and Ship pathway (T1) changing from 60 to 
270 minutes; 
2. Onset-to-tPA treatment delay for the Mothership pathway (T2) equals to 165 minutes; 
3. In-hospital delay time in the ECC to receive endovascular thrombectomy for both 
pathways (T4) equals to 40 minutes; 
4. Transfer delay time between non-ECC and ECC for the Drip and Ship pathway (T3) 
changing from 125 to 170 minutes. 
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Figure 5-2 First example for different scenarios for a female patient with a 50 y.o, and severity of 17 
Figure 5-2 illustrates the results for this patient for different scenarios. In Table 5-3 different rows and 
columns respectively reflect values of T1 and T2. In this table, cells shown in yellow denote the 
scenarios where in all cases this patient will benefit (losing less DALYs) the Drip and Ship pathway 
over the mothership pathway. Cells shown in dark green denote the scenarios where in all cases this 
patient will benefit the Mothership pathway over the Drip and Ship pathway. Lastly, cells shown in 
light green, show the proportions (out of 1000 simulation runs) where the patient will benefit either 
the Mothership pathway or the Drip and Ship pathway.  
In this table, for values of T3 equal to 125, 140, 155, and 170 minutes, and for lower values of T1 (less 
than 135 minutes) in majority of the scenarios the patient will benefit the Drip and Ship pathway over 
the Mothership pathway. As we increase the values of T1 (more than 135 minutes) in majority of the 
scenarios the patient will benefit the Mothership pathway over the Drip and Ship pathway. As 
indicated by dark green shades in Table 5-3, for these scenarios the patient will benefit the Mothership 
pathway over the Drip and Ship pathway in all cases. 
For this patient, for the scenarios where the sum of T1, T3 and T4 (onset-to-IA treatment time) for the 
Drip and Ship pathway exceeds 360 minutes, we assume that the patient will benefit the Mothership 
pathway over the Drip and Ship pathway. For T3 equals to 170 minutes for instance, and for values of 
T1 more than 150 minutes the onset-to-IA treatment time exceeds 360 minutes, thus, in all cases the 
patient will benefit the Mothership pathway over the Drip and Ship pathway. For all the other 
scenarios, it can be observed in the Table 5-3, that there is a linear trend in results for fixed values of 
T2, T3, and T4 when we change the values of T1. 
The granularity of delay times (15 minutes) used in this model to generate the results were selected by 
seeking the opinion of the experts and neurologists who work in several treating centres in 
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Melbourne, Australia. The values of T3 (125, 140, 155, 170 minutes) and T2 (165 minutes) in this 
example were selected from the mid-range values assigned to these parameters in the experimental 
design. For these scenarios, there was a linear trend in results generated by the model with an 
exception in results for a fixed value of T3, where the model is very sensitive to small changes in the 
values of T1. This can be observed in Table 5-3, for value of T3 equals to 125 minutes, and in 
changing the values of T1 from 120 to 135 minutes, where the results are changing from 9% to 72% 
for choosing the Mothership pathway over the Drip and Ship pathway. 
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               T3 
T1 
125 140 155       170 
60 0% 0% 0% 1% 
75 0% 0% 1% 2% 
90 0% 1% 2% 4% 
105 2% 3% 7% 14% 
120 9% 20% 35% 55% 
135 72% 90% 97% 99% 
150 100% 100% 100% 100% 
165 100% 100% 100% 100% 
180 100% 100% 100% 100% 
195 100% 100% 100% 100% 
210 100% 100% 100% 100% 
225 100% 100% 100% 100% 
240 100% 100% 100% 100% 
255 100% 100% 100% 100% 
270 100% 100% 100% 100% 
Table 5-3 Proportions of going to the ECC, for a female patient with a 50 y.o, severity of 17, T2 =165, T4 = 40. 
T1, onset-to-tPA treatment delay for the Drip and Ship pathway; T2, onset-to-tPA treatment delay for the 
mothership pathway; T3, transfer delay time between non-ECC and ECC for the Drip and Ship pathway; T4, in-
hospital delay time in the ECC to receive endovascular thrombectomy for both pathways 
Example 2: The second example shows the results generated for different scenarios by fixing the 
values of T1, T2, T4 and tabulating the values of T3 as presented in Figure 5-3. As described below, the 
values assigned to T1, and T2 are selected from the mid-range values used to run the experimental 
design: 
1. Onset-to-tPA treatment delay for the Drip and Ship pathway (T1) changing from 135 to 180 
minutes; 
2. Onset-to-tPA treatment delay for the Mothership pathway (T2) equals to 165 minutes; 
3. In-hospital delay time in the ECC to receive endovascular thrombectomy for both pathways 
(T4) equals to 40 minutes; 
4. Transfer delay time between non-ECC and ECC for the Drip and Ship pathway (T3) changing 
from 35 to 260 minutes. 
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Figure 5-3 Second example for different scenarios, for a female patient with a 50 y.o, and severity of 17 
Figure 5-3 illustrates the results for this patient for different scenarios. In Table 5-4 different rows and 
columns respectively reflect values of T1 and T2. In this table, for value of T1 equals to 135 minutes; 
and for lower values of T3 (less than 125 minutes) in majority of the cases the patient will benefit 
more the Drip and Ship pathway over the Mothership pathway, while as we increase the values of T3 
(more than 125 minutes) in majority of the cases the patient will benefit the Mothership pathway over 
the Drip and Ship pathway. As it can be observed in Table 5-4, with increased values of T1, in 
majority of the cases the patient will benefit the Mothership pathway over the Drip and Ship pathway, 
thus maximizing her life-time benefits. 
For this patient, similar to the first example for the scenarios where the sum of T1, T3 and T4 (onset-to-
IA treatment time) for the Drip and Ship pathway exceeds 360 minutes, we assume that the patient 
benefit by Mothership pathway over the Drip and Ship pathway. The values of T1 (135, 150, 165, 180 
minutes) and T2 (165 minutes) in this example were selected from the mid-range values assigned to 
these parameters in the experimental design. For these scenarios, there was a linear trend in results 
generated by the model in most cases.  
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      T1 
T3 
135 150 165       180 
35 0% 1% 100% 100% 
50 0% 21% 100% 100% 
65 1% 76% 100% 100% 
80 4% 98% 100% 100% 
95 18% 100% 100% 100% 
110 42% 100% 100% 99% 
125 72% 100% 100% 100% 
140 90% 100% 100% 100% 
155 97% 100% 100% 100% 
170 99% 100% 100% 100% 
185 100% 100% 100% 100% 
200 100% 100% 100% 100% 
215 100% 100% 100% 100% 
230 100% 100% 100% 100% 
245 100% 100% 100% 100% 
260 100% 100% 100% 100% 
Table 5-4 Proportions of going to the ECC, for a female patient with a 50 y.o, severity of 17, T2 =165, T4 = 40. 
T1, onset-to-tPA treatment delay for the Drip and Ship pathway; T2, onset-to-tPA treatment delay for the 
mothership pathway; T3, transfer delay time between non-ECC and ECC for the drip and ship pathway; T4, in-
hospital delay time in the ECC to receive endovascular thrombectomy for both pathways 
Example 3: The third example shows the results generated for different scenarios by fixing the values 
of T2, T3, T4 and tabulating the values of T1 as presented in Figure 5-4. As described below, the values 
assigned to T1, and T3 are selected from the mid-range values used to run the experimental design: 
1. Onset-to-tPA treatment delay for the Drip and Ship pathway (T1) changing from 60 to 270 
minutes; 
2. Onset-to-tPA treatment delay for the Mothership pathway (T2) changing from 135 to 180 
minutes; 
3. In-hospital delay time in the ECC to receive endovascular thrombectomy for both pathways 
(T4) equals to 40 minutes; 
4. Transfer delay time between non-ECC and ECC for the Drip and Ship pathway (T3) equals to 
155minutes. 
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Figure 5-4 Third example for different scenarios, for a female patient with a 50 y.o, and severity of 17 
Figure 5-4 illustrates the results for this patient for different scenarios. In Table 5-5 different 
rows and columns respectively reflect values of T1 and T2. In this table, for value of T2 equals 
to 135 minutes and lower values of T1 (less than 90 minutes) in majority of the cases the 
patient will benefit the Mothership pathway over the Drip and Ship pathway over the, while 
as we increase the values of T2, the number of cases where the patient will benefit the Drip 
and Ship pathway over the Mothership pathway increases. 
For this patient, similar to the first example for the scenarios delay times where the sum of 
T1, T3 and T4 (onset-to-IA treatment time) for the Drip and Ship pathway exceeds 360 
minutes, we assume that the patient benefit the Mothership pathway over the Drip and Ship 
pathway. The values of T2 (135, 150, 165, 180 minutes) and T3 (155 minutes) in this example 
were selected from the mid-range values assigned to these parameters in the experimental 
design. For these scenarios, there was a linear trend in results generated by the model in most 
cases. Where there is a less linear trend in the results, the model is sensitive to small changes 
in T1. 
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               T2 
T1 
135 150 165       180 
60 4% 2% 0% 0% 
75 11% 3% 1% 0% 
90 33% 9% 2% 0% 
105 90% 33% 7% 1% 
120 100% 94% 35% 5% 
135 100% 100% 97% 39% 
150 100% 100% 100% 98% 
165 100% 100% 100% 100% 
180 100% 100% 100% 100% 
195 100% 100% 100% 100% 
210 100% 100% 100% 100% 
225 100% 100% 100% 100% 
240 100% 100% 100% 100% 
255 100% 100% 100% 100% 
270 100% 100% 100% 100% 
Table 5-5 Proportions of going to the ECC, for a female patient with a 50 y.o, severity of 17, T3 =155, 
T4 = 40. T1, onset-to-tPA treatment delay for the Drip and Ship pathway; T2, onset-to-tPA treatment 
delay for the Mothership pathway; T3, transfer delay time between non-ECC and ECC for the Drip 
and Ship pathway; T4, in-hospital delay time in the ECC to receive endovascular thrombectomy for 
both pathways 
Three examples described in this section, demonstrated how the results of the ‘Individual 
Patient’ model change by fixing two of T1, T2, and T3 parameters and tabulating the 
remaining parameter. To show how the results of this model changes for patients with 
different characteristics, below we provide example three provided for the first patient by 
fixing the values of T2, T3, and T4 and tabulating the values of T1. 
2. Patient 2 (age 50, NIHSS 17, p 0.33): Table 5-6 demonstrates the results for this patient 
for different scenarios where different rows and columns respectively reflect values of T1 
and T2. By comparing the results obtained for this patient with that of the female patient 
in Table 5-6 it can be concluded that there is no significant difference between the 
results for a female and male patient with other similar characteristics. 
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               T2 
T1 
135 150 165       180 
60 5% 2% 1% 0% 
75 12% 4% 1% 0% 
90 35% 10% 3% 1% 
105 88% 35% 9% 1% 
120 100% 92% 37% 8% 
135 100% 100% 93% 40% 
150 100% 100% 100% 94% 
165 100% 100% 100% 100% 
180 100% 100% 100% 100% 
195 100% 100% 100% 100% 
210 100% 100% 100% 100% 
225 100% 100% 100% 100% 
240 100% 100% 100% 100% 
255 100% 100% 100% 100% 
270 100% 100% 100% 100% 
Table 5-6 Proportions of going to the ECC, for a male patient with a 50 y.o, severity of 17, T3 =155, 
T4 = 40. T1, onset-to-tPA treatment delay for the Drip and Ship pathway; T2, onset-to-tPA treatment 
delay for the Mothership pathway; T3, transfer delay time between non-ECC and ECC for the Drip 
and Ship pathway; T4, in-hospital delay time in the ECC to receive endovascular thrombectomy for 
both pathways 
3. Patient 3 (age 30, NIHSS 17, p 0.33): Table 5-7 demonstrates the results for this patient 
for different scenarios where different rows and columns respectively reflect values of T1 
and T2. By comparing the results obtained for this patient, with that of the female patient 
in Table 5-6 it can be concluded that for majority of the simulation runs there is a slight 
decrease in the proportion of choosing the mothership pathway for this patient due to her 
younger age. 
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               T2 
T1 
135 150 165       180 
60 6% 3% 1% 0% 
75 10% 5% 2% 0% 
90 29% 9% 3% 1% 
105 80% 29% 8% 2% 
120 100% 84% 31% 7% 
135 100% 100% 87% 32% 
150 100% 100% 100% 90% 
165 100% 100% 100% 100% 
180 100% 100% 100% 100% 
195 100% 100% 100% 100% 
210 100% 100% 100% 100% 
225 100% 100% 100% 100% 
240 100% 100% 100% 100% 
255 100% 100% 100% 100% 
270 100% 100% 100% 100% 
Table 5-7 Proportions of going to the ECC, for a female patient with a 30 y.o, severity of 17, T3 =155, 
T4 = 40. T1, onset-to-tPA treatment delay for the Drip and Ship pathway; T2, onset-to-tPA treatment 
delay for the Mothership pathway; T3, transfer delay time between non-ECC and ECC for the Drip 
and Ship pathway; T4, in-hospital delay time in the ECC to receive endovascular thrombectomy for 
both pathways 
4. Patient 4 (age 80, NIHSS 17, p 0.33): Table 5-8 demonstrates the results for this patient 
for different scenarios where different rows and columns respectively reflect values of T1 
and T2. For this patient, the result of the model is more sensitive to changes in delay 
times potentially due to old age of the patient. 
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               T2 
T1 
135 150 165       180 
60 4% 1% 0% 0% 
75 10% 2% 0% 0% 
90 44% 8% 1% 0% 
105 99% 45% 6% 0% 
120 100% 100% 47% 4% 
135 100% 100% 100% 51% 
150 100% 100% 100% 100% 
165 100% 100% 100% 100% 
180 100% 100% 100% 100% 
195 100% 100% 100% 100% 
210 100% 100% 100% 100% 
225 100% 100% 100% 100% 
240 100% 100% 100% 100% 
255 100% 100% 100% 100% 
270 100% 100% 100% 100% 
Table 5-8 Proportions of going to the ECC, for a female patient with a 80 y.o, severity of 17, T3 =155, 
T4 = 40. T1, onset-to-tPA treatment delay for the Drip and Ship pathway; T2, onset-to-tPA treatment 
delay for the Mothership pathway; T3, transfer delay time between non-ECC and ECC for the Drip 
and Ship pathway; T4, in-hospital delay time in the ECC to receive endovascular thrombectomy for 
both pathways 
5. Patient 5 (age 50, NIHSS 7, p 0.09): Table 5-9 demonstrates the results for this patient 
for different scenarios where different rows and columns respectively reflect values of T1 
and T2. Compared to other patients, this patient benefit more by receiving IV tPA 
treatment earlier in the non-ECC by choosing the Drip and Ship pathway over the 
Mothership pathway for values of T1 less than 120 minutes due to her younger age and 
lower severity. 
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               T2 
T1 
135 150 165       180 
60 1% 0% 0% 0% 
75 1% 0% 0% 0% 
90 1% 1% 0% 0% 
105 8% 6% 0% 0% 
120 43% 23% 13% 0% 
135 100% 68% 54% 8% 
150 100% 100% 73% 61% 
165 100% 100% 100% 100% 
180 100% 100% 100% 100% 
195 100% 100% 100% 100% 
210 100% 100% 100% 100% 
225 100% 100% 100% 100% 
240 100% 100% 100% 100% 
255 100% 100% 100% 100% 
270 100% 100% 100% 100% 
Table 5-9 Proportions of going to the ECC, for a female patient with a 50 y.o, severity of 7, T3 =155, 
T4 = 40. T1, onset-to-tPA treatment delay for the Drip and Ship pathway; T2, onset-to-tPA treatment 
delay for the Mothership pathway; T3, transfer delay time between non-ECC and ECC for the Drip 
and Ship pathway; T4, in-hospital delay time in the ECC to receive endovascular thrombectomy for 
both pathways 
6. Patient 6 (Age 50, NIHSS 27, p 0.70): Table 5-10 demonstrates the results for this 
patient for different scenarios where different rows and columns respectively reflect 
values of T1 and T2. Even though this patient has the same age as the previous patient, 
due to higher severity of this patient, in majority of the simulation runs the patient will 
benefit the Mothership pathway over the Drip and Ship pathway, for values of T1 less 
than 120 minutes. 
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               T2 
T1 
135 150 165       180 
60 72% 30% 8% 1% 
75 99% 77% 29% 6% 
90 100% 99% 81% 29% 
105 100% 100% 99% 84% 
120 100% 100% 100% 99% 
135 100% 100% 100% 100% 
150 100% 100% 100% 100% 
165 100% 100% 100% 100% 
180 100% 100% 100% 100% 
195 100% 100% 100% 100% 
210 100% 100% 100% 100% 
225 100% 100% 100% 100% 
240 100% 100% 100% 100% 
255 100% 100% 100% 100% 
270 100% 100% 100% 100% 
Table 5-10 Proportions of going to the ECC, for a female patient with a 50 y.o, severity of 27, T3 
=155, T4 = 40. T1, onset-to-tPA treatment delay for the Drip and Ship pathway; T2, onset-to-tPA 
treatment delay for the Mothership pathway; T3, transfer delay time between non-ECC and ECC for 
the Drip and Ship pathway; T4, in-hospital delay time in the ECC to receive endovascular 
thrombectomy for both pathways 
As demonstrated in results section, patients with different characteristics benefit differently 
by choosing different pathways of the hyperacute stroke care system. The results of the 
‘Individual Patient’ model presented in this chapter can provide important insights on the 
gained benefits for the patients, thus, providing assistance in choosing appropriate pathway 
of the hyperacute stroke care system, so patients can maximize their life-time benefits.  
5.7 Comprehensive validation of the ‘Individual Patient’ model 
In this section, we are validating the ‘Individual Patient’ model using the generic validation 
framework discussed earlier in Chapter 3. Since this model was developed based on the ‘IV 
tPA’ and ‘Endovascular Thrombectomy’ models, both validated in Chapter 4 of this thesis; 
in this section, we focus on validating the new developed parts of the model. 
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5.7.1 Data validity 
Both input data and parameters data were used to build the ‘Individual Patient’ model were 
validated as follows: 
An observational cohort of stroke patients:  We obtained relevant stroke patients data from 
Box Hill Hospital and Royal Melbourne Hospital and included all dataset to generate the 
patient-specific probabilities of LVO used as predictive parameter to estimate the eligibility 
of the patients to receive endovascular thrombectomy. The dataset was maintained in 
accordance to the best practice guidelines. It was also stored and documented on a password 
protected computer during the process of model development. 
General population life expectancy:  An updated version of life expectancy tables (at the 
time of developing this model) for the period of 2013-2015 (Australian Bureau of Statistics) 
were adopted and validated (as described earlier in Section 4.7.1 of Chapter 4 for the ‘IV 
tPA’ model) to estimate DALYs. 
The pooled analysis of tPA effect and IA effect over time, and parameters to calculate 
expected DALYs used to build the ‘Individual Patient’ model were adopted from the 
validated ‘Endovascular Thrombectomy’ model. 
The summary of different validation methods and techniques used to obtain data validity of 
the ‘Individual Patient’ model has been provided in Table 5-11. 
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Validation task Why we performed the validation task How we performed the validation task The conclusions/results of the validation 
task 
Representativeness of the dataset Based on: (Biau, et al., 2008; Ellenberg, 1994) 
General population life expectancy To ensure that the data source used to 
estimate the life expectancies is 
trustworthy. 
We used the latest official data for age 
and sex specific life-expectancies of the 
residents of Victoria, Australia at the time 
of developing the model, obtained from 
ABS. We compared these with similar 
life-expectancy data from Finland which 
was the source country of the cohort used 
in this model to develop the logistic 
regression model. We observed minimal 
differences (the average life expectancy at 
birth for men is 80.3 years in Australia 
versus 78.3 years in Finland and for 
women 84.3 years versus 84.1 years). 
Increased confidence in the accuracy of the 
estimations for the general population life 
expectancy. 
 
Observational cohort data To ensure that the data source used to 
estimate the probability of the stroke 
patients to receive endovascular 
thrombectomy is trustworthy. 
We obtained data from the Royal 
Melbourne Hospital and Box Hill 
Hospital. 
Increased accuracy of the parameters used to 
estimate the probability of the patients to 
receive endovascular thrombectomy. 
Table 5-11  Validation tests and techniques utilized for data validation of different components of the ‘Individual Patient’ model 
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5.7.2 Conceptual model validity 
The conceptual framework of the ‘Individual Patient’ model was described in 11 Stages as 
shown in Table 5-2. The validation of these parts involves validating the model assumptions 
and its logical and mathematical structure. Different methods and validation tests similar to 
the ‘IV tPA’ and ‘Endovascular Thrombectomy’ models were used to validate the 
conceptual model. These included: degeneracy test, data relationship correctness test, 
mathematical and statistical methods, tracing and structured walkthrough. With exception to 
parts of the model previously validated in the ‘IV tPA’ and the ‘Endovascular 
Thrombectomy’ models, the process of validating the conceptual framework of the 
‘Individual Patient’ model is described below:  
 Validation of the model assumptions 
All the six mentioned assumptions were validated by formally obtaining the opinion of team 
of clinical experts and neurologists. The choice of 270 minutes as the upper time limit to 
receive tPA treatment, and 360 minutes as the upper time limit to receive endovascular 
thrombectomy were adopted according to majority of international stroke clinical guidelines 
(Berkhemer, et al., 2015; Campbell, et al., 2015; Jauch, et al., 2013; Saver, et al., 2015). 
Also, based on the recent stroke trials (Saver, et al., 2016) all eligible patients first receive IV 
tPA and then undergo the process of receiving endovascular thrombectomy therapy, which 
was the basis assumption in conceptualizing the ‘Individual Patient’ model.  
The values assigned to delay time parameters (including the selection of minimum and 
maximum values) were verified by running face validity and obtaining the opinion of clinical 
experts. The choice of incrementing delay time parameters by 15-minutes was also validated 
by clinicians, given the fact that running the model with lower granularity of delay times was 
not mathematically possible for this model. 
 Validation of model structure/formulation 
The logical structure of the conceptual model was validated through checking the mRS 
probability distributions, numerical relationships in the model, change over time formulation, 
endovascular thrombectomy eligibility formulation, and DALYs mathematical formulation 
after both tPA and endovascular thrombectomy interventions. While some of these have 
been previously validated in Chapter 4, here we discuss the validation process of the new 
developed parts of the model while referring to different stages of the model building 
process as described in Table 5-2. These stages can be categorized into two groups: first 
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group includes Stages 3-8 where we describe the process of formulating the problem, and 
second group includes Stages 1-2 and 9-11 where we use simulation to generate the outputs 
of the model for different scenarios, and for different patient groups. While later in this 
chapter, in the operational validity section we further discuss the validation of the simulation 
part, here we focus on validating the model formulation developed in Stages 3-8. 
mRS probability distributions: This includes generating the patient-specific probabilities of 
achieving mRS category at baseline onset-to-tPA treatment time (Stage 3), estimating the 
probabilities of achieving a specific mRS after IV tPA intervention (Stage 4), and estimating 
the probabilities of achieving a specific mRS after endovascular intervention (Stage 6). As 
described in Table 5-2, in Stages 4 and 6 we adopted the validated analytical expressions of 
the odds ratio lines respectively from the ‘IV tPA’ model and the ‘Endovascular 
Thrombectomy’ model. In Stage 3, we adopted the validated logistic regression model from 
the ‘Endovascular Thrombectomy’ model. 
Change over time formulation: This includes Stages 4 and 6, which were developed by 
adopting elements of the ‘IV tPA’ and the ‘Endovascular Thrombectomy’ models previously 
validated in Chapter 4. Additionally, we used three set of 1000 normally distributed random 
numbers to sample according to an underlying Normal distribution from the feasible space of 
the odds ratio lines bounded by 95% confidence interval limits. As a result, we avoided 
underestimating or overestimating the effect of time delays on treatment benefits regarding 
both interventions. 
Endovascular thrombectomy eligibility formulation: For estimating the eligibility of the 
patients to receive endovascular thrombectomy, we used LVO and stroke severity as two key 
parameters to build a prediction model. As mentioned earlier, this choice of parameters was 
based on the opinion of a neurologist team, since there was no adequate prediction tool with 
enough accuracy to be used for this purpose. To build this model, we used the combined 
dataset obtained from Royal Melbourne Hospital and Box Hill Hospital, and randomly 
selected 80% of data to construct a binary logistic regression model to estimate the patient-
specific probabilities of LVO as a dependant variable and baseline NIHSS as an independent 
variable. Once we generated these probabilities, we used the Receiver Operating 
Characteristics (ROC) analysis to identify the cut-point value of the LVO (area under ROC 
curve at cut-point = 0.78), used as a diagnostic tool to estimate the eligibility of the patients 
to receive endovascular thrombectomy. We then applied the LVO prediction model in the 
remaining 20 percent of the dataset by using the cut-off point generated earlier to split the 
probabilities into two groups. Lastly, we compared the predicted probabilities of the new 
148 
 
developed model with that of the observed probabilities in 20 percent of data, using the ROC 
analysis threshold (with 0.85 under the ROC area). The probability estimated by this model 
was used in Stage 8 of the model building process described in Table 5-2, for specifying the 
eligibility of the patients to receive endovascular thrombectomy. 
While we used LVO and NIHSS as two key parameters to develop this prediction model, 
other studies globally are investigating development of more accurate prediction methods. In 
some of these studies, researchers and clinicians suggest to use Los Angeles Motor Scale 
(LAMS) as a key parameter for specifying the eligibility of the patients to receive 
endovascular thrombectomy (Holodinsky, et al., 2017). For validation purposes, we 
compared the results of our prediction model with that of the model developed based on 
using the LAMS parameter. 
DALYs mathematical formulation: Different parameters used to estimate DALYs were 
adopted from the validated ‘IV tPA’ model, described earlier in Stages 5 and 7 of Table 5-2.   
Lastly in the same table, Stages 1, 2, 10, and 11 describe the process of designing the 
conceptual framework to run the model simulation. The validity of the experimental design 
related to this is discussed in details in Operational validity section of this chapter. 
The summary of these validation methods and techniques used to obtain the conceptual 
model validity of the ‘Individual Patient’ model has been provided in Table 5-12. 
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Validation task Why we performed the validation task How we performed the validation task The conclusions/results of the validation 
task 
Degeneracy test Based on: (Gass, 1983; Sargent, 2013) 
Delay time assumptions  An appropriate selection of the internal 
parameters directly affects the accuracy of 
the logical behaviour of the conceptual 
model. 
We assumed 40-minutes in-hospital delay 
time to receive endovascular 
thrombectomy in the ECC. This value 
was selected based on the opinion of a 
neurologist team. 
Increased credibility of the model as the vast 
majority of the stroke care units will consider 
the time delay appropriate. 
An appropriate selection of the internal 
parameters directly affects the accuracy of 
the logical behaviour of the conceptual 
model. 
For T1 and T2, we assumed 60 and 270 
minutes respectively as the minimum and 
maximum delays. The lower ranges for 
these parameters were selected based on 
the opinion of a neurologist team. The 
upper time limits for these parameters are 
the evidence-based values adopted by 
majority of international stroke 
guidelines. The upper and lower range for 
T3 were also selected based on the opinion 
of the neurologist team.  
Increased credibility of the model as most 
clinicians will consider these values 
appropriate. 
An appropriate selection of the internal 
parameters directly affects the accuracy of 
the logical behaviour of the conceptual 
We incremented the values for T1, T2, and 
T3 by 15-minutes. We obtained the 
opinion of a mathematician expert and 
While running the model with less granularity 
of delay time parameters was not feasible for 
this model, the logical behaviour of the model 
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model. clinicians to check the validity of the 
values assigned to these parameters. 
was reasonable. 
Baseline onset-to-tPA treatment time 
assumption 
To ensure that the assigned baseline 
onset-to-tPA delay time is allowing the 
model to encapsulate the effect of earlier 
treatment with respect to IV tPA 
intervention.  
The baseline onset-to-tPA treatment time 
was set to 270 minutes for the individual 
patients’ data.  
Increased credibility of the model in 
formulating the effect of earlier treatment 
with respect to tPA intervention. 
Data relationship correctness    
Endovascular thrombectomy eligibility 
probability 
To ensure that there is a logical 
relationship between the parameters used 
in the prediction model and the 
probability of receiving endovascular 
thrombectomy.  
LVO and NIHSS were as key parameters 
to build a predictive parameter, used for 
estimating the eligibility of the patients to 
receive endovascular thrombectomy. This 
parameter choice was validated based on 
the opinion of clinicians. 
Also, we compared the results of our 
prediction model with that of the model 
developed based on using the LAMS 
parameter. 
This increased the overall precision of the 
estimates used to generate the probabilities of 
the patients to receive endovascular 
thrombectomy therapy, thus increasing the 
validity of the model. 
Tracing Based on: (Balci, 1994; Sargent, 2013) 
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Endovascular thrombectomy eligibility 
probability 
To ensure that the logical behaviour of the 
prediction model is correct and the 
required accuracy obtained. 
The statistical process of constructing the 
prediction model was performed 
separately by different members of the 
model development team and results were 
compared for any inconsistency. 
Prediction model used to estimate the 
probability of the individual patients to 
receive endovascular thrombectomy was 
verified. 
Mathematical and statistical validation 
methods 
Based on: (Balci, 1994; Gass, 1983; Schellenberger, 1974) 
Change over time formulation To ensure that the equations used to build 
the conceptual model are accurate enough. 
We adopted relevant modelling 
components of the OR models developed 
in Chapter 4, to formulate the change over 
time formulation for the ‘Individual 
Patient’ model. Additionally, we used 
three set of 1000 normally distributed 
random numbers to sample according to 
an underlying Normal distribution from 
the feasible space of the odds ratio lines 
bounded by 95% confidence interval 
limits. 
Avoiding underestimating or 
overestimating the effect of time delays 
on treatment benefits regarding each of 
the treatment interventions, thus 
providing correct representation of the 
relationship between odds ratio and treatment 
time. 
 
Endovascular thrombectomy eligibility 
probability 
To ensure that the probability equation 
used as predictive parameter to estimate 
the eligibility of the patients to receive 
endovascular therapy is logically correct. 
We randomly selected 80% of the 
combined observational cohort and 
constructed a logistic regression model to 
estimate the probability of LVO as a 
We ensured that the prediction model 
constructed based on 80 percent of the cohort 
was reflecting the nature of the relationships 
in the remaining 20 percent, therefore being 
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predictive parameter to estimate the 
eligibility of the patients to receive 
endovascular therapy. The statistical 
validity of the regression model was 
evaluated in the remaining 20% of the 
observational cohort.  
valid for the full cohort. 
Table 5-12  Validation tests and techniques utilized for conceptual model validation of different components of the ‘Individual Patient’ model 
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5.7.3 Computational verification 
Similar to the ‘IV tPA’ and ‘Endovascular Thrombectomy’ models, this was performed by 
verifying the computations in Excel and code scripts in Stata as described earlier is Section 
4.7.3 of Chapter 4, using debugging, walkthrough and execution tracing techniques.  
5.7.4  Operational validity 
To achieve operational validity, the outputs of the ‘Individual Patient’ model were verified to 
obtain the accuracy needed for the intended use of the model. Additionally, using modelling 
elements of the validated ‘IV tPA’ and the ‘Endovascular Thrombectomy’ models, there was 
an increased credibility in the outputs generated by this model. Since this model was the first 
OR model used to provide insights regarding the life-time benefits for the individual patients 
over two pathways of the hyperacute stroke care system, there was no data available in real-
life system to be used for validating the simulation results. Below, we discuss different 
techniques used to validate the operational model of the ‘Individual Patient’ model, while the 
summary of these methods have been provided in Table 5-13. 
 Validation of the model output 
The expected DALYs generated for two pathways of the ‘Individual Patient’ model were 
compared between different simulation scenarios of the model, for patients with different 
characteristics to validate the outcomes. 
To build the ‘Individual Patient’ model, we used selected modelling elements of the ‘IV tPA’ 
and ‘Endovascular Thrombectomy’ models which both have been validated previously in 
Chapter 4. This eventually increased the credibility of the outputs for the ‘Individual Patient’ 
model. Additionally, as described previously, for each individual patient with a given 
scenario, we ran 1000 simulations to increase the credibility of the outputs generated by this 
model. 
 Validation of the model application 
The intended use of the model and its limitations were validated by the model developers to 
ensure the operational validity of the model as a decision support tool. For our model, these 
included the following considerations: 
1. Intended model use for patients with different characteristics: As shown by 
results of the ‘IV tPA’ and ‘Endovascular Thrombectomy’ models developed in 
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Chapter 4, the benefit of earlier treatment is different for patients with different 
characteristics. Similarly, for the ‘Individual Patient’ model it is important to 
generate the outcomes for different group of patients, thus understanding how 
patients with specific characteristics can maximize their life-time benefits over two 
pathways of the hyperacute stroke care system. To achieve this, we ran simulations 
for 64 males and 64 females, to whom we assigned different age and severities and 
compared the results for different patients. Even though these characteristics were 
selected on a basis that they represent wide range of patients, caution should be 
exercised in using the outcomes of the model for patients with characteristics other 
than those used in this model.  
2. Intended model use for different scenarios: For T1 and T2, we assumed 60 minutes 
as the minimum range, and 270 minutes as the maximum range, with 15-minutes 
interval between values within this range. For T3, we assumed 35 minutes as the 
minimum range, and 260 minutes as the maximum range, with 15-minutes interval 
between the values within this range. For the in-hospital delay time (T4), we 
assumed 40-minutes delay for all delay time scenarios. While it was not feasible to 
generate the results with the higher granularity of delay times, the current results 
generated by the model for different scenarios were consistent and had a monotonic 
trend. An exception to this was results of the model generated for very low values of 
transfer time between ECC and non-ECC, where we noticed sudden changes in the 
proportion of going to ECC by increasing the values of onset-to-tPA treatment time 
to the non-ECC, suggesting less credibility of the outcomes generated in that part of 
the model. 
Additionally, we fix the value of T4 (i.e. the in-hospital delay time to receive 
endovascular thrombectomy in the ECC) to 40 minutes for all scenarios. In reality, 
different stroke care units have different in-hospital delays; thus, caution should be 
exercised in generalizing the outcomes of this model.  
3. Intended model use for true effect of the IV tPA and endovascular treatment 
interventions: In practice, it is not clear for the clinicians how long it takes for the 
individual stroke patient to fully realizing the effect of IV tPA treatment. Thus, while 
the goal is to deliver both IV tPA and endovascular thrombectomy interventions to 
the eligible patients at the earliest possible time, it is not evident how different 
patients would benefit from each of these interventions separately, if we stretch or 
shorten the delay time between the two interventions. 
4. Increased credibility of the outputs generated by the model using simulation: 
We used 1000 simulation runs to generate the outputs of the model for each patient, 
and then estimating the proportion that a patient will benefit more by the Mothership 
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pathway over Drip and Ship pathway. Using simulations evidently increased the 
credibility of the outputs generated by this model. 
5. Actual model use to provide insights for the benefits of individual patients: The 
‘Individual Patient’ model was developed to provide better understanding of the 
benefits of the individual patients over two pathways of the hyperacute stroke care 
system. The results of this model can be potentially used by stroke care system, and 
ambulance service providers to ensure that individual stroke patients gain their 
utmost benefit by choosing the right stroke care system pathway. We expect that the 
findings of this model promote design and implementation of policies for more 
effective and efficient management of the individual stroke patients in the 
hyperacute stroke care system. 
156 
 
Validation task Why we performed the validation task How we performed the validation task The conclusions/results of the validation 
task 
Output analysis Based on: (Balci, 1994; Gass, 1983; Sargent, 2001) 
Model output To identify any unusual behaviour of the 
model and pin-pointing errors. 
We compared the results for different 
scenarios and for patients with different 
characteristics to validate the model 
outputs. 
We found errors in the outputs as a result of 
either incorrect logic or implementation of 
the model which were subsequently 
corrected. 
Intended use of the model Based on: (Sargent, 2013) 
Model output To ensure that the model’s outputs are 
accurate enough for the intended use of 
the model. 
We used selected modelling components 
of the ‘IV tPA’ and ‘Endovascular 
Thrombectomy’ models to build the 
‘Individual Patient’ model.  
  
All the modelling components of the ‘IV 
tPA’ and ‘Endovascular Thrombectomy’ 
models used to develop the ‘Endovascular 
Thrombectomy’ model were previously 
validated in Chapter 4. This increased the 
credibility of the outputs generated by the 
‘Endovascular Thrombectomy’ model. 
Model application To verify the decisions made based on the 
model outputs. 
We discussed the limitations and 
boundaries of application of the model in 
Section 5.7.4.2 of this chapter. 
Users of the DS model will understand the 
limitations and will not overgeneralize or use 
the model outside of its intended use. 
Robustness Based on: (Balci, 1994; Boehm, et al., 1976; Gass, 1983; Myers, et al., 2011; Sargent, 2013; Whitner & Balci, 1989) 
Model output To check the model’s behaviour while 
changing the parameters and inputs of the 
For each individual patient and a given 
scenario, we ran 1000 simulations to 
Increased credibility of the model’s outputs. 
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model. generate the model outputs. Out of these 
runs, we then specified the proportion that 
the patient will benefit the Mothership 
pathway over Drip and Ship pathway.  
Table 5-13  Validation tests and techniques utilized for operational model validation of different components of the ‘Individual Patient’ model 
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5.8 Summary and conclusions  
In this chapter, we discussed different stages of developing a new OR model used to address 
the following research question: ‘How OR models can be designed, developed, and validated 
to assist with maximizing the individual patients’ life-time benefits over  two pathways of the 
hyperacute stroke care system?’ This was achieved by using selected modelling elements of 
the previously validated ‘IV tPA’ and ‘Endovascular Thrombectomy’ models to build the 
‘Individual Patient’ model in this chapter. Regarding the intended use of the model, this 
model is categorized as a model for ‘investigation and improvement’ as it is used to 
understand the link between the long-term benefits for the individual stroke patients and a 
selected stroke treatment pathway, thus providing assistance in maximizing the life-time 
benefits for stroke patients over two pathways of the hyperacute stroke care system. 
While OR models developed in previous chapter were used to reflect on the population 
benefits regarding two different treatment interventions for stroke patients, the ‘Individual 
Patient’ model developed in this chapter was used to better understand the long-term benefits 
associated with two different treatment pathways for the individual stroke patients. As the 
result, we found that the long-term gained benefits due to earlier treatment are different for 
patients with various characteristics. These include patients’ age, gender, stroke severity, and 
treatment delay times before IV tPA and endovascular thrombectomy interventions. It is 
expected that the findings of this model provide important insights for the clinicians and 
emergency services providers as they are facing the challenges of redesigning the hyperacute 
stroke care system since the emergence of new evidence about the effectiveness of the 
endovascular thrombectomy treatment in late 2014 and early 2015.  
The generic validation framework described earlier in Chapter 3 was employed in this 
chapter to systematically perform data validation, conceptual model validation, 
computational model verification, and operational validation of the model. Having very 
limited data on the model behaviour to be used for validating the model outputs, the 
validation of the model was performed based on critically testing all the model inputs, 
assumptions, parameters used to develop the model as well as running simulation to increase 
the credibility of the outcomes generated by the model. 
Results obtained from this model can provide assistance in designing an efficient and 
effective hyperacute stroke care system capable of addressing new treatment needs for the 
patients.  
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 Chapter 6: Discussion and conclusion 
Introduction 
In this chapter, we summarize findings, contributions, limitations of the research presented 
earlier, and outline future directions identified by addressing the research questions. Sections 
of this chapter are organized based on the three research questions formulated in Chapter 1. 
6.1 Research question 1  
How OR models can be designed, developed, and validated to provide an improved 
understanding of the earlier treatment benefits on patients’ life-time outcome for two 
different treatment interventions in hyperacute stroke care system? 
To address this research question, we first conducted a literature review in Chapter 2 of this 
thesis using different search methodologies to find OR stroke related studies reported in 
OR/MS and clinical literature. We then adopted a conceptual framework proposed by 
Churilov and Donnan (2012) to classify the papers identified as a result of this literature 
review in relation to both the specific parts of the stroke care system (problem area) being 
addressed and the nature and purpose of the OR intervention. 
Even though OR models have been applied successfully by researchers to address different 
problems in the stroke care system, prior to the research reported in this thesis, there was no 
OR model used to measure the population benefits due to earlier provision of IV tPA and 
endovascular thrombectomy treatments for the stroke patients. In Chapter 4 of this thesis, we 
designed and developed two OR models, namely the ‘IV tPA’ and the ‘Endovascular 
Thrombectomy’ models, used to investigate the gained population benefits associated with 
existing treatment interventions for the stroke patients. 
6.1.1 Findings 
As a result of literature review classification conducted in Chapter 2, we concluded that OR 
interventions such as stroke care process design and performance, stroke team scheduling 
and workforce planning, and stroke service planning were addressed more frequently than 
other interventions, while there was a lack of research attention in using stroke units, 
imaging and surgical equipment evaluation and selection models OR interventions to 
address different problems in the stroke care system. With regard to different problem areas, 
stroke prevention, pre-hospital, stroke unit care, rehabilitation and social and community 
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care fields were among the most addressed areas; while information and support for stroke 
patients, appropriate management of TIAs, appropriate stroke care expertise, and financial 
viability were among the least addressed areas in the literature.  
As a result of the ‘IV tPA’ and the ‘Endovascular Thrombectomy’ models developed in 
Chapter 4, we found that few minutes of earlier treatment in delivering IV tPA and 
endovascular thrombectomy can be translated into days, weeks, and even months of healthy-
life for stroke patients. Following is the list of findings for these OR models: 
 Both models are categorized as models for investigation and improvement according 
to Pidd (2010) taxonomy as they are used to provide insights on the effect of time 
delays associated with IV tPA and endovascular thrombectomy treatment 
interventions on patients’ life time outcomes 
 One minute earlier of IV tPA treatment time provides on average extra 1.8 days of 
healthy life for the stroke patients; while one minute earlier of endovascular 
thrombectomy provides on average extra 3.2 days of healthy life for the stroke 
patients. Thus, it was concluded that faster treatment is even more important in the 
endovascular therapy. 
 For both IV tPA and endovascular thrombectomy treatment interventions, female 
and young patients benefit more by earlier treatment due to their longer lifetime.  
6.1.2 Contributions and implications 
The literature review conducted in Chapter 2 demonstrated the extent of stroke related OR 
studies reported in OR/MS literature by different authors and how these studies have used 
OR interventions to address specific problem areas in the hyperacute stroke care system. The 
result of this literature review was partially published in a conference paper “Stroke care 
systems: can simulation modelling catch up with the recent advances in stroke treatment?”, 
in 2015 in the Proceedings of Winter Simulation Conference (Keshtkaran, et al., 2015). 
The ‘IV tPA’ model developed in this research, was the first OR model used for 
investigating the benefits of faster access to IV tPA treatment on patients’ life-time 
outcomes. Findings of this model had significant impacts on increasing the awareness of the 
public policy decision makers on the importance of faster delivery of the IV tPA treatment to 
stroke patients. The non-technical overview of this model was presented for a clinical 
audience in 2014 in the leading journal of the field, Stroke, titled “Stroke thrombolysis; save 
a minute, save a day”(Meretoja, et al., 2014). Since its publication, this article has been cited 
more than 60 times according to Scopus database, at the time of submitting this thesis. This 
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publication led to a significant media exposure including sources like Bloomberg (Gale, 
2014), the Times (Whipple, 2014), Reuters (Seaman, 2014), Herald Sun (2014), and ABC 
national television news in Australia (ABC News 24, 2014). Moreover, American Heart and 
Stroke associations produced an infographics encapsulating the findings for the consumers 
(American Heart Association/American Stroke Association, 2014). The model’s findings are 
also used by the Australian National Stroke Foundation and Victorian Stroke Telemedicine 
Initiative (State of Victoria, Australia) to advocate for wider use of stroke thrombolysis 
telemedicine in remote and rural areas (Bladin & Cadilhac, 2014).  
Similarly, the ‘Endovascular Thrombectomy’ model developed in this research, was the first 
OR model used for investigating the benefits of earlier access to endovascular thrombectomy 
therapy on patients’ life-time outcomes, thus, advocating for the importance of equipping the 
clinical centres with necessary expertise and facilities for faster delivery of this intervention 
to stroke patients. The non-technical overview of the ‘Endovascular Thrombectomy’ model 
has been accepted for publication in Neurology journal (Meretoja, et al., 2017) and authors 
expect to receive considerable interest by researchers and clinicians by its publication. Both 
‘IV tPA’ and ‘Endovascular Thrombectomy’ models were validated using the generic 
validation framework developed in Chapter 3; thus, providing an improved confidence for 
decision makers to use the recommendation proposed by these models. Discussion on 
validation of these OR models is provided in Section 6.3 of this chapter in addressing the 
third research question of this thesis.  
6.1.3 Limitations of the research and future directions 
Since data used to develop the ‘IV tPA’ and the ‘Endovascular Thrombectomy’ models were 
obtained from different clinical centres and potentially different countries, caution should be 
exercised before generalizing the results for different populations of stroke patients. To build 
the ‘Endovascular Thrombectomy’ treatment, we assumed an average 90 minutes delay 
between the IV tPA and thrombectomy treatments. In Chapter 4, we validated the outputs of 
the model to ensure the validity of this delay time parameter used to build the model, 
however it should be noted that in practice this delay time can be shorter or longer for 
different clinical centres. 
Given the significant effect of small treatment time reductions on patients’ lifetime 
outcomes, further research is needed to investigate how different OR interventions can be 
employed to further reduce treatment delay times in the hyperacute stroke care system. This 
can be achieved by using a system approach and continuous improvement practices to 
shorten both the pre-hospital and in-hospital delays (Fonarow, et al., 2011; Köhrmann, et al., 
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2011; Meretoja & Kaste, 2012; Meretoja, et al., 2012; Tilley, et al., 1997). Furthermore, few 
studies have reported on the effectiveness of using the portable Computed Tomography (CT) 
vehicles and point-of-care laboratories in reducing treatment delay times upon the 
availability of these services for the hyperacute stroke care system (Walter, et al., 2012; 
Weber, et al., 2013). Since application of such services implies significant capital investment 
and personnel training for the system, it is necessary to conduct the cost-effectiveness 
analysis before promoting the practice change by use of these services. Results obtained by 
the ‘IV tPA’ and ‘Endovascular Thrombectomy’ models developed in this thesis can be used 
as model inputs to evaluate the feasibility of these services. 
6.2 Research question 2  
How OR models can be designed, developed, and validated to assist with maximizing the 
individual patients’ life-time benefits over two pathways of the hyperacute stroke care 
system? 
To provide background information to the second research question we conducted a 
literature review in Chapter 2 of this thesis as discussed in Section 6.1. Then, to address the 
identified research gap regarding lack of OR models used to investigate the individual 
patient’s benefits associated with different pathways of the hyperacute stroke care system, in 
Chapter 5 of this thesis we designed and developed the ‘Individual Patient’ OR model. This 
model used to address very recent and important questions raised by the clinicians and stroke 
care providers with the emergence of new evidence about the effectiveness of the 
endovascular thrombectomy treatment in late 2014 and early 2015, such as “Should primary 
stroke centres be bypassed to transport patients to comprehensive centres, even if it means 
delaying the start of IV tPA? How much delay in bypass is acceptable? How much of a delay 
to start IV tPA would eliminate the benefit of earlier thrombectomy (Warach & Johnston, 
2016, p. 1266)”?  
6.2.1 Findings 
Following is the list of findings for the ‘Individual Patient’ model: 
 The ‘Individual Patient’ model is categorized as a model for investigation and 
improvement according to Pidd (2010) taxonomy as it is used to provide insights on 
the individual patient’s benefits associated with different pathways of the hyperacute 
stroke care system. 
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 The long-term gained benefits due to earlier treatment are different for patients with 
various characteristics. This includes patients’ age, gender, stroke severity, and 
treatment delay times before IV tPA and endovascular thrombectomy interventions. 
 Both stroke severity and eligibility of the patients to receive endovascular 
thrombectomy are functions of the presence of Large Vascular Occlusion (LVO). 
 We ran simulations for the total of 3600 scenarios of time delays over 128 individual 
patients, each simulated 1000 times. Results of this model were reported as 
proportion of runs when a patient benefits more (loosing less DALYs) by 
Mothership pathway over the Drip and Ship pathway. 
6.2.2 Contributions and implications 
The ‘Individual Patient’ model developed in this thesis was used to compare the stroke 
patients’ long term treatment benefits associated with different pre-hospital and in-hospital 
delay times of the Drip and Ship and Mothership pathways in the hyperacute stroke care 
system. Results obtained from this model provide insights on how individual patients with 
different characteristics can maximize their long-term benefits over two pathways of the 
hyperacute stroke care system. 
The ‘Individual Patient’ model was validated using the generic validation framework 
developed in Chapter 3; thus, providing an improved confidence for decision makers to use 
the recommendation proposed by this model. Discussion on validation of this OR model is 
provided in Section 6.3 of this chapter to address the third research question of this thesis.  
6.2.3 Limitations of the research and future directions 
The main assumptions and limitations of the experimental results to build the ‘Individual 
Patient’ model were as follows: 
 We assumed an average 40 minutes in-hospital delay for receiving the endovascular 
thrombectomy in the endovascular capable centre (ECC). In practice, different 
clinical centres may have shorter/longer delay times.  
 Since it was not feasible to generate the results of this model with higher granularity 
of delay times, we incremented delay time parameters used to build this model by 15 
minutes.  
 Lastly, at the time of developing this model, no adequate prediction tool was 
available to estimate the patients’ eligibility for thrombectomy treatment with 
enough accuracy. Hence, we consulted an expert team of neurologists who advised 
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on using stroke severity and Large Vascular Occlusion (LVO) as the two main 
parameters to build a prediction model. Using new prediction methods and eligibility 
scales (Kamal, et al., 2014; Nazliel, et al., 2008) can potentially increase the 
accuracy of the outcomes generated by this model. 
Other factors at the patients’ level, process level, and system level can be conceptualized to 
improve the precision of the outcomes generated by the model. Regarding the patients’ level, 
an example is comorbidities; regarding the process level, examples are the capacity of the 
stroke care units in the hospitals, the number of non-endovascular (nECC) and endovascular 
capable (ECC) centres, and operating days and hours of both nECC and ECC centres; and 
regarding the system level examples are the financial impacts of different strategies (such as 
using mobile stroke unit, ambulances with computed tomographic scanners) within the 
hyperacute stroke care system. To conceptualize all these factors multiscale simulation 
models (Borshchev, 2013) can be applied to develop more efficient and effective hyperacute 
stroke care systems. 
6.3 Research question 3   
What are the conceptual and application issues of conducting comprehensive validation of 
an OR model for investigation and improvement in the context of health systems and service 
operations? To address this research question, in Chapter 3 of this thesis we provided a 
discussion on different conceptual and application issues of conducting comprehensive 
validation of OR models used for investigation and improvement in the context of health 
systems and service operations. In the same chapter, we also proposed a validation 
framework that can be used to validate OR models in both health and non-health contexts. 
We adopted his validation framework in Chapter 4 and 5 of this thesis to validate the three 
OR models developed in this research. 
OR models used to address different decision problems emerging in health systems have 
often a complex nature, as model developers use a wide variety of data sources and empirical 
estimates to develop these models. Interactions between different components of these 
models often lead to complexity on health OR models. Moreover, such models are usually 
developed to support unique and new investigations, which often lead to designing a new 
system, improving a system or just providing an understanding of a very complex situation 
(Pidd, 2010), with the aim of improving the efficiency and effectiveness of the entire system. 
Even though different authors in OR/MS literature emphasize the importance of validating 
OR models, as demonstrated by the results of a literature review conducted in Chapter 3, 
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there is a lack of reported knowledge about practical aspects of how to validate OR models 
in the context of health systems and service operations.  
6.3.1 Findings 
We proposed a generic validation framework by reviewing a wide variety of methodological 
published articles reported by different authors in OR/MS literature over the last three 
decades. This framework can be used to systematically address the generic aspects of model 
validity (i.e. data validity, conceptual model validity, computational verification, and 
operational validity) using relevant validation tasks and techniques. The validation process 
based on this framework consists of addressing the applied validation task, describing the 
purpose of performing each validation task (i.e. Why), the process of validation (i.e. How), 
and the results and conclusions obtained. This validation framework was used to validate 
three OR models developed in Chapters 4 and 5 in the context of the hyperacute stroke care 
system. 
We found that some of the validation tasks are more generic (e.g. data relationship 
correctness, tracing, walkthrough, or historical data validation) and can be applied to 
different types of models (e.g. simulation, optimization, and analytical/statistical modelling), 
while other validation tasks might be only applicable to a specific type of model. Moreover, 
we concluded that the importance of a particular validation task is tightly coupled with the 
intended use of the model; therefore, for models used for investigation and improvement, 
there is often more emphasis on the application of validation techniques used to critically 
testing all the model inputs, assumptions, and parameters; since often there is lack of 
empirical data to conduct the ‘output-based’ validation of such models. 
The three OR models developed in this research are categorized as models for investigation 
and improvement according to Pidd (2010) as they were used to explicitly provide insights 
on the effect of time delays associated with IV tPA and endovascular thrombectomy 
treatment interventions on patients’ life time outcomes. The process of developing these OR 
models involved using different data bases and parameters obtained from relevant literature 
with no empirical data available on model behaviour to validate the outputs of the model. 
Thus, the validation process of these models consisted of critically testing all the model 
inputs, assumptions, parameters to have a better understanding of the model boundaries and 
its application.  
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6.3.2 Contributions and implications 
Having validated these complex health OR models, we demonstrated how different aspects 
of data validity, conceptual model validity, computerized verification, and operational 
validity can be systematically validated given the complex nature of such models designed 
for investigation and improvement purposes. This is a novel contribution to OR/MS 
literature, since as discussed in Chapter 3, even though different authors in OR/MS literature 
generally agree on the importance of validating OR models, examples from the literature 
where authors provide a systematic and comprehensive validation of such models is scarce. 
Since the validation framework proposed in this thesis was developed based on the generic 
validation techniques and aspects of model validity reported in OR/MS literature, it is not 
specific to health OR models and can be utilized to validate all different types of models in 
the field of OR/MS.  
Discussion on validation of the ‘IV tPA’ presented in Chapter 4 of this thesis was published 
in the European Journal of Operational Research in 2016, titled “Validation of a decision 
support model for investigation and improvement in stroke thrombolysis” (Keshtkaran, et al., 
2016). 
6.3.3 Limitations of the research and future directions 
As demonstrated by results of the literature review conducted in Chapter 3, there is a lack of 
reported knowledge about the practical aspects of how to validate an OR model in the 
context of health systems and service operations. We believe the validation framework 
proposed and used in this thesis to validate OR models with investigation and improvement 
purposes can be used with some refinements for the validation of OR models with other 
purposes as classified by Pidd (2010). Moreover, it seems plausible that this validation 
framework can be used to validate models in the context of simulation, optimization, and 
analytical/statistical modelling – we suggest these hypotheses as potential directions for 
future research. Also, the question of the additional validation techniques that can be used 
for each modelling methodology in this framework is an important subject that can be further 
investigated. Lastly, since this framework was developed based on the generic validation 
techniques reported in OR/MS literature, it may have a wider applicability beyond the health 
systems OR - it is likely that various validation aspects may require different amount of 
attention depending on the specific application area, which could also be the topic of future 
research. 
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6.4 Summary 
This research investigated the issue of design, development and validation of OR models 
used for investigation and improvement of the hyperacute stroke care systems. Two of the 
OR models developed in this research used for the first time to quantify the effect of faster 
treatment on patient life time outcomes. Insights obtained from these models are supposed to 
directly lead to an increased awareness of public policy decision makers, stroke campaigns, 
and stroke care system providers of the importance of faster treatment for stroke patients. 
The third OR model developed in this research addresses some of the most burning questions 
raised by clinicians in the field to support more effective and efficient provision of the 
services to hyperacute stroke patients. To conclude, all three OR models developed and 
validated in this thesis are novel and contribute to both OR/MS and clinical literature. 
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